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Abstract 
Through years of evolution and in order to maintain viable protein 
homeostasis, cells have developed defense mechanisms against the 
accumulation of misfolded proteins and aggregates. This mechanism 
comprises a complex network of specialized proteins designated as heat shock 
proteins (HSPs). Tumor necrosis factor receptor (TNFR)-associated protein 1 
(TRAP1) is a 90 KDa HSP family member that has received large attention 
over the past years. The interest in TRAP1 originated from its identification as 
a mitochondrial chaperone whose expression is augmented in several human 
neoplasias. Since its identification, TRAP1 was described to play important 
anti-oxidant and anti-apoptotic roles, conferring tumor cells growth 
advantage. Despite the increasing knowledge, the mechanisms of TRAP1 
cytoprotective actions are not yet fully understood.  In fact, reports in 
literature are sometimes contradictory or describe alterations without 
providing a detailed mechanism of action. 
The present dissertation aims to contribute with new insights on the role of 
TRAP1 in conferring mitochondrial protection and regulating cellular quality 
control systems. We hypothesize that TRAP1 contributes to tumor 
homeostasis allowing cell growth and survival under stressful environments 
by preserving mitochondrial functionality and viability as well as through the 
regulation of cellular quality control systems, including autophagy and 
apoptosis. To test the hypothesis, the A549 lung carcinoma cell line was used 
due to its high expression of TRAP1. TRAP1 depletion in this system was 
achieved through small interference RNA.  In addition, a parallel study was 
performed using MRC-5 cells, a normal lung fibroblast cell line, with low 
TRAP1 content. The use of the MRC-5 cell line would allow exploring the 
effects of TRAP1 silencing in a non-tumor cell line, with a low basal expression 
of that protein. 
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We initially verified that TRAP1 localization in A549 cells was predominantly 
mitochondrial, whereas TRAP1 was localized in non-mitochondrial areas in 
MRC-5 cells. Overall, the results presented in this thesis regarding 
mitochondrial function are in agreement with previous observations showing 
that TRAP1 contributes to the maintenance of mitochondrial membrane 
potential and to decrease ROS production in tumor cells, while the same was 
not observed in normal MRC5 cells. Although TRAP1 function in mPTP 
modulation has been previously described, we show for the first time the 
direct effect of TRAP1 silencing on basal mPTP state. Surprisingly, and 
contrarily to what was expected, mPTP existed in a more closed conformation 
in A549 TRAP1-depleted cells. Another breakthrough of the present work 
regards ROS modulation in the tumor cell line, which according to our results 
may involve p66SHC phosphorylation in Ser36 residue. Additionally, TRAP1 
silencing in A549 cells resulted in mitochondrial fragmentation, possibly 
involving DRP-1 fission protein. 
Although increased lysosome content (in A549 cells) and decreased p62 levels 
(in both cell lines) suggest an increased autophagic flux, our data showed a 
decrease in the expression of several macroautophagy markers in TRAP1-
depleted cells. However, these apparently contradictory results are explained 
by a lower ubiquitin content and increased LAMP2A levels suggesting the 
activation of an alternative autophagy pathway, involving chaperone-
mediated autophagy (CMA). Nonetheless, this activation of CMA was only 
observed in A549 cells. Moreover, incubation of TRAP1-silenced cells with the 
autophagy inducer rapamycin resulted in increased cellular growth, mainly 
in A549 cells, suggesting that autophagy signaling in these cells are pro-
tumorigenic. Regarding TRAP1 silencing effects on apoptotic signaling, results 
for both cell lines showed an increase in caspase 3/7-like activity with no 
alterations in the apparent activity of initiator caspases (8, 9 and 12). 
Additionally, TRAP1 silencing shifts the BAX/BCL-xL balance in favor of 
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apoptosis in A549 cells suggesting that these cells have an active apoptotic 
signaling, whereas MRC-5 cells are not affected. 
In conclusion, besides TRAP1 differential expression in normal versus cancer 
cells, its subcellular localization may contribute to the distinct effects 
observed after TRAP1 silencing (or chemical inhibition). The present work 
also suggests that p66SHC is a good candidate to mediate TRAP1 ROS 
modulation in cancer. Moreover, our data suggests that TRAP1 controls 
mitochondrial morphology through DRP1 content and, additionally, plays an 
important role in the maintenance of cellular quality control systems. Our 
results are relevant to clarify not only the role of TRAP1 as an anti-cancer 
target but also as to understand off-target effects of TRAP1 
silencing/inhibition in non-tumor cells. 
Keywords: TRAP1, mitochondria, apoptosis, autophagy,oxidative stress. 
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Resumo 
De modo a manter a qualidade e homeostase das proteínas, as células 
desenvolveram mecanismos de defesa para evitar a acumulação de agregados 
proteicos e proteínas defeituosas, que envolve uma rede complexa de 
proteínas especializadas designadas de proteínas de choque térmico (HSPs). A 
TRAP1 (do Inglês Tumor necrosis factor receptor-associated protein 1) é membro 
da família da proteína de choque térmico de 90KDa (HSP90). O crescente 
interesse na proteína TRAP1 advém do facto de ser uma chaperona 
mitochondrial cuja expressão se encontra aumentada nas células tumorais. 
Desde a sua descoberta, várias funções foram atribuídas à TRAP1 incluindo 
actividade antioxidante e antiapoptotica, conferindo vantagem seletiva às 
células tumorais. Contudo, ainda muito falta saber sobre o papel cito-protetor 
da TRAP1, considerando que muitas das informações obtidas na literatura são 
fragmentadas, sem providenciar um mecanismo detalhado de ação para a 
TRAP1. 
Esta dissertação tem como principal objetivo contribuir com novas 
informações acerca do papel da TRAP1 na manutenção da função mitocondrial 
bem como na regulação de sistemas de controlo de qualidade. A nossa hipótese 
é a de que a TRAP1 contribui para manutenção da homeostase tumoral, 
permitindo o crescimento e sobrevivência celulares em ambientes de elevado 
stresse, através da preservação da função e viabilidade mitocondrial e pela 
regulação de sistemas de controlo de qualidade como a autofagia e apoptose. 
Deste modo, usou-se uma linha celular de cancro de pulmão, A549, que 
expressa elevados níveis de TRAP1. Para trabalho, silenciamos a TRAP1 
utilizando ARN pequeno de interferência. Para além dos estudos conduzidos 
em A549, um estudo complementar foi efetuado usando uma linha celular de 
fibroblastos pulmonares normais, MRC-5, que expressa níveis reduzidos de 
TRAP1. Esta última linha celular foi escolhida de modo a explorar os efeitos do 
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silenciamento da TRAP1 numa linha celular não tumoral com baixa expressão 
daquela proteína. 
De acordo com os dados publicados, a TRAP1 revelou uma localização 
predominantemente mitocondrial nas células tumorais. Contudo, os nossos 
resultados sugerem uma distribuição extra-mitocondrial da TRAP1 nas células 
MRC-5. Esta localização diferencial ajuda à melhor compreensão dos distintos 
efeitos do silenciamento da TRAP1 nas duas linhas celulares. Deste modo, ao 
contrário do observado nas MRC-5, os resultados demonstram que a TRAP1 
contribui nas células tumorais para a manutenção do potencial de membrana 
mitocondrial e para a regulação de espécies reativas de oxigénio (ERO). O 
silenciamento da TRAP1 resultou num aumento da disfunção mitocondrial 
com repercussões ao nível da sua morfologia. Verificou-se que, especialmente 
em células A549, a TRAP1 modula o poro de permeabilidade transitória (PTP) 
mitocondrial, cujo estado nunca tinha sido directamente avaliado. Outra 
novidade do nosso trabalho resultou do estudo do papel da TRAP1 na 
regulação das ERO, que poderá envolver a fosforilação da p66SHC no seu 
resíduo de Ser36. 
Tendo em conta que a acumulação de mitocôndrias danificadas resulta na 
ativação de sistemas de controlo de qualidade, tais como autofagia e apoptose, 
o silenciamento da TRAP1 resultou num aumento do conteúdo lisossomal (nas 
A549) e redução da expressão da proteína p62 (nas duas linhas celulares). 
Apesar dos resultados sugerirem um aumento do fluxo autofágico, existiu uma 
redução na expressão de diferentes proteínas envolvidas em autofagia, 
principalmente em A549. Apesar de aparentemente contraditórias, estas 
observações são explicadas tendo em conta a redução dos níveis de ubiquitina 
bem como do aumento da expressão da LAMP2A resultantes do silenciamento 
da TRAP1 em células A549. Além destas alterações, o silenciamento da TRAP1 
resultou ainda num aumento da atividade aparente da caspase 3/7 e em 
alterações no equilíbrio da razão BAX/BCL-xL em prol da via apoptótica 
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sugerindo a ativação da via de morte celular nas A549, não afetando contudo 
as MRC-5. 
Em resumo, diferente expressão da TRAP1, bem como diferenças na 
localização intracelular entre células tumorais e normais poderão estar na 
base dos distintos efeitos do silenciamento desta chaperona nas linhas 
celulares estudadas. Nas células tumorais, o silenciamento da TRAP1 parece 
ter efeitos mais devastadores, que incluem a acumulação de mitocôndrias 
danificadas e, eventualmente, de proteínas deformadas resultando de 
reduzido fluxo autofagico. Deste modo e numa tentativa de recuperação, as 
células respondem aumentando os níveis de vias alternativas para remoção de 
lixo intracelular que contudo são mais limitados. Esta crescente acumulação 
de lixo culmina então com a ativação da via de morte celular por apoptose. 
Assim, estes resultados são uma mais-valia para a compreensão da função 
cito-protetora da TRAP1 e ajudam a clarificar não só o papel da TRAP1 como 
alvo de terapia anti-cancro mas também na compreensão dos efeitos do seu 
silenciamento e/ou inibição em células não tumorais. 
Palavras chave: TRAP1, mitocondria, apoptose, autofagia, stresse oxidativo. 
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Although cancer was recognized thousands of years ago as a medical condition, 
paleopathologic findings indicate this disease is actually older than mankind. The 
knowledge on cancer advanced greatly along human history until our current 
understanding of cancer as a highly complex disease that results from a multistep process. 
This progress on cancer knowledge contributed not only to the understanding of the 
process of neoplastic transformation, but also to the development of new therapies. This 
chapter is an overview of the major cancer developments and advances along history for a 
better understanding of how the overall knowledge of cancer accompanied the greatest 
scientific discoveries. The chapter will also focus on the importance of the global burden 
of this disease and the progress made regarding therapeutic approaches. It will start from 
a historical perspective (Section 1.1) and move to modern knowledge of cancer (Section 
1.2.), followed by information on global cancer incidence and mortality (Section 1.3). 
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1.1 Historical notes 
Contrarily to what some might think, cancer is not a modern disease. Evidence from 
fossils, bones and mummified bodies support the fact that cancer was recognized several 
thousand years ago. The origin of the word cancer is attributed to the Greek physician 
Hippocrates to whom the cancerous growth reminded of a moving crab, adhering to 
surrounding structures with his claws. These observations led to the Greek term karkinos, 
and later to the Latin word cancer, to describe masses of cancerous cells. However, 
despite naming “cancer” Hippocrates did not discover the disease. In fact, historically, the 
world oldest documented case of cancer dates back to about 3000 B.C. in Egypt. The 
Edwin Smith Papyrus recorded eight cases of breast tumors. In the document, the writer 
concluded that it was a serious disease for which there was no treatment available [1]. 
Since then, the knowledge on neoplastic transformation has progressively increased. In 
the seventeenth century, Hooke applied the word “cell” and with it created the 
understanding that it represents the biological unit of living organisms. Another 
important advance was the implementation of autopsy as a tool for the study of human 
pathologies provided bases to the better understanding of disease development. Several 
physicians, such as Giovanni Morgagni in 1761, performed routine postmortem 
examinations establishing a correlation between patient illness and pathologic findings 
[2]. Latter, the Scottish surgeon John Hunter suggested that some cancers could be 
surgically removed proposing guidelines to how a surgeon could decide which cancer to 
operate on [3]. However, it was not until one century later that surgery as a method for 
cancer treatment became widely used. In 1846, the development of general anesthesia 
allowed the elimination of excruciating pain experienced by surgical patients as well as 
the progress of classic cancer operations such as the radical mastectomy [4]. 
With the evolution of scientific tools, such as the development of the modern microscope, 
the correlation between microscopic alterations and illness was established. In the 
nineteenth century, Rudolf Virchow’s work supported emerging ideas on cell division 
stating that all living cells originate from other living cells. These observations reinforced 
his theory that diseases involve changes in normal cells, and that pathology is ultimately a 
disease of the cell [5]. This assumption had a high impact on cancer surgery improvement 
as it allowed pathologists to identify abnormal tissue from selected samples for more 
precise diagnostics. 
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The twentieth century saw extraordinary advances in cancer therapy. In 1903, five years 
after Marie Curie discovery of radium, the first use of a radioactive element to cure cancer 
was made [6]. Today, radiation is delivered with precision to destroy tumor cells limiting 
the damage caused to nearby normal tissues. During World War II the study of the effects 
of a number of chemicals developed as war agents, provided new insights to cancer 
treatment. In the course of this work, a nitrogen compound, showed its effectiveness in 
the cure of lymphomas [7]. These works potentiated rapid advances in chemotherapy. In 
1958, scientists demonstrated that the combined use of chemotherapeutic agents caused 
remission of acute leukemia [8]. 
Moreover, the knowledge of the origin of cancer also suffered a fast evolution along this 
period of time with contributions from both epidemiology and molecular biology. 
Advances in epidemiology contributed to the identification of many specific events that 
cause cancer, such as exposure to coal tars or ionizing radiation whereas molecular 
biology focused on the interactions between genes and external factors [9-11]. At this 
point, scientists knew that chemicals, radiation, and viruses could cause cancer, and that 
Figure 1.1 – Major events on the history of cancer. A timeline of cancer discoveries and
theories. 
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it could also be hereditary. However, the discovery of deoxyribonucleic acid (DNA) 
chemical structure by James Watson and Francis Crick, as well as the understanding of 
how genes worked allowed the perception that DNA damage by multiple factors could 
lead to cancer development [12]. The next breakthrough came with the discovery of two 
particularly important cancer-related gene families, oncogenes and tumor suppressor 
genes. The discovery of oncogenes and proto-oncogenes, i.e. normal genes that after 
mutations or deletions acquire the ability to function as an oncogene, provided 
information about how cells proliferate, since these specific genes cause cell to grow out of 
control. Conversely, tumor suppressor genes operate to constrain or suppress cell division 
[13]. The importance of specific genetic changes in cancer was soon used to develop 
targeted therapies to overcome the downstream impact of genetic alterations.  
The last decades led to a remarkable understanding of cancer (Fig.1.1). The development 
of techniques of molecular biology, as well as the improvement in specialized tools, were 
highly responsible for this success. 
1.1.1 Theories on cancer development 
As previously mentioned, the increased knowledge of human body, epidemiology, and 
molecular biology contributed to advances on the understanding of cancer and its 
development. 
Centuries of research led to several theories explaining the causes of cancer (Fig.1.1). 
While ancient Egyptians blamed cancers on gods, Hippocrates believed that cancer was 
caused by an unbalance in humor content, the humoral theory of cancer. Hippocrates 
(460-370 BC) theorized that the human body was composed by four humors (body fluids) 
– blood, phlegm, yellow bile, and black bile. According to the humoral theory, cancer 
would then be caused by an excess in black bile [14]. With the decline and fall of ancient 
Greece, the humoral theory of cancer was adopted by the Romans and remained 
unchanged for 1,300 years. 
The humoral theory was later replaced by the lymph theory. In 1695, Stahl and Hoffman 
proposed that life consisted of continuous and appropriate movement of body fluids, 
namely blood and lymph, through solid parts. According to this theory, malignant cancers 
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resulted from fermentation and degeneration of the lymph [15]. The lymph theory 
prevailed for almost 150 years and was abandoned due to lack of evidences. 
In the 1830s, the German pathologist Johannes Müller and his student Rudolf Virchow 
revolutionized the view on cancer with the demonstration that cancer is a disease of cells 
and not lymph. Müller proposed that cancer cells originate from building blocks called 
blastema [2]. However, Virchow disapproved the blastema theory by demonstrating that 
cancer cells are derived from other cells. 
During the nineteenth century, several theories proposed explanations for the origin of 
cancer, some of which are still accepted as valid, although with minor modifications, 
nowadays. Virchow postulated that chronic irritation was the cause of cancer, despite 
incorrectly believing that metastatic cancers were spread by a liquid [16]. Later, Karl 
Thiersch demonstrated that cancer metastasizes from the spread of malignant cells and 
not through fluid. The discovery of X-rays in 1895 and the observations that exposure to 
this form of radiation could induce tissue damage supported the idea that cancer arises 
from chronic irritation. While Virchow proposed the chronic irritation theory, Hugo 
Ribbert named trauma as the cause of cancer [17]. 
Cancer was soon thought to be a contagious disease. In 1649, the contagious theory was 
publicized and all cancer patients were isolated in hospitals outside the cities [18]. This 
theory was later rejected due to failure in experimentally verification [2]. Although 
cancer itself is not contagious, discoveries in the early twentieth century regarding 
certain virus and bacteria yielded clues about the molecular mechanisms that trigger the 
development of human cancer. In 1911, Peyton Rous described a sarcoma in chicken 
caused by what was later known as the Rous sarcoma virus [19]. Since then several virus 
have been linked to cancer [20, 21]. 
Although the hereditary causes of cancer have been debated for centuries, a report 
published in 1913 on several examined cases showed the influence of hereditary on 
carcinogenesis [22]. In 1915, Yamagiwa and Ichikawa were able to induce cancer in 
laboratory animals by applying coal tar to their skin [9]. This and other similar 
experiments brought clues about the existence of specific substances that cause cancer, 
the so-called carcinogens.  
The fragmented findings regarding cancer origin and development created confusion 
about the disease. Moreover, the discovery of compounds that potentiate carcinogenesis, 
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as well as the identification of certain bacteria and virus as cancer promoters seemed to be 
in conflict with findings showing that cancer is hereditary. The identification of DNA as 
the carrier of the cellular genetic code, as well as the understanding on how this code is 
translated, allowed great advances on the conception of a unified view on cancer origin 
and development. 
1.2 Modern knowledge on cancer 
Cancer is a disease characterized by an uncontrolled growth and division of abnormal 
cells, which culminates with acquisition of the ability of the cell to invade and colonize 
other tissues in the organism. In normal cells, processes of cell division and death are 
highly regulated ensuring the homeostasis of cell number and maintenance of tissue 
architecture. On the other hand, cancer cells are resistant to signals that control cell 
growth and even evade programmed cell death following their own agenda regarding 
proliferation. 
Carcinogenesis constitutes a multistep process through which cells acquire a series of 
genetic alterations that drive the progressive transformation of normal into malignant 
cells [23]. These alterations may be either inherited and/or result from a sequence of 
genetic events that leads to the acquisition of somatic mutations, these being acquired 
genetic alterations induced by spontaneous stochastic events, carcinogens and/or viral or 
bacterial infection. In addition to the mentioned alterations, epigenetic changes have also 
been associated with tumor development [24]. Epigenetics refers to alterations in the 
pattern of gene expression that are mediated by mechanisms independent from DNA 
sequence alterations, namely DNA methylation and histone modifications including 
methylation, acetylation, and phosphorylation [25]. These mechanisms usually result in 
inappropriate gene silencing or activation in tumor cells. 
Classically, two classes of cancer-related genes, oncogenes and tumor suppressor genes 
are described. Alterations in these genes are shown to induce clonal expansion leading to 
neoplastic initiation [26]. As previously introduced in Section 1.1, oncogenes refer to the 
mutated version of normal cell genes termed proto-oncogenes. These genes encode 
proteins involved in cell cycle progression as well as inhibition of cell differentiation and 
cell death pathways. The normal form of those proteins is of great importance for normal 
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cell development and tissue and organ maintenance. The malignant phenotype is acquired 
upon dominant gain-of-function mutations in these genes leading to increased cell 
division, and decreased cell differentiation and cell death [27]. Advances in the 
knowledge and identification of oncogenes were made through the study of retrovirus 
[28, 29]. The first oncogene discovered was SRC, identified by Peyton Rous following 
studies with Rous Sarcoma Virus (Fig.1.1) [19]. This gene is involved in a series of signal 
transduction cascades that influence cellular proliferation, differentiation, motility, and 
survival [30]. Similar studies led to the identification of the MYC oncogene, which is 
overexpressed in a wide range of human cancers. MYC oncogene is transcription factor 
that regulates the expression of several genes involved in cell proliferation, cell growth, 
and apoptosis [31]. Another example of oncogene is BCL-2 which unlike MYC oncogene 
promotes cellular survival rather than proliferation [32].  
Working in the opposite manner, tumor suppressor genes are known participants of 
several high conserved cellular functions such as regulation of cell cycle and apoptosis, 
differentiation, surveillance of genomic integrity and repair of DNA errors, signal 
transduction, and cell adhesion [33]. Consequently, inactivation of these genes confers 
tumor cell growth and survival advantages. Some authors defend the division of tumor 
suppressor genes in two major categories depending on their functions as gatekeeper or 
caretaker genes [34]. Gatekeeper genes are involved in the control of cell cycle 
progression, cell death, and differentiation while caretaker genes are involved in genomic 
stability maintenance and thus reducing the mutation rates of genes [34, 35]. Despite this 
simplified distinction between gatekeeper and caretaker tumor suppressor genes, one 
should take into account the fact that some genes may belong to both families, as the 
example of TP53 (also P53) [36]. 
The first tumor suppressor gene was identified by studies in retinoblastoma and led to 
subsequent identification of the retinoblastoma gene RB (Fig.1.1) [37, 38]. This gene 
encodes a nuclear protein that plays a central role in cell cycle progression being 
responsible for an important G1 checkpoint, blocking S-phase entry, and cell growth, 
promoting terminal differentiation and cell cycle exit [39]. Another well-studied tumor 
suppressor gene is TP53. This protein is often referred to as the “guardian of the genome” 
and plays critical roles in genetic stability maintenance, cell cycle regulation, metabolism, 
induction of apoptosis, senescence and differentiation control, both through genomic and 
non-genomic mechanisms [40]. 
  
1. CHAPTER 
10 Inês A. Barbosa │ University of Coimbra 
Clonal expansion initiation requires one or more mutations, somatic and/or inherited, 
which confer selective advantage to neoplastic cells over normal cells. Mutations in tumor 
suppressor genes can occur in the germ line while mutant versions of proto-oncogenes are 
rarely hereditary [26]. Although mutations that yield activated oncogenes might occur 
during gametogenesis, these usually disrupt normal tissue development due to their 
typical dominant nature. Consequently, embryos carrying these mutations are unlikely to 
be viable. In contrast, germ line mutations of tumor suppressor genes are often 
compatible with normal embryonic development, since these alleles are recessive at the 
cellular level [41]. It is however important to understand that germ line mutations in these 
genes do not cause cancer but rather predispose cells for further neoplastic development. 
Inheritance of these mutations increases the risk of tumor progression, as individuals 
often develop multiple tumors that occur at an earlier age than individuals whose cancer-
gene mutations occurred somatically. 
Taking all the above information into account, cancer should be understood as a highly 
complex and heterogeneous process, and as a disease resulting from the occurrence of a 
complex series of events [42, 43]. As referred, no single mutations causes cancer; in fact, 
it takes a stepwise accumulation of genetic alterations that affect discrete signaling 
pathways, each contributing for a specific aspect to the acquisition of a malignant 
phenotype. 
Although one cannot define the exact number of mutations required to achieve 
malignancy, as it varies between and within cancer types, research in the past decades led 
to the identification of several features acquired during the multistep development of 
human tumors. In 2000, Douglas Hanahan and Robert A. Weinberg proposed six 
hallmarks of cancer that provided an organized view for a better understanding of the 
diversity and complexity of neoplastic disease [44]. These include the acquisition of 
sustained proliferative signaling, ability to evade growth suppressors and cell death, 
development of limitless replicative potential, sustained angiogenesis, and activation of 
tissue invasion and metastasis (Fig.1.2). A decade later, the same authors revised their 
previous work integrating new obtained information in the field [45]. The conceptual 
progress on cancer research came to support and broaden the range of tumor capabilities. 
The redesigned work proposes the inclusion of two new emerging hallmarks, the ability of 
cancer cells to evade detection and elimination by immune system, and cellular energy 
metabolism reprograming [45]. Moreover, the authors suggested tumor-promoting 
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inflammation as an enabling characteristic. Additionally, the acquisition of the multiple 
hallmarks depends on the occurrence of alterations in the genomes of neoplastic cells, 
consequently genomic instability and mutations also constitute enabling characteristics 
for tumor progression [45]. Additionally, several studies also point out the importance of 
tumor microenvironment contribution to tumorigenesis, contrasting with the 
reductionist view of a tumor as nothing more than a group of fairly homogeneous cancer 
cells [46]. 
According to Hanahan and Weinberg the multistep pathway to malignancy involves the 
successive acquisition of these hallmark features by normal cells. The progressive 
development of such functional traits is thought to be common to most tumors albeit 
through different mechanistic strategies. The concept of cancer hallmarks is widely 
recognized and accepted throughout the scientific community as it provides useful basis 
for the understanding of cancer complexity. Moreover, considering the high 
heterogeneous nature of a tumor, its biology can only be addressed through the study of 
the individual specialized cell types within it. 
Figure 1.2 - The hallmarks of cancer. Acquired capabilities of cancer cells which allow them
to survive, proliferate, and disseminate. These functions are acquired by different tumors
through different mechanisms. Adapted from [45] with permission (Appendix A). 
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1.2.1 Cancer therapies: overview 
The remarkable progress of research into the mechanisms of cancer pathogenesis in the 
last decades led to important advances in the development of new therapies (Fig.1.1).  The 
increased understanding on the pathophysiology of the disease allowed a clear evolution 
of traditional cancer treatments, such as surgery, radiotherapy, and chemotherapy and 
the rise of new emerging therapeutic approaches, namely hormone therapy, 
immunotherapy and targeted therapy.  
For many centuries, surgery was the only available treatment for cancer and although a 
lot has changed since the first documented surgeries on cancer patients, this still 
constitutes one of the most important and widely used treatment methods. Today, 
surgical techniques and technologies are more precise, allowing a less invasive approach 
without sacrificing the efficiency of the process. These advances also contributed to the 
emergence of strategies to destroy tumors without removing them, including the use of 
cryosurgery and the use of lasers [47, 48]. Furthermore, robotic-assisted surgery has 
been introduced for treatment of several types of cancer, namely prostate and pancreatic 
cancer [49, 50]. However, surgery relies on prevention and early detection to minimize 
its impact and adverse effect as well as increases cure. 
Radiation therapy was introduced not long after x-ray discovery in 1895 by Wilhelm 
Roentgen, soon undergoing a great evolution as the early protocol of a single massive dose 
of radiation was shown to have severe side effects [6]. Today, due to advances in radiation 
physics and computer technology, it is possible to aim radiation more precisely. In 1990, a 
computer technique termed three dimensional planning began to be employed, compiling 
computed tomography (CT) scan information into a special computer to precisely pinpoint 
the location of tumors [51]. A decade later, additional technological leaps and the 
development of highly sophisticated machines allowed several other radiation therapy 
techniques to emerge, including the intensity-modulated radiation therapy (IMRT) and 
stereotactic radiosurgery (SRS) [52, 53]. 
Chemotherapy still constitutes an efficient cancer treatment. The increasing number of 
new drugs as well as their proper combination revealed to be advantageous in the battle 
against cancer. Research has been made regarding new drug delivery techniques in order 
to target cancer cells more effectively and to reduce the side effects. These include drug 
attachment to monoclonal antibodies, which can be designed to guide chemotherapy 
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drugs directly to tumor cells, and liposomal therapy [54, 55]. In the latter technique, drugs 
are incorporated inside liposomes allowing drug penetration in cancer cells. A new 
emerging technology consists in a nanoparticle-based drug delivery system [56, 57]. 
Cancer nanotechnology basic rationale consists in the development of nanoscaled 
molecular platforms carrying therapeutic compounds, which allows a precise tumor cell 
target while avoiding harming normal cells, and high reduction of side effects caused by 
the treatment. 
In the work developed by Thomas Beatson in 1896, the connection between ovaries and 
breast cancer development provided a foundation for the modern use of hormone therapy 
[58]. Later, in 1939, Charles Huggins discovered the importance of hormones in the 
development of certain cancers [59]. The better understanding of how hormones 
influence cancer growth provided insights to the development of a new class of drugs 
have been used to treat prostate and breast cancer [60, 61]. 
The increased knowledge on cancer biology led to the development of biological agents 
that mimic some of the natural signals that control cell growth to cancer therapy, 
including immunotherapy, which stimulates the immune system to fight cancer. 
Advances in the understanding of the molecular principles underlying the immune 
system role on cancer led to the development of several anti-cancer strategies that include 
immunostimulants, monoclonal antibodies, and cancer vaccines [62]. 
Research in molecular oncology has also increased the number of identified proteins 
whose malfunction contributes to the formation and maintenance of tumors. Some of 
these proteins constitute attractive targets for novel anti-cancer therapeutic agents. 
Targeted therapy refers to the systemic administration of drugs that specifically act on 
well-defined targets or biologic pathways which, when activated or inactivated, may 
cause regression or destruction of tumor cells, while minimizing adverse effects on 
nearby tissues [63, 64]. Moreover, the increased number of targeted anticancer 
therapeutics can be categorized according to their effects on the hallmark capabilities [45]. 
Considering cancer heterogeneity the appropriate combined use of several anticancer 
therapies may contribute more efficiently for treatment of the disease. Furthermore, the 
increased screening and the rise of more sensitive techniques results in a timely detection 
of tumors, which consequently increases therapeutic approach efficiency. Although there 
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is still no one cure for cancer, the advances on cancer knowledge so far led to remarkable 
improvements regarding cancer therapy and prevention. 
1.3 Cancer Incidence and Statistics 
Cancer is the leading cause of death worldwide accounting for 7.6 million deaths (or about 
13% of all deaths) in 2008. Cancer has a higher incidence in economically developing 
countries (4.8 million) than in economically developed countries (2.8 million) [65]. In 
2008, lung (1.37 million deaths), stomach (736,000 deaths), liver (695,000 deaths), 
colorectal (608,000 deaths), female breast (458,000 deaths), and cervical cancer 
(275,000 deaths) were the most prevalent cancer types accounting for about 40% of all 
diagnosed cases [66]. 
The global burden is expected to grow up to 21.4 million new cancers cases and 13.2 
million cancer deaths by 2030, based on population growth and aging as cancer incidence 
rises dramatically with age [67]. However, these numbers may get even higher due to the 
adoption of western lifestyles, namely smoking, poor diet, and reduced physical activity. 
Cancer occurrence varies geographically. The factors that contribute to these regional 
differences are related with the prevalence of major risk factors, availability and quality 
of cancer screening and treatment. For example, approximately 15% of all cancers are 
attributed to infections, this percentage being higher in developing countries (26%) than 
in developed countries (8%) [66]. Moreover, around 47% of cancer cases and 55% of 
cancer-associated deaths occur in less developed regions [68]. 
Cancer risk highly increases with age since around 78% of newly diagnosed cancers occur 
at the age of 55 or older in developed countries, this rate being lower in developing 
countries due to differences in age structure of the populations [66]. Although, inherited 
genetic alterations also contribute for increased cancer risk only about 5% of cancers are 
strongly hereditary. 
Between the years of 2002 to 2008, an estimate 68% survival rate for all diagnosed 
cancers was observed compared with the 49% in the years comprised between 1975 and 
1977 1. This improvement in survival reflects the progress in cancer diagnosis in an earlier 
                                                                
1 Statistics available on the public domain http://www.cancer.org. 
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stage and improvement of available treatments. In fact, a substantial proportion of all 
cancers can be prevented with the acquisition of healthier lifestyles, i.e. avoiding risk 
factors such as cigarette smoking or heavy alcohol consumption. Tobacco is by far the 
most important cancer risk factor being responsible for 22% of overall cancer deaths and 
71% of lung cancer deaths in 2008 [69, 70]. Other important risk factors include alcohol 
abuse, unhealthy diet and physical inactivity. 
Infectious agents, such as human papilloma virus (HPV), hepatitis B virus (HBV), and 
Helicobacter pylori, constitute other major cancer risk factor with estimated 16.4% new 
cases in 2008 [71]. Cancer associated with specific infections may also be prevented 
through behavioral changes, vaccination and/or antibiotics.  
In addition to prevention, regular screening tests allow early cancer detection and 
removal of pre-cancerous growths. Earlier detection results in less extensive treatment 
approaches allowing for better outcomes, and reduced mortality rates. However, 
screening has been proven to be effective in reducing mortality for only breast, cervical 
and colorectal cancers.  
Cancer awareness campaigns have been largely contributing for society knowledge of risk 
factors and their avoidance, leading to the observed increase in survival rates and quality 
of life. This reveals the importance of raising “educated populations”, meaning that the 
understanding of cancer complexity and how a healthy lifestyle and regular screening 
might contribute to a decrease in cancer incidence and mortality. Although the 
identification and study of factors that affect cancer development, cancer epidemiology, 
has revealed to be of extreme importance in the prevention of some types of cancer, the 
high complexity of this disease implies a multidisciplinary approach. 
1.3.1 Lung Cancer 
Lung cancer constitutes the most common deadly cancer, accounting for 13% of the total 
cancer cases diagnosed and 18% of the deaths in 2008 with a considerably higher 
incidence in men than in women [68]. In men, the highest lung cancer incidence rates 
were in Northern America, Europe, and Eastern Asia while the lowest rates were in sub-
Saharan Africa (Fig.1.3). Among women, the highest lung incidence rates were in 
Northern America, Northern Europe, and Eastern Asia (Fig.1.3). Interestingly, despite the 
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higher lung cancer rates, the prevalence of smoking is low among Chinese women. This 
apparent contradiction is explained by indoor air pollution from unventilated coal-fueled 
stoves and cooking fumes [72]. 
Geographic variations in lung cancer rates reflect differences in the stage and degree of 
tobacco consumption [73]. Moreover, the observed differences in lung cancer rates 
between genders are related with the fact that women only started smoking in large 
numbers decades later than men. 
Cigarette smoking constitutes the most important risk factor for lung cancer. Tobacco 
smoke contains several carcinogens, which include complex aromatic hydrocarbons, and 
nitrosamines [74]. These carcinogens may induce cellular genetic alterations that in turn 
may lead to oncogenic transformation. Other risk factors include second-hand smoke, 
occupational or environmental exposures to radon and asbestos, as well as to air pollution 
Figure 1.3 - Lung cancer incidence. World age-standardized lung cancer incidence rates by 
sex and world area. Source: GLOBOCAN 2008, in globocan.iarc.fr. 
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[75]. In addition, genetic susceptibility is also known to increase the risk of lung cancer 
development [76]. Moreover, some individuals might also spontaneously develop lung 
cancer without any exposure to carcinogens. 
Overall, lung cancer is one of the most preventable cancers. Worldwide burden of lung 
cancer could be decreased by implementation of tobacco control interventions that 
include significantly increasing the price of cigarettes, banning smoking in public places, 
restricting advertisement, and counter advertising in order to achieve lower smoking 
rates.  
Treatment and prognosis depend on the type of lung cancer (small versus non-small cell) 
and stage at diagnosis. Standard oncological therapies are effective in the treatment of 
some lung cancer cases. Localized carcinomas are usually removed through surgery. 
Moreover, survival with early detection of non-small cell lung cancer improved by 
combination treatment with chemotherapy followed by surgery. However, considering 
the rapid lung cancer cell division, by the time small cell lung cancers are detected, these 
are already disseminated resulting in a poorer prognosis when compared to early 
detection of non-small cell lung cancer [77]. 
Lung cancer is usually characterized by a poor prognosis with a five-year survival rate of 
around 15%. The five-year survival rate reaches the 53% for cases of early detection2. 
However, the majority of the cases are only diagnosed in an advanced stage of 
progression. Despite the advances in treatment methods, and combined therapies, lung 
cancer is still one of the most lethal cancers. 
 
                                                                
2 Statistics from 1975 to 2007 available at http://seer.cancer.gov/csr/1975_2007/. 
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Mitochondria have many roles in normal cells: they are the main producers of energy via 
oxidative phosphorylation, they produce many metabolic intermediates, and they 
mediate the intrinsic and extrinsic apoptotic pathways [78]. Mitochondria have these 
same essential roles in cancer cells. However, mitochondria undergo profound changes 
during oncogenesis, which commonly result in altered energy metabolism, resistance to 
apoptosis and increased production of reactive oxygen species (ROS). This section aims to 
review recent developments in cancer mitochondrial metabolism research, with the goal 
of better understanding the role of mitochondrial changes in the pathogenesis of cancer 
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and the potential for novel therapies targeting these changes. It starts by reviewing 
mitochondrial oncogenic alterations “Mitochondria in tumors cells”. This will include 
alterations of mitochondrial metabolism (Section 2.1) and oxidative stress (Section 2.2) in 
cancer cells; followed by what is known about the role of mtDNA alterations in cancer 
progression (Section 2.3) and alterations in mitochondrial mitochondrial membrane 
potential in tumors (Section 2.4). 
2.1 The Warburg Effect and mitochondrial metabolism 
in tumor cells 
2.1.1 The Warburg effect 
Often called the furnace of the cell, mitochondria synthesize the vast majority of chemical 
energy (in the form of adenosine triphosphate, ATP) that cells use for anabolism and 
catabolism. Under normoxic conditions, cells normally rely on aerobic respiration which 
makes use of both cytosolic and mitochondrial processes to generate energy via oxidation 
of glucose, fatty acids and amino acids. In this process, glucose is partially oxidized to 
pyruvate in the cytosol. Pyruvate is then imported into mitochondria where it is fully 
oxidized in two stages, including a first set of reactions in the tricarboxylic acid (TCA) 
cycle and then a stepwise oxidation of resulting metabolites through the electron 
transport chain (a process also known as oxidative phosphorylation or OXPHOS). Other 
metabolic substrates that feed into the TCA cycle are fatty acids via beta oxidation to 
acetyl coenzyme A (acetyl-CoA), and glutamine via serial deamination of glutamine to 
glutamate and then to alpha-ketoglutarate [79]. 
Although aerobic respiration in mitochondria is the most efficient method of energy 
generation, it requires non-limiting oxygen availability. When oxygen levels are low, 
untransformed cells rely on an alternative cytosolic process, glycolysis, followed by lactic 
acid fermentation. In this process, glucose is converted to pyruvate by means of 
glycolysis, but pyruvate is then reduced to lactate by lactate dehydrogenase in the 
presence of NADH (nicotinamide adenine dinucleotide) rather than being transported into 
the mitochondria. This process generates far less energy per molecule of glucose than 
OXPHOS, but allows the cell to continue generating energy under hypoxic conditions. 
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The initial observation linking altered mitochondrial metabolism to cancer was made by 
Otto Warburg in a classic study of tumor energy metabolism [80]. Using slices of living 
tissue, Warburg observed that whereas normal cells use lactic acid fermentation only in 
the absence of oxygen, tumor cells show increased levels of lactic acid production even 
under aerobic conditions [80]. Warburg proposed that neoplastic cells undergo a 
metabolic shift from aerobic respiration to aerobic glycolysis, involving lactic acid 
fermentation, which would occur even at normal oxygen tensions. This shift is now 
recognized as the Warburg effect. Warburg further proposed that cancer cells rely on less 
efficient aerobic glycolysis to achieve their energy requirements due to defects in the 
oxidative phosphorylation metabolic pathway [81]. According to this model the first step 
in cancer development is an irreversible defect in the OXPHOS pathway which stimulates 
an upregulation of lactic acid fermentation [81]. 
Subsequent work has confirmed that a shift from oxidative phosphorylation to glycolysis 
as primary energy source is prevalent among many types of cancers [82]. Further, this 
work has substantiated the key role of mitochondrial alterations in development of cancer 
[83]. However, the Warburg effect is now seen in the context of a set of concerted changes 
in energy metabolism and mitochondrial function that support oncogenesis. This process, 
often referred to as metabolic reprogramming [84], is proposed to support deregulated 
proliferation that is an essential feature of cancer cells. 
2.1.2 Metabolic reprogramming provides a selective advantage 
for cancer cells 
Metabolic reprogramming in cancer is commonly characterized by two major changes in 
energy metabolism: reliance on glycolysis rather than oxidative phosphorylation for 
oxidation of glucose, and increased use of glutamine as an energy source (Fig.2.1). 
Glycolytic remodeling  
Since glycolysis is far less efficient than oxidative phosphorylation in generating ATP, the 
question arises as to how glycolysis can provide a selective advantage for rapidly dividing 
cancer cells, which have high metabolic requirements. Warburg initially proposed that 
increased glycolysis is an adaptive response to tumor hypoxia, which is consistent with 
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the fact that tumor cells have to survive in adverse environments characterized by 
variable oxygen and nutrient supplies, pressuring these cells to adapt their metabolism to 
the new environment. However, as Warburg himself pointed out, tumors are often highly 
glycolytic before being exposed to low oxygen conditions suggesting hypoxia is not the 
only trigger for the metabolic shift [84]. 
An alternate explanation is that although glycolysis generates far less ATP per glucose 
than oxidative phosphorylation, it does generate ATP more rapidly. Even in severe 
pathology and malnutrition, the liver maintains serum glucose concentration within a 
narrow range. In a situation where glucose supply is not a problem, the more rapid 
generation of ATP by glycolysis may be better suited to supply the energy needs of rapidly 
proliferating cells than the arguably more “efficient” OXPHOS. In support of this idea, 
normal embryonic cells undergoing rapid proliferation display similar reliance on 
glycolysis [85]. Further, alterations that result in increased intracellular glucose levels are 
common in cancer cells (Fig.2.1). These include increased expression of glucose 
transporters [86], and alternate hexokinase isoforms [87] and increased transcription of 
glycolytic enzymes [88-90]. An additional selective advantage may be provided by export 
of lactate generated by increased glycolysis, which may contribute to oncogenesis via 
decreased extracellular pH, leading to increased activity of pro-invasion factors such as 
matrix metalloproteases and hyaluran, and, re-moving the physical barriers to tumor cell 
expansion and invasion into healthy tissue [91-93]. 
However, the most compelling explanation for metabolic remodeling of the glycolytic 
pathway is that it creates the capability to generate increased levels of biosynthetic 
intermediates via increased flux through several biosynthetic pathways. For example, the 
pentose phosphate pathway has an increased importance in cancer cells, because their 
rapid proliferation requires rapid generation of nucleotides as well as fatty acids and 
other components of cell membranes. As a result, glucose-6-phosphate is diverted from 
ATP production to the generation of ribose-6-phosphate and NADPH (nicotinamide 
adenine dinucleotide phosphate) [94, 95]. Increased use of the pentose phosphate 
pathway may be promoted by a tumor-specific pyruvate kinase isoform, PKM2, which 
catalyzes the final rate-limiting step in glycolysis. The increased expression of PKM2 in 
cancer cells is due to mutually exclusive exon splicing [96] and was shown to be required 
for aerobic glycolysis in tumor cells as well as for tumor growth [90]. The PKM2 isoform 
has a lower Km than the other three PK isoforms, and PKM2 is further inhibited by 
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phosphorylated tyrosines, which are abundant in cancer cells with hyperactive growth 
factor signaling pathways. Expression of the PKM2 isoform may promote the channeling 
of glycolytic intermediates through the pentose phosphate pathway. Tumor cells 
expressing the low-activity PKM2 isoform show an increase in upstream glycolytic 
metabolites [88], suggesting that the slower glycolysis promoted by less active PKM2 
allows glycolytic intermediates to be used for alternate biosynthetic pathways as well as 
for the maintenance of redox balance needed for to support a rapid cell division [97]. 
Glutamine metabolism  
Tumor cells undergo a second major shift in energy metabolism, a dramatic upregulation 
in glutamine consumption (Fig.2.1). Rossignol et al demonstrated that HeLa cells, which 
ordinarily show high rates of glycolysis typical of cancer cell, can survive using glutamine 
alone as a carbon source in a process that requires the TCA cycle and oxidative 
phosphorylation [98]. This work demonstrated that the shift to glycolysis could be 
reversed and thus that it was not necessarily due to mitochondrial defects. In addition, the 
work by Rossignol et al provided an indication of the importance of glutamine metabolism 
for growth of transformed cells. Conversion of glutamine into lactate via malate 
dehydrogenase produces NADPH, which is required for de novo synthesis of fatty acids, 
thus fulfilling an important metabolic need of cancer cells [99]. Glutamine has also been 
reported to be essential for RAS-mediated anchorage independent growth of HCT116 
colorectal cancer cells. In this case, glutamine metabolism via the TCA cycle generates 
ROS that stimulate ERK (extracellular signal-regulated kinase) proliferation signaling 
pathways [100]. Similarly, glutaminase was found to be essential for transformed 
phenotype of NIH-3T3 cells and the human breast cancer cell lines MD-MBA-231 and 
SKBR3 [101]. These studies have established altered glutamine metabolism as a second 
metabolic alteration in cancer cells, thus supporting that the shift to glycolysis is only one 
part of a complex network of metabolic reprogramming (Fig.2.1). 
Regulation of metabolic reprogramming 
In many cases, metabolic reprogramming seems to be directed by oncogenic changes in 
several interconnected cell signaling pathways including phosphatidylinositol 3-kinase 
(PI3K) and AMP-activated protein kinase (AMPK) pathways. In normal cells these 
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Figure 2.1 - Metabolic remodeling in cancer cells. Metabolic reprogramming in cancer is 
characterized by two major adjustments in energy metabolism, increased glycolysis and 
increased use of glutamine as an energy source. These alterations are due to oncogenic 
changes in several interconnected cell-signaling pathways, which seem to be responsible for 
the observed metabolic shift. PIK3 activation by various growth factors triggers (bold 
arrows) a signaling cascade that includes AKT and mTOR. Moreover, mutations in AMPK 
activator LKB1 are also known to contribute for AKT/mTOR pathway activation through 
repression (dash arrows) of mTOR inhibition. In turn, mTOR/AKT pathway activation 
results in GSK3 inhibition and consequent concomitant expression of GS, and also in the 
upregulation of MYC and HIF1α transcription factors, contributing to metabolic changes. In 
contrast to normal cells, HIF1α expression is stabilized in tumor cells even under normoxic 
conditions due to PTEN, VHL, and PHD loss of function mutations (in red). HIF1α 
constitutive expression promotes transcription (square dot arrows) of genes responsible for 
an increase in glycolytic pathway those include increased expression (in green) of GLUT1 
and GLUT3 transporters; alternate isoforms of glycolytic pathway enzymes HK2 and PKM2; 
LDHA, and PDK1. Expression of MYC is also known to favor the glycolytic pathway through 
increased expression of glucose transporters and glycolytic enzymes (square dot arrows). 
PKM2 increased activity promotes a shuttle of glycolytic substrates through the pentose 
phosphate pathway. Furthermore, MYC promotes an increase in glutamine metabolism 
through increased transcription of transporters like SLC5A1, and through increased 
expression of GLS. Abbreviations: AKT — serine/threonine protein kinase; AMPK — AMP-
activated protein kinase; GLS — glutaminase; GLUT — glucose transporter; GS — glycogen 
synthase; GSK-3 — glycogen synthase kinase 3; HIF1α — hypoxia inducible factor 1, alpha 
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subunit; HK2 — hexokinase 2; α-KG — alpha ketoglutarate; LDHA — lactate dehydro-
genase A; LKB1 — serine/threonine kinase 11; mTOR — mechanistic target of rapamycin 
(serine/threonine kinase); MYC — v-Myc myelocytomatosis viral oncogene homolog; PDH 
— pyruvate dehydrogenase; PDK1 — pyruvate dehydrogenase kinase, isoenzyme 1; PHD — 
prolyl hydroxylase; PIK3 — phosphatidylinositol 3-kinase; PIP — phosphatidylinositol 
phosphate; PKM2 — pyruvate kinase, muscle 2; PTEN — phosphatase and tensin homolog; 
SLC5A1 — solute carrier family 5 (sodium/glucose cotransporter), member 1; VHL — Von 
Hippel–Lindau tumor suppressor. 
pathways regulate metabolic pathways in response to environmental conditions including 
nutrient availability, O2 levels and growth factors. Cancer cells, however, accumulate 
mutations that remove environmental constraints (Fig.2.1). PI3 kinase is activated by 
various growth factors binding to their receptor tyrosine kinases. PI3 kinase in turn 
activates a signaling cascade including AKT and mTOR kinases. These kinases upregulate 
expression of the MYC and hypoxic transcription factor (HIF) transcription factors, which 
in turn, upregulate the glycolytic pathway as a whole [80]. 
In normal cells, HIF1α is rapidly degraded under normoxic conditions and only stabilized 
under hypoxic conditions. When stabilized, HIF1α, in complex with HIF1β, promotes 
increased transcription of genes necessary for normal cells to increase glycolytic capacity. 
These include GLUT1 and GLUT3 glucose transporters, nine of the ten glycolytic enzymes, 
lactate dehydrogenase (LDH), the enzyme that catalyzes conversion of pyruvate to 
lactate, and pyruvate dehydrogenase kinase (PDK), which inhibits pyruvate oxidation in 
mitochondria [102]. However, common oncogenic mutations inactivate PTEN 
(phosphatase and tensin homolog), a PI3 kinase inhibitor, and VHL (von Hippel-Lindau 
tumor supressor), required for oxygen-dependent destabilization of HIF1α. Thus, in 
tumor cells, HIF1α can be stabilized even under normoxic conditions so that glycolysis is 
enhanced even in the presence of oxygen [103]. 
Expression of MYC also favors the glycolytic pathway through increased expression of 
glucose transporters and glycolytic enzymes. MYC also promotes increased glutamine 
metabolism associated with oncogenesis through increased transcription of transporters 
SLC5A1 and SLC7A1, and through increased expression of the glutaminase GLS1 [80]. 
Increased expression of glutaminase occurs through transcriptional regulation and 
through repression of inhibitory miRNA23a and miRNA23b [104]. MYC is normally 
activated in response to signaling pathways initiated by growth factors binding to their 
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receptors. In cancer, MYC is commonly activated in the absence of growth factor signaling 
by mutations that cause constitutive activation of AKT and mTOR [80]. 
In contrast to PI3K, AMPK acts to limit glycolysis by acting as a cellular energy sensor. In 
response to elevated AMP/ATP ratios, AMPK promotes oxidative phosphorylation and 
inhibits proliferation, in part by inhibiting mTOR kinase. Interestingly, mutations in the 
up-stream AMPK activator, LKB1, are common in cancers [105]. 
Multiple mechanisms for activation of HIF1α and MYC point to the importance of the shift 
to glycolysis for cancer cells [80]. The fact that activation is triggered by common 
oncogenic signaling pathways suggests that this shift is an essential component of the 
oncogenic program. 
Recently, HIF1α activation has been implicated in driving metabolic changes in cancer-
associated fibroblasts. Cancer-associated fibroblasts have been found to be deficient in 
Caveolin-1 (Cav-1) [101]. Loss of Cav-1 combined with increased ROS produced by 
neighboring cancer cells results in stabilization of HIF1α. HIF1α-mediated upregulation of 
glycolytic enzymes results in the over-production of pyruvate and lactate that can be 
secreted into the medium and fuel the oxidative metabolism in adjacent tumor cells. This 
phenomenon is termed the “Reverse Warburg effect” [106-108]. 
Mitochondrial succinate dehydrogenase and fumarate hydratase as tumor 
suppressors 
Although Warburg initially characterized cancer as an injury to respiration, until recently 
no respiratory chain oncogenes or tumor suppressors had been identified. However, the 
importance of HIF1α signaling was underscored by the discovery of succinate 
dehydrogenase (SDH) and fumarate hydratase (FH) as tumor suppressors [109]. Both SDH 
and FH are TCA cycle enzymes which act to convert succinate to fumarate and fumarate 
to malate, respectively. SDH is also a functional member of the electron transport chain 
(ETC) forming complex II [109]. Oncogenic mutations result in an accumulation of their 
substrates, succinate and fumarate, in the cytosol, leading to a pseudohypoxic response 
and activation of glycolytic enzymes [110] through inhibition of prolyl hydratase enzyme, 
the first step of HIF degradation [111]. Loss of function mutations in SDH lead to the 
development of paraganglioma and phaeochromocytoma [112], while mutations in FH 
have been implicated in leiomyoma, leiomyosarcoma, and renal cell carcinoma [111]. 
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2.1.3 Targeting aerobic glycolysis 
Since one of the main phenotypes presented in most cancer cells is their high glycolytic 
rate [113], the exploitation of the Warburg effect could represent an approach to perturb 
and efficiently kill malignant cells by using proper glycolytic inhibitors (Fig.2.2 and Table 
2.1). 2-Deoxyglucose (2-DG), a glucose analog which is metabolically inactive, and 3-
bromopyruvate, a lactic acid analog undergoing preclinical trials, constitute two examples 
of chemical compounds that inhibit glycolysis. Both 2-DG and 3-bromopyruvate 
treatment lead to ATP depletion which in turn results in dephosphorylation of the pro-
apoptotic BAD protein, BAX migration to mitochondria, permeabilization of 
mitochondrial outer membrane and consequent cell death [114] with minimal toxic effects 
to normal cells [115]. Suppression of intracellular ATP level by 2-DG alone or in 
combination with glucose-free medium promotes Fas-induced phosphatidylserine 
externalization during apoptosis [116]. 2-DG compromises glycolytic metabolism through 
the ability to competitively inhibit hexokinase, decreasing its association with the outer 
mitochondrial membrane and decreasing the threshold for mitochondrial induction of 
apoptosis [117]. In addition, 2-DG enhances the anticancer activity of doxorubicin and 
paclitaxel [118], and acts synergistically with histone deacetylase inhibitors [119]. 3-
Bromopyruvate also inhibits hexokinase, and when used in combination with mTOR 
inhibitors, displays synergistic effects on leukemia and lymphoma cells [120, 121]. 
Whether 3-bromopyruvate will move forward to clinical trials is still uncertain at this 
time. 
Lonidamine, a derivative of indazole-3-carboxylic acid, inhibits glycolysis under hypoxic 
conditions [122] and has also been demonstrated to inhibit the mitochondrial adenine 
nucleotide translocase (ANT) [123]. Despite its anticancer efficacy, lonidamine is toxic to 
non-tumor tissues. In fact, toxicity was observed when lonidamine was co-administrated 
with doxorubicin, cyclophosphamide or cisplatin to a mouse xenograft model [124]. In a 
dog model, lonidamine was also shown to cause hepatoxicity [125]. Despite the potential 
liabilities to non-tumor tissues, lonidamine is currently undergoing phase III/IV clinical 
trials, after promising phase II–III trials [126, 127]. 
Dichloroacetate (DCA), a pyruvate analog, stimulates pyruvate dehydrogenase enzyme 
(PDH) through the inhibition of PDK1. DCA has an inhibitory impact in cancer cells with 
altered mitochondrial activity [128], while showing no effect on normal cells [129]. 
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Table 2.1 - Summary of the anti-cancer agents and phase of their clinical development. 
Agent Cellular Target Phase of clinical development References 
  Pre-Clinical Clinical Trials  
  
in
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o 
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e 
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Ph
as
e 
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2-DG HK2 ✓ ✓ ✓ ✓ − − NCT00633087 a 
2-ME Cu–ZnSOD ✓ ✓ ✓ ✓ − − [130] 
MnSOD 
3-Bromopyruvate HK2 ✓ ✓ − − − − [115] 
5-Aminolevulinic acid OXPHOS ✓ ✓ ✓ − − − [131] 
ABT-263 BCL-2 ✓ ✓ ✓ ✓ − − [132] 
ABT-737 BCL-2 ✓ ✓ − − − − [133] 
Antimycin A OXPHOS ✓ ✓ − − − − [134] 
As2O3 OXPHOS ✓ ✓ ✓ ✓ ✓ ✓ [135] 
ANT, VDAC 
Berberine OXPHOS ✓ ✓ − − − − [136] 
ANT 
Bismaleimido-hexane ANT ✓ − − − − − [137] 
Bullatacin OXPHOS ✓ ✓ − − − − [138] 
Cisplatin DNA ✓ ✓ ✓ ✓ ✓ ✓ [139] 
Curcumin BAX, ✓ ✓ ✓ ✓ − − [140] 
 BCL-2, BCL-XL 
DCA PDH ✓ ✓ ✓ − − − [128] 
Dithiodipyridine ANT ✓ ✓ − − − − [141] 
Doxorubicin OXPHOS ✓ ✓ ✓ ✓ ✓ ✓ [142] 
EGCG HSP70, HSP90 ✓ ✓ − − − − [143, 144] 
p68 
F16 OXPHOS ✓ − − − − − [145] 
FGIN-1-27 PBR ✓ ✓ − − − − [146] 
Gossypol BCL-2, BCL-XL  ✓ ✓ ✓ ✓ − − [147] 
HA14-1 BCL-2 ✓ ✓ − − − − [148] 
Lonidamine HK2 ✓ ✓ ✓ ✓ ✓ ✓ [126, 127] 
ANT 
Menadione Redox-cycling 
agent 
✓ ✓ ✓ ✓ − − [149] 
Metformin AMPK ✓ ✓ ✓ ✓ − − [150] 
MKT-077 mtDNA ✓ ✓ ✓ − − − [151] 
Motexafin gadolinium AKT ✓ ✓ ✓ ✓ ✓ − [152] 
Obatoclax BCL-2, BCL-XL  ✓ ✓ ✓ ✓ − − [153] 
Oligomycin OXPHOS ✓ − − − − − [134] 
PEITCs GSH ✓ ✓ − − − − [154] 
Phloretin GLUT2 ✓ ✓ − − − − [155] 
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Agent Cellular Target Phase of clinical development References 
  Pre-Clinical Clinical Trials  
  
in
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I 
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e 
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e 
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PK11195 PBR ✓ ✓ − − − − [156] 
Resveratrol OXPHOS ✓ ✓ ✓ ✓ − − [157] 
Rhodamine-123 OXPHOS ✓ ✓ ✓ − − − [151, 158] 
Ro5-4864 PBR ✓ ✓ − − − − [159] 
Rolliniastatin OXPHOS ✓ ✓ − − − − [160] 
Rotenone OXPHOS ✓ ✓ − − − − [161] 
Sanguinarine OXPHOS ✓ ✓ − − − − [162] 
Thenoyltrifluoroacetone OXPHOS ✓ − − − − − [163] 
Troglitazone PPARγ ✓ ✓ ✓ ✓ − − [164] 
Vinblastine DNA ✓ ✓ ✓ ✓ − − [165] 
α-TOS OXPHOS ✓ ✓ − − − − [166] 
β-Lapachone NQO1 ✓ ✓ − − − − [167] 
* Clinical trials number identifier found in http://clinicaltrials.gov at April 16, 2012. 
Abreviations: AKT – serine/threonine protein kinase; AMPK – AMP-activated protein 
kinase; ANT – Adenine nucleotide translocase; BCL-2 – B-cell CLL/lymphoma 2; BCL-XL – B-
cell lymphoma extra large; BAX – Bcl-2 associated X protein; DCA – Dichloroacetate; 2-DG – 
2-Deoxyglucose; DNA – Deoxyribonucleic acid; mtDNA – Mitochondrial DNA; EGCG – 
Epigallocatechin-3-gallate; GLUT – Glucose transporter; GSH – Glutathione; HK2 – 
Hexokinase 2; 2-ME – 2-Methoxyestradiol; OXPHOS – Oxidative phosphorylation; NQO1 – 
NAD(P)H quinone oxidoreductase 1; PBR – Peripheral benzodiazepine receptor; PDH – 
Pyruvate dehydrogenase; PEITC – Phenyl ethyl isothiocyanates; PPARγ – Peroxisome 
proliferator activated receptor gamma; SOD – Superoxide dismutase; α-TOS – alpha 
tocopherol succinate; VDAC – Voltage-dependent anion channel. 
DCA indirectly stimulates con-version of pyruvate to acetyl-CoA and up-regulates 
mitochondrial metabolism [128, 168]. It is suggested that mitochondria in several types of 
tumors are particularly susceptible to this transition as their metabolism is not able to 
quickly restart oxidative phosphorylation; instead, mitochondria suffer apoptotic 
alterations and trigger cell death [128, 168]. DCA is currently undergoing Phase I clinical 
trials after several in vitro studies and clinical trials for the improvement of mitochondrial 
diseases [128]. Despite this, doubts remain on the joint use of DCA with other conventional 
and clinically used chemotherapeutics [169]. 
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Besides the effects of inhibition of the glycolytic pathway, suppression of glucose 
transport might also sensitize tumor cells to anti-cancer agents. For instance, phloretin, a 
glucose transporter inhibitor, was reported to profoundly enhance the anticancer effects 
of daunorubicin [170], although further studies need to be performed to even consider the 
use of that agent in clinical trials. 
2.2 Altered mitochondrial oxidant production in cancer 
cells 
Reactive oxygen species are a component of cell signaling pathways in normal cells, 
regulating proliferation, gene transcription and metabolism, among others [171]. Some 
species, especially hydrogen peroxide (H2O2), act as important intracellular messengers 
which can regulate both cell death and survival [172, 173]. The mitochondrial electron 
transport chain is considered one important site for ROS production, with ten different 
sites recognized to participate in ROS generation [174] and several more regulated by 
redox alterations [175]. Antioxidant mechanisms in mitochondria have both an enzymatic 
and non-enzymatic component. Enzymes such as manganese-superoxide dismutase 
(SOD2), glutathione peroxidase (GPx), glutathione reductase (GRed), peroxiredoxins, 
glutaredoxins and proteins such as cytochrome c itself can contribute to ROS 
detoxification [174]. Non-enzymatic defenses include reduced glutathione (GSH) and a 
high NAD(P)H/NAD(P) ratio. When ROS generation overloads antioxidant defenses, 
generalized oxidative stress occurs, which can trigger cell death [176]. 
In cancer cells, ROS production is often augmented [177], which in turn acts to induce 
genetic instability through the accumulation of mutations [178]. The exposure to a 
hypoxic environment enhances mitochondrial ROS production [179], although this 
appears to be counter-intuitive. Cells exposed to hypoxia respond acutely through 
production of endogenous metabolites and proteins that regulate metabolic pathways. 
However, when present in a continuous low oxygen microenvironment, cells activate 
adaptive mechanisms including HIF1α [180], which also result in increased ROS 
production by still fairly unknown mechanisms [181] and which contribute to metabolic 
remodeling. One particular source of mitochondrial ROS is p66Shc, which has been 
implicated in carcinogenesis. As an example, p66Shc-derived ROS has been implicated in 
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androgen-induced prostate cancer cell proliferation and early prostate carcinogenesis 
[182]. p66SHC was initially thought to use reducing equivalents derived from the 
mitochondrial ETC to produce H2O2 in the intermembrane space [183]. Recent evidence 
suggests that p66Shc increases mitochondrial oxidative stress by negatively regulating 
SOD2 activity [184]. p66SHC null fibroblasts were shown to be resistant to ROS-induced 
apoptosis in a TP53 dependent manner, indicating that p66Shc has a downstream effect 
from TP53 [184, 185]. Among the mitochondrial enzymatic systems described above, 
SOD2 is one of the most effective antioxidant enzymes with anti-tumor activity [186]. In 
fact, overexpression of SOD2 in several cell lines leads to tumor growth retardation [187]. 
Further, SOD2 activity was found to be rather low in many cancers [187], with evidence 
pointing to a defect in gene expression rather than to its deletion, most likely due to 
epigenetic silencing [186]. For certain tumor cells, the activity of total SOD has also been 
found to be reduced [188]. However, overexpression of mitochondrial SOD2 correlates 
with poor prognosis, advanced stages of progression, and an invasive and metastatic 
profile in cancers of the gastrointestinal tract while SOD expression and activity appear 
unchanged in some tumor cells [189, 190]. The heterogeneity of SOD expression levels 
suggests that different cancers or cancer stages may have different optimal levels of 
oxidative stress or may use alternate pathways to manage oxidative stress. 
Another important contributor to ROS generation in mitochondria from cancer cells is the 
respiratory chain, namely proteins that are found mutated in cancer. For example, a 
mutation in SDH subunit C results in increased superoxide anion production, oxidative 
stress, increased glucose consumption and genomic instability [191]. The effects were 
mimicked by inhibitors of the respiratory chain and also resulted in increased glucose 
deprivation‐induced stress on cancer cells [192]. Mutations of SDH gene, including those 
affecting subunit C, have been associated with rare paragangliomas [193], suggesting that 
mitochondrial oxidative stress resulting from SDH mutations may be one driving force for 
the development of this type of tumors. 
Based on these observations, it appears that alterations in mitochondrial antioxidant 
machinery and free radical production exist in mitochondria from tumor cells, although 
differences vary according to the tumor type. One logical explanation is that antioxidant 
defenses must be regulated to a point in which ROS are high enough to be effective in 
generating a malignant phenotype, but controlled enough to avoid triggering cell death. 
Nevertheless, increased oxidative stress in cancer not only contributes to metabolic 
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remodeling via HIF1α, but also promotes the malignant phenotype via the activation of 
several survival pathways, disruption of cell-death signaling, and increased cell 
proliferation [178]. In addition, it has been proposed that increased mitochondrial and 
non-mitochondrial oxidative stress in the primary site may increase the likelihood of 
metastasis progression [194] and regulate angiogenesis [195]. 
2.2.1 Targeting mitochondrial oxidative stress in tumor cells 
As described above, some types of tumors are characterized for having increased 
oxidative stress and altered modulation of antioxidant defenses. In some particular cases, 
it can be envisioned that overloading the antioxidant defenses by increasing 
mitochondrial oxidative stress over a certain threshold may lead to cell death. In normal 
cells, the same process would take longer to occur since basal mitochondrial oxidative 
stress would be lower. In fact, many anti-tumor agents have been reported to act as pro-
oxidant agents, disturbing the mitochondrial respiratory chain and leading to further 
increase in mitochondrial oxidative stress [196], with example being cisplatin, vinblastine 
and doxorubicin [165] (Fig.2.2 and Table 2.1). These three agents were thought to inhibit 
cancer cell proliferation primarily through DNA-related mechanisms; however 
mitochondria is an important secondary target. Anthracyclines are chemotherapeutic 
agents that have multiple effects on mitochondria of both healthy and tumor cells [197]. 
For example, Oliveira and Wallace demonstrated that doxorubicin-induced cardiac 
toxicity relates with oxidative stress, inhibition of mitochondrial respiration and 
increased mitochondrial permeability transition (MPT), which also involved inhibition of 
ANT expression [142]. Other studies indicate that menadione (2-methyl-1,4-
naphthoquinone), bismaleimido-hexane, and dithiodipyridine also act as ANT thiol 
oxidizing agents overcoming BCL-2 mediated protection [137]. Despite the interesting 
results in vitro, these three agents require further characterization before being tested 
under clinical trials. 
In addition, agents such as motexafin gadolinium and β-lapachone (ARQ 501) are also 
known for triggering excessive ROS production. The former is characterized by a high 
oxidizing potential inhibiting antioxidant systems whereas the second undergoes several 
redox cycles catalyzed by NAD(P)H quinone oxidoreductase 1 (NQO1) [167]. From the two, 
  
 SECTION 2.2
PhD in Biology – Specialization in Cell Biology 33
only motexafin gadolinium is currently undergoing Phase II clinical trials, although 
results were modest against refractory chronic lymphocytic leukemia [198]. 
Chemicals that resemble ubiquinone can act to inhibit complex II via competitive binding; 
examples are some benzoquinone derivatives, monoamine oxidase inhibitors and vitamin 
E analogs. For instance, agents such as α-tocopherol succinate (α-TOS) a vitamin E analog, 
represent excellent candidates for cancer therapy. α-TOS competes with ubiquinone in 
binding to Q sites on complex II of the respiratory chain. This connection disrupts the 
electron flux and destabilizes the mitochondrial membrane, consequently generating 
superoxide anion [166]. Furthermore, α-TOS promotes BAX translocation to the 
mitochondria and subsequent cytochrome c release resulting in programmed cell death 
[199]. Treatment with α-TOS seems to be selective for tumor cells since it is not toxic for 
normal cells due to their differential metabolism of the parent compound [200, 201]. 
Despite very promising in vitro data, still no clinical trials are being performed with α-
TOS. 
In addition to the mentioned drugs, arsenic trioxide also promotes ROS increase by 
increasing electron leakage in the mitochondrial electron chain [202]. Numerous results 
show that arsenic trioxide (As2O3) treatment of cultured cells decreased oxygen 
consumption and increased superoxide production, indicating a disturbance of 
mitochondrial respiration [202-204]. At low doses, arsenic trioxide exerts an anticancer 
effect on tumor cells with no acute toxic effects on normal cells [205]. Arsenic trioxide is 
currently undergoing phase III/IV clinical trials and human data shows that consolidation 
to standard induction and consolidation therapy significantly improves event-free and 
disease-free survival in adults with newly diagnosed acute promyelocytic leukemia (ACL) 
[135]. Also, arsenic trioxide was found to be effective when used alone in terms of durable 
response and safe in new cases of diagnosed ACL [206]. 
On the other hand, inhibition of antioxidant systems constitutes an alternative approach 
to increase ROS accumulation in tumor cells. High levels of GSH have been associated 
with tumor drug resistant phenotype therefore depletion of cellular GSH can restore 
sensitivity to the cytotoxic effect of an anticancer drug. Phenyl ethyl isothiocyanates 
(PEITCs) stimulates or activates phase II detoxification enzymes exerting a potent 
chemotherapeutic effect without elevated toxicity to normal cells [154]. PEITC's 
mechanism of action relies on the inhibition of glutathione antioxidant pool by modifying 
thiol groups in malignant cells [207]. Consequently, the excessive ROS output results in 
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oxidative mitochondrial damage and cell death. The idea looks attractive in vitro but 
clinical trials are needed to demonstrate the validity of this approach. 
2-Methoxyestradiol (2-ME), an endogenous metabolite of 17β-estradiol, not only inhibits 
tumor angiogenesis but also inhibits both cytosolic Cu–ZnSOD and mitochondrial MnSOD, 
as well as enhances superoxide anion generation and induces apoptosis in leukemia cells 
through a ROS-mediated mechanism [208]. Preclinical studies showed 2-ME selective 
cytotoxicity for leukemia cells in comparison to normal lymphocytes [209]. 2-ME 
synergizes with rotenone, a complex I inhibitor and pro-oxidant under some conditions, 
that is responsible for increasing cellular free radical accumulation and trigger apoptosis 
[210]. 2-ME has been investigated against advanced, platinum-resistant ovarian cancer 
and primary peritoneal carcinomatosis in a small group of patients. Although the anti-
tumor activity was modest in this particular study, toxicity was found to be low, opening 
the door to further developments of the molecule [211]. Oncogenic changes in 
mitochondria were originally thought to represent mitochondrial dysfunction which 
forced a shift to glycolysis. However, accumulated evidence now suggests that 
mitochondrial changes provide a selective advantage to cancer cells and that these 
changes are more complex and dynamic than a simple switch to glycolysis. For example, 
glutamine metabolism via the TCA cycle has been identified as a second major metabolic 
shift in cancer cells (see Section 2.1.2.2). In accord with this more recent model, 
mitochondrial inhibition has been widely used in cancer therapy. 
In animal models, the complex I inhibitor rotenone by itself exhibits anti-tumor activity 
[212], which is a feature common to other inhibitors of mitochondrial respiratory chain, 
including antimycin A, a complex III inhibitor and oligomycin, a complex V inhibitor. The 
two latter agents were demonstrated to induce apoptotic cell death in cultured human 
lymphoblastoid cells [134]. Inhibition of the mitochondrial respiratory chain can induce 
other forms of cell death as well. Rotenone, by acting as a complex I inhibitor, can 
selectively induce autophagic cell death via a ROS-mediated mechanism in the 
transformed cell line HEK 293 and in cancer cell lines U87 and HeLa [213]. Mitochondrial 
dependence of effects of rotenone or other OXPHOS inhibitory drugs are supported by 
reports that cells lacking functional mitochondria are not as susceptible to those molecules 
[214, 215]. 
Understandably, the toxic nature of classic mitochondrial inhibitors limits their possible 
clinical application but can provide evidence that the concept works and serve as useful 
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experimental standards by which to judge the efficacy of other ETC targeted drugs. 
However, in addition to its inhibitory effect on mitochondrial respiration, rote-none has 
also microtubule-depolymerizing activity [216]. Therefore, this fact should be taken into 
account when interpreting data from cells with higher proliferation rates, including 
tumor cells. In fact, the use of rotenone to induce Parkinson's disease has already been 
questioned, since it appears that the mechanism involved in disease development does not 
involve complex I inhibition by rotenone but its anti-microtubule activity instead [217]. 
However, the microtubule and electron transport chain effects of rotenone may be linked. 
An interesting recent report also demonstrated that destabilization of tubulin by rotenone 
depolarizes mitochondria through VDAC (voltage-dependent anion channel) modulation, 
and consequently regulates not only respiration but also the metabolic status of cancer 
cells [216]. 
Acetogenins such as rollinistatin and bullatacin are among the most potent inhibitors of 
the mitochondrial complex I, and they are also effective inhibitors of tumor cell 
proliferation [218]. Thenoyltrifluoroacetone, a chelating agent, can slow tumor cell cycle 
progression, and increase ROS production and glutathione oxidation by inhibiting 
mitochondrial complex II [163]. The data appear to suggest that inhibition of complex II, 
the tumor suppressor succinate dehydrogenase, can be a good choice as a mitochondrial 
target in neuroblastoma cells, as inhibition by malonate also leads to increased ROS 
production, p38 MAPK activation and BAX mediated apoptosis [219]. None of the 
compounds described here has been tested in humans, being still in an early phase of the 
drug development process. 
Natural compounds have long been studied for their anticancer properties; besides the 
vitamin E analogs referred to above, another example is epigallocatechin-3-gallate 
(EGCG), a green tea polyphenol known for its ability to induce apoptosis. Elevated 
concentration of EGCG causes ROS accumulation in malignant cells but not in normal 
cells; this characteristic makes the compound a good candidate for therapy [154]. 
Although extensive in vitro data exist, there is still the need for solid human data to 
demonstrate the preventive or chemotherapeutic effects of EGCG. This is further 
confirmed by some epidemiologic studies demonstrating that dietary green tea prevents 
the development of some types of cancer including colorectal [143] and prostate [144]. 
Resveratrol, a natural stilbene, was shown to act as a mitocan, i.e. a compound which 
specifically target mitochondria in tumor cells [220]. Resveratrol can act directly at 
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several different sites from complexes I to III, possibly competing with ubiquinone 
binding sites. Moreover, it interacts with complex V, the Fo–F1 ATP synthase [221]. 
Although resveratrol is generally considered a potent antioxidant, it can also act in favor 
of oxidant status in cells, inducing apoptosis through the mitochondrial pathway [222]. 
Although the balance between anti- and pro-oxidant can regulate distinct signaling 
pathways, it is generally accepted that the pro-oxidant activity of resveratrol is 
implicated in the anti-cancer mechanism [223]. Resveratrol is currently undergoing 
phase I/II clinical trials and the safety threshold was calculated to be under 5g/day, 
despite the occurrence of mild to moderate side effects [157]. Plans are underway to 
pursue clinical trials to investigate the effects of resveratrol against lymphoma and 
colorectal cancer, as well to confirm the role of resveratrol in the prevention of colon 
cancer [224]. 
Another interesting approach in cancer therapy involving increased oxidative stress in 
the tumor involves photodynamic therapy (PDT). This technique uses non-toxic 
molecules, called photosensitizers, which become pharmacologically active in the 
presence of specific wavelengths [225]. The delivery of a suitable light dose to 
photosensitized tissues can result in a localized eradication of neo-plastic lesions with 
reduced damage to healthy adjacent tissues. The efficacy of the process is dependent on 
the presence of oxygen, suggesting a role for ROS in the therapeutic mechanism [226]. 
This is strengthened by the observation that upon light absorption, the photosensitizer 
switches from its singlet state to a triplet state and consequently may react with molecular 
oxygen forming an excited-state single oxygen [227]. PDT may be used in superficial 
tumors where light penetration in tissues is more favored. The most common 
photosensitizers are porphyrin derivatives, although other molecules can also be used 
[226]. 
Mitochondria are thought to be a key target of PDT, since PDT-induced cell death seems to 
predominantly involve a mitochondrial-dependent apoptotic pathway [225]. The 
hydrophobicity and charge nature of certain porphyrins influence their cellular 
distribution, resulting in mitochondrial accumulation. In the mitochondrial inner 
membrane, porphyrin sensitizers have been described to significantly inhibit cytochrome 
c oxidase and FoF1 ATP synthase, thus disturbing oxidative phosphorylation [228]. In 
some cases photosensitizers specifically enter mitochondrial pathways. For example, the 
pre-photosensitizer 5-aminolevulinic acid enters the heme biosynthetic pathway leading 
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to accumulation of PpIX in mitochondria [226]. In addition, some photosensitizers were 
shown to interact with specific mitochondrial molecules/proteins, such as cardiolipin or 
Figure 2.2 - Chemotherapeutic agents targeting mitochondrial alterations. Mitochondria
in cancer cells present metabolic alterations, increased oxidative stress, aberrant apoptotic
machinery, ΔΨm alterations and structural changes. Inhibition of OXPHOS through targeting
of complex I and/or complex II can be an anti-tumor approach. Besides inhibiting complex I,
resveratrol was also described to interact with complex V. Other anti-tumor agents such as
2-DG, 3-bromopyruvate, 5-thioglucose, and mannoheptulose are known to inhibit HKII,
decreasing its ability to bind to the outer membrane VDAC, compromising tumor cell
glycolytic metabolism. ANT, other possible regulator of the mPTP, has also been considered
a therapeutic target. Its inhibition may slow cellular glycolytic rate and prone mitochondria
to apoptotic stimuli. Recently, several small molecules that mimic Bcl-2-like proteins BH3
domain have been developed, which act by binding to and/or antagonize Bcl-2 and Bcl-XL.
α-TOS and curcumin were described to induce Bax translocation to mitochondria and outer
mitochondrial membrane permeabilization. Alterations in the cell redox balance can also be
a useful strategy. Antioxidant systems suppression can contribute for lethal oxidative stress
in cancer cells. One example is 2-ME which inhibits mitochondrial MnSOD activity. Also
shown in the figure is PDH stimulation by dichloroacetate, which increases mitochondrial
capacity in cancer cells, decreasing the Warburg phenotype, and MKT-077, whose effects
on mitochondria include direct damage to mtDNA. 
  
2. CHAPTER 
38 Inês A. Barbosa │ University of Coimbra 
the peripheral benzodiazepine receptor (PBR), leading to their mitochondrial 
accumulation [226]. PBR overexpression in tumor cells (see Section 3.1) may suggest 
enhanced mitochondrial porphyrin accumulation based on a specific interaction with that 
receptor. 
An alternative and paradoxical approach relies on the use of anti-oxidants in anti-tumor 
therapeutics. Antioxidants have been described to counteract harmful effects of ROS and 
consequently contribute in the treatment of oxidative stress-associated diseases, such as 
cancer. The use of antioxidants as anti-cancer therapeutics has been controversial 
because it is thought that these agents may confer a protective advantage to cancer cells 
rather than inducing cell death. In fact, many antioxidant agents have been shown to be 
unsuccessful in tumor treatment (reviewed in [229]). Nevertheless, given the role of ROS 
in activating signaling pathways leading to metabolic remodeling, mitochondrial-directed 
antioxidants including MitoQ may contribute to normalizing the metabolic phenotype in 
cancer cells. This antioxidant agent has already been demonstrated to decrease the 
hypoxic induction of ROS and to destabilize HIF1α protein, reducing its transcriptional 
activity [230]. In vitro assays revealed that MitoQ was 30-fold more cytotoxic to breast 
cancer cells than to healthy mammary cells, apparently acting through Nrf2 negative 
regulation of autophagy and cell growth [231]. 
2.3 Mitochondrial DNA mutations and cancer 
Mitochondrial DNA (mtDNA) is a 16,569 base pair super-coiled, double-stranded molecule 
that contains 37 genes coding for 13 polypeptides of mitochondrial electron transport 
chain, 22 tRNAs, and 2 rRNAs for protein synthesis [232]. mtDNA includes a non-coding 
DNA region which consists of three hypervariable regions and a displacement loop (D-
loop). The D-loop region harbors regulatory elements required for replication and 
transcription [233, 234]. Proteins involved in the replication, transcription, and 
translation of mtDNA are encoded by nuclear genes and targeted to mitochondria [233]. 
The ETC consists of five multi-enzymatic complexes formed from gene products of 74 
nuclear and the 13 mitochondrial genes [235]. Mitochondrial DNA is more susceptible to 
mutation than nuclear DNA. Besides being in close proximity to the electron transport 
system where ROS are produced, mtDNA, unlike nuclear DNA, has no protective his-
tones and chromatin structure, has limited repair capabilities, and has no introns [236]. 
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Consistent with these characteristics, many studies have identified mitochondrial DNA 
alterations in cancers including ovarian, thyroid, salivary, kidney, liver, lung, colon, 
gastric, and breast cancers [233, 236-239]. Welter et al described a 40 bp insertion 
localized in the COX I gene specific of renal cell oncocytoma [240], and later, deletion 
mutations in the gene coding for NADH dehydrogenase subunit III were observed in renal 
carcinoma [241]. In addition to mutations in protein-coding regions, mutations that may 
affect function have been identified in tRNA genes and the D-loop regulatory region [242, 
243]. 
Consistent with the importance of metabolic remodeling to oncogenesis, cancer-specific 
mtDNA mutations have been reported and in some cases a functional defect has been 
identified. However, it has been difficult to determine the functional significance of 
mtDNA alterations in carcinogenesis for several reasons. First, there are as many as 
several hundred mitochondria in each cell and mtDNA in a cancer or normal cell may be 
the same (homeoplasmy) or different (heteroplasmy). Therefore to understand the 
significance of a mutation it is necessary not only to identify its sequence but also to 
determine its frequency relative to wild type. Second, there are no tools to experimentally 
manipulate specific mitochondrial DNA alterations. The traditional tools of genetics, such 
as transgenic mice, and molecular biology, such as RNA interference, cannot be used 
reliably. However, it may be possible to discern the significance of specific cancer 
mitochondrial genomes using mitochondrial swaps or cybrids, in which a cell depleted of 
mtDNA is repopulated with mtDNA from a different donor, although maintaining the 
same nuclear background [244]. In this context, cybrids harboring the mitochondrial 
DNA (mtDNA) polymorphism G10398A found in African-American women with 
aggressive breast cancer were shown to have slower proliferation rate and cell cycle, 
increased complex I activity and augmented production of ROS and more depolarized 
mitochondria. The G10398A cybrid also showed resistance to apoptosis triggered by 
etoposide and increased ability to form metastasis in vivo [245]. 
Finally, mitochondrial function, including DNA metabolism, is also determined by the 
nuclear genome raising the problem of separating nuclear and mitochondrial effects. 
Studies relating alterations in mtDNA and cancer risk or aggressiveness have just begun 
but they suggest that mtDNA alterations during development of cancer are more complex 
than previously suspected [246, 247]. 
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2.3.1 Mitochondrial DNA as a predictive marker in the 
diagnosis and staging of cancer 
As described above, mtDNA alterations have been identified in several cancers. This 
raises the question of whether these alterations can be used to stratify cancer patients 
according to distinct mitochondrial phenotypes, allowing for the development of tailored 
therapies. 
Hsu et al demonstrated a lower mtDNA content in breast cancer tissues when compared to 
normal counterparts [248], with other work previously confirming the same observation 
[249]. Interestingly, cancer cells exhibiting low mtDNA content were more susceptible to 
anthracycline treatment [248]. The authors proposed that the low mtDNA content might 
lead to an increase in electron leakage during cancer cell respiration which culminates in 
an increase of oxidative stress and consequently, to an increased susceptibility to 
chemical agents that further increase ROS levels, such as anthracyclines. Thus, the low 
mtDNA content might constitute a biomarker for cancer detection and a sign that 
chemotherapeutics that act by increased oxidative stress should be used. Nevertheless, in 
clear contrast, an in-crease in mtDNA copy number was observed in patients with a 
higher risk for breast cancer [250]. The observed increase in mtDNA copy number was 
observed to be inversely correlated with antioxidant levels suggesting that increased 
oxidative stress leads to a compensatory production of mtDNA in order to protect 
mitochondrial genome from damage [250]. This apparent discrepancy may be resolved by 
recent results from Bai et al, who showed in a large clinical sample of breast cancer 
patients that the mtDNA content of stage II breast tumor was lower than both stage 0–I 
and more advanced stage III tumors [251]. These work  and others [252-256] suggest that 
mtDNA content alterations are tumor and stage specific and clearly more research is 
required to gain a deeper knowledge of how these alterations impact the mitochondrial 
and redox phenotype of tumor cells. 
Besides alterations in mtDNA copy number, numerous mutations on the mitochondrial 
genome have been reported in cancer. These mutations can occur in both the non-coding 
and the coding regions of mtDNA and may arise in the female germ line leading to cancer 
predisposition, or arise in somatic tissues. Mutations in mtDNA may be heteroplasmic, 
when both mutated and wild-type mtDNA coexist, or homoplasmic. Heteroplasmic, but 
not the correspondent homoplasmic, mtDNA mutations have been described to contribute 
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to tumor progression [257]. The most common somatic mtDNA deletion occurs between 
nucleotides 8470 and 13,477, mtDNA4977, and it is known to accumulate during the aging 
process, being found in several tissues. Tumor cells were shown to have decreased 
mtDNA4977 content relative to cells in non-tumor tissues. A possible explanation raised by 
the authors is that this specific deletion may induce metabolic changes that, in the case of 
normal cells, are of minimal impact in contrast with cells under stress, such as tumor cells 
in which even low frequencies of this mutation are not tolerable, possibly resulting in 
bioenergetic failure and cell death [258]. Studies on non-melanoma skin cancer are 
consistent with previous results demonstrating accumulation of mtDNA4977 deletions in 
normal but not in tumor tissue. It was suggested that this may imply a protective role of 
mtDNA deletions in the process of tumor formation, since carcinogenesis would require a 
bioenergetic transformation in which the cells with high mutated mtDNA would be 
incompetent [259]. 
2.4 Altered mitochondrial transmembrane electric 
potential in cancer cells 
In 1961, Peter Mitchell proposed a breakthrough hypothesis, the chemiosmotic theory 
[260], suggesting that in mitochondria, electrons from reducing equivalents are 
transported downstream of the electrochemical potential of specialized protein 
complexes, the ETC. Electron transfer allows generation of adequate free energy (ΔG), so 
that some of those complexes pump protons from within the matrix to the intermembrane 
space (IMS). Ultimately, this establishes a separation of charges (ΔΨ) and chemical species 
(protons; ΔpH) both contributing to the generation of the proton motive force (Δp). Since 
the inner mitochondrial membrane is highly impermeable, the Δp becomes a sink of 
energy to drive other biochemical reactions, namely ATP synthesis. ATP synthase 
(Complex V), a transmembranar protein, catalyzes ATP phosphorylation in the matrix 
side and uses Δp to release the tightly bound nucleotides from the enzyme [261]. 
In the early 80’s, Chen and his coworkers demonstrated that transformed cells and 
several carcinoma cell lines show increased uptake of rhodamine 123, a fluorescent probe 
used to measure ΔΨm, when compared to their control non-tumor counterparts [262]. 
Since then, it is considered that mitochondria from cancer cell are hyperpolarized. 
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However, explanations for such phenotype are scarce. In normal cells, the regulation of 
ΔΨm depends on cellular energy demand and therefore ATP production; however, cancer 
cells suffer a metabolic shift towards glycolysis decreasing mitochondrial ATP production, 
which consequently can increase ΔΨm. This could explain the decrease in ΔΨm upon DCA 
treatment which leads to pyruvate usage by mitochondria and shift of the Krebs cycle 
towards oxidative metabolism [263]. In the same work, it was shown that cancer cells 
have decreased activity and expression of Kv1.5 potassium channels. The resulted 
increase in [K+]c could promote electroneutral exchange of potassium/protons in 
mitochondria and ultimately convert ΔpH to ΔΨm. Nonetheless, the detection of 
overexpressed uncoupling proteins in cancer [264] is apparently contradictory to the 
notion of mitochondrial hyperpolarization, although it has been widely described that 
uncoupling proteins have other functions besides mitochondrial uncoupling [265]. 
2.4.1 Targeting mitochondrial hyperpolarization in tumor cells 
Another possible therapeutic approach takes advantage of the higher mitochondrial 
transmembrane electric potential of most cancer cells. Positively-charged lipophilic 
molecules can accumulate within mitochondria causing non-specific cell death (Fig.2.2 
and Table 2.1) [266]. Rhodamine-123 is selectively toxic toward carcinoma cells [158, 267] 
and was shown to accumulate in mitochondria [268]. Kidney and breast cancer cells that 
also retained rhodamine-123 were also highly affected [269]. Although never tested in 
clinical trials, the data obtained with rhodamine-123 serve as proof of concept for further 
variations of the same theme. 
Belonging to the cyanine dyes family, the analog MKT-077 (FJ-776) was demonstrated to 
damage mitochondrial DNA and to promote mitochondrial swelling of CX-1 carcinoma 
cells without significant ad-verse effects in nuclear DNA [270] and to inhibit the growth of 
five different human cancer cell lines [271]. MKT-077 was indeed a very promising anti-
cancer agent, which was initially proposed to have mild and reversible toxicity in non-
target organs [272], despite the fact that pre-clinical trials demonstrated that MKT-077 
caused a reversible depletion of mtDNA in rat heart, as well as a reversible disruption of 
liver mitochondrial bioenergetics [272]. Phase I clinical trials revealed that the compound 
indeed accumulates preferentially in tumors [151], due to their higher ΔΨm [273]. Despite 
this, the development of serious renal toxicity in some patients stopped further trials, and 
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its development as a promising anti-cancer drug was arrested [274]. Nevertheless, the 
studies demonstrated the concept of selective targeting of mitochondria in cancer cells in 
vivo, although new agents with decreased liabilities are clearly needed. 
The compound F16 was demonstrated to accumulate to a greater extent in the 
mitochondrial matrix, without strongly binding to mitochondrial membranes. 
Mitochondrial damage, opening of the MPT pore, cell cycle arrest and cell death are 
observed after F16 treatment [145]; significantly, these effects are observed in cells 
resistant to apoptosis [275]. This compound so far has not progressed beyond in vitro 
studies. 
Dequalinium, another lipophilic cation, can drastically alter the morphology of 
mitochondria [276]; in fact, when incubated with BT20 cells, dequalinium-DNA can be 
imported into the mitochondrial matrix, where most of the effects are caused [277]. No 
plans for clinical trials are available, which limits the development of this agent as a 
possible chemotherapeutic. 
As described in the previous section, the phytochemical berberine accumulates primarily 
at lower doses in mitochondria in melanoma cells, although it can still be secondarily 
accumulated in the cytoplasm and nucleus at higher concentrations [278]. The 
accumulation of the cationic molecule berberine by mitochondria results into a series of 
alterations of mitochondrial function, including inhibition of respiration, lower calcium 
loading capacity, decreased mtDNA copy number and increased ROS generation [278, 
279]. No clinical trials have been performed to explore if this effect is also observed in 
vivo, although this may well be a very important and promising compound for anti-cancer 
therapy. 
Although the majority of the above mentioned compounds were shown to specifically 
target tumor cells in contrast to their normal counterparts, further pre-clinical in vivo 
studies are necessary to establish the rationale for further clinical trials. In addition, even 
compounds effective in animal models may prove to be unsafe in clinic as seen with MKT-
077 [274]. 
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Cells are the basic building blocks of living organisms harboring a high complexity of 
functions and characteristics. The maintenance of cellular homeostasis is of great 
importance as it allows the preservation of tissue architecture and function, thus ensuring 
normalcy. In order to maintain an effective internal regulation the cell needs quality 
control mechanisms to identify, correct, and prevent the occurrence of mistakes. The 
consequences of deregulated quality control systems are disastrous and often associated 
with the development of different pathologies and acquisition of a malignant phenotype. 
This section constitutes a review of two of the major quality control systems, apoptosis 
(Section 3.1) and autophagy (Section 3.2) as well as their implications in cancer 
development. 
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3.1 Apoptosis 
Apoptosis, also called programed cell death type I, has been a high focus of study since its 
discovery in 1972 [280] as it constitutes a mechanism of extreme importance, not only in 
tissue development and homeostasis, but also in the pathogenesis of different diseases 
such as cancer. 
Cells undergo several changes during apoptosis, namely DNA fragmentation and 
chromatin condensation; along this process cells lose their attachment to the surroundings 
and shrink. A particular characteristic of the apoptotic mechanism is membrane blebbing, 
which precedes the formation of apoptotic bodies. These small cytoplasmic fragments 
encapsulated in cellular membranes are then eliminated by phagocytosis [281]. Due to this 
orderly disposal of cells, inflammation reactions do not generally occur in apoptosis.  
Apoptosis is a complex process that occurs via multiple pathways and which is triggered 
in response to a variety of extrinsic or intrinsic signals (Fig.3.1). The apoptotic machinery 
is composed of upstream regulators and downstream effector components [282]. The 
regulators are divided into two major circuits, one receiving and processing extracellular 
signals, referred to as the extrinsic pathway, which is activated by the engagement of 
“death receptors”, and another that senses and integrates internal signals, the intrinsic 
pathway, which involves mitochondria as a central crossroad for death signaling. Both 
extrinsic and intrinsic circuits then culminate with the activation of intracellular cysteine 
proteases, caspases 8 and 9 respectively, which in turn activate a proteolysis cascade that 
involves effector caspases, caspase 3, 6, and 7, responsible for apoptosis execution 
(Fig.3.1) [283]. All caspases exist as inactive zymogen which activation involves the 
proteolytic cleavage of their prodomains to attain a large catalytic subunit plus a small 
fragment. 
Apoptosis activation is controlled by a balance between pro- and antiapoptotic proteins of 
the BCL-2 family that function as a “life/death switch” integrating inter- and intracellular 
signals [282]. The different members of the family might share two to four BCL-2-
homology domains (BH) or can form a specific subgroup of the so called BH3-only 
proteins. Moreover, BCL-2-like proteins can also be sorted accordingly to their function. 
The antiapoptotic proteins include BCL-2, BCL-xL, and BCL-w, and inhibit apoptosis 
mainly by binding to and consequently suppressing pro-apoptotic triggering proteins, 
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such as BAX, and BAK [282]. The group of proteins sharing a single BH, the BH3 motif 
(BH3-only proteins) which include PUMA, Noxa, BID, and BIM, bind and inhibit the 
antiapoptotic BCL-2 proteins acting as pro-apoptotic proteins [284]. Overall, BH3-only 
Figure 3.1 - Apoptotic pathways: extrinsic vs intrinsic. The left side of the figure depicts the 
extrinsic pathway beginning with the arrival of apoptotic stimuli, which are internalized by
means of death receptors (Fas, TNFαR, DR3, DR4, and DR5). In this picture only Fas receptor 
is shown which forms trimmers upon ligand binding and recruits pro-caspase 8 via FADD 
adaptor protein. Active caspase 8 will trigger caspases cascade by activation of caspase 3, 6
and 7. On the right, the intrinsic pathway is shown in the right side with mitochondria being 
the hub for the mechanism of antiapoptotic/proapoptotic proteins. Stress signals will alter the
ratio of these proteins and potentiate mitochondrial outer membrane permeabilization
(MOMP) releasing cytochrome c into the cytosol. Cytochrome c interacts with APAF-1 and 
pro-caspase 9 to form the apoptosome and trigger caspase cascade by activation of caspase
efectors (3, 6 and 7). Nevertheless, the two pathways are not independent as in some
circumstances caspase 8 can activate Bid which will promote MOMP establishing the bridge 
between the extrinsic and intrinsic pathways. Adapted from [285]. Abbreviations: Cyto-c –
cytochrome c; BAX – BCL-2 associated X protein; BCL-XL – B-cell lymphoma extra large; BID –
BH3 interacting domain death agonist; BCL-2 – B-cell CLL/lymphoma; BIM – BCL2-like 11; 
FADD – Fas-Associated protein with Death Domain. 
  
3. CHAPTER 
48 Inês A. Barbosa │ University of Coimbra 
proteins and antiapoptotic BCL-2 proteins are positive and negative regulators of 
BAX/BAK respectively and the overall cell fate depends ultimately on the ratio of those 
proteins.  
Upon a death signal, pro-apoptotic proteins undergo post-translational modifications that 
include dephosphorylation and cleavage resulting in their activation and subsequent 
translocation to mitochondria. In mitochondria, these proteins disrupt the integrity of the 
mitochondrial outer membrane releasing pro-apoptotic signaling proteins including 
cytochrome c [281]. Released cytochrome c interacts and binds to apoptotic protease-
activating factor 1 (APAF-1) inducing ATP-dependent activation and oligomerization of 
seven APAF-1/cytochrome c complexes (apoptosome) [286] which ultimately cleaves pro-
caspase 9 and activates a cascade of caspases that acts to induce multiple cellular changes 
associated with apoptosis. 
Important during embryonic development [287], programed cell death also constitutes a 
barrier to pathological development as it normally eliminates cells whose cell cycle control 
is disturbed by oncogenic mutations. Tumor cells develop a variety of strategies in order 
to overcome apoptosis including abnormal expression of some key regulatory factors. 
Impaired apoptosis potentiates malignant progression at multiple steps allowing cell 
survival and contributing to genomic instability. 
3.1.1 Abnormal mitochondrial apoptotic signaling in cancer 
cells 
Genotoxic stress and excessive oncogenic signaling initiate intracellular signaling 
pathways leading to apoptosis. Release of pro-apoptotic factors from the mitochondria is 
the decisive step in most apoptotic pathways. This release can be triggered by two 
processes, mitochondrial outer membrane permeabilization (MOMP) and mitochondrial 
permeability transition (MPT). Extrinsic or intrinsic signals can cause mitochondrial 
translocation of pro-apoptotic proteins such as BAK or BAX, which form hetero- and 
homodimer channels in the outer mitochondrial membrane resulting in MOMP (reviewed 
in [288]). These channels allow release of pro-apoptotic factors enclosed in the inter-
membrane space, including cytochrome c, the apoptosis-inducing factor (AIF), 
OMI/HTRA2 and SMAC/Diablo, among others. Release of those factors leads to activation 
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of executor caspases and their translocation to the nucleus triggering death-dependent 
responses [289]. On the other hand, internal mitochondrial stress caused by calcium 
overload or oxidative stress can result in increased permeability of the inner 
mitochondrial membrane (IMM) often designated as MPT. The effect is due to formation 
of non-specific protein pores in the IMM which allow equilibration of solutes <1.5 KDa 
between the matrix and cytosol. The structural entity of the pore remains highly debated 
[290, 291], with recently findings suggesting the phosphate carrier [292] or ATP synthase 
dimers [293] as possible structural components of the pore. The classic model of the MPT 
pore has been thus remodeled to alter the role of ANT and VDAC from pore components to 
pore modulators [294, 295]. Nevertheless, cyclophilin D (Cyp-D) retains its role as a pore 
regulator by interacting with an intermembrane protein, probably the ANT or the ATP 
synthase, and inducing a conformational change upon calcium binding [291, 295]. The 
sudden increase of membrane permeability leads to osmotic readjustment with 
consequent mitochondrial swelling and damage to the outer membrane, resulting in 
uncontrolled release of pro-apoptotic factors [296]. 
The transcription factor TP53, the most frequently mutated tumor suppressor in human 
cancer, is a well-studied hub linking stress response to apoptosis. In addition to its well 
known role promoting transcription of pro-apoptotic factors such as APAF1, BAX, PUMA 
and Noxa, TP53 also plays a direct role in apoptosis. In response to stress, TP53 
translocates to mitochondria, where it displaces inhibitors of pro-apoptotic channel-
forming proteins such as BAK [297]. 
Uncontrolled growth of cancer cells leads to a series of cellular stresses that would trigger 
apoptotsis [298, 299]. In addition to transcriptional effects these mutations also affect 
activation of BAK and BAX at the outer mitochondrial membrane (OMM). Also, tumor 
mitochondria commonly display increased binding of the enzyme hexokinase II (HKII) to 
VDAC at the OMM. HKII–VDAC complexes appear to inhibit apoptosis by blocking 
binding of pro-apoptotic proteins to the OMM [121, 300]. Cancer cells display altered MPT 
regulation [301] that may involve HKII binding to the VDAC as well. In addition, cancer 
cells commonly display increased mitochondrial localization of several heat shock 
proteins, including HSP60, HSP90 [302] and the tumor necrosis factor receptor-
associated protein 1 (TRAP1) [303]. These heat shock proteins inhibit apoptosis by binding 
Cyp-D, thus apparently blocking MPT in response to pro-apoptotic insults [302, 304]. 
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The mitochondrial protein peripheral-type benzodiazepine receptor (PBR), also known as 
18 kDa translocator protein (TSPO), is also implicated in oncogenesis. The PBR is 
primarily located in contact sites between the inner and outer mitochondrial membranes, 
where it associates with VDAC and ANT [305]. Paradoxically, the PBR promotes apoptosis 
via activation of VDAC [306] but also to promote oncogenesis. Elevated PBR expression in 
tumors is associated with increased metastatic potential in several cancers [307]. This 
oncogenic effect is likely due to non-apoptotic functions of PBR possibly dependent on 
nuclear localization which has been associated with tumor aggressiveness [308]. 
3.1.2 Targeting the aberrant mitochondrial apoptotic 
machinery 
One anticancer strategy to target the increased mitochondrial resistance to apoptosis in 
tumor cells is to develop small molecules which mimic the BH3 dimerization domain that 
exists in all BCL-2 related proteins, leading to activation of pro-apoptotic BCL-2-like 
proteins (Fig.2.2 and Table 2.1). Two typical examples are the chromene derivative HA14-
1, which binds to the BCL-2 protein and induces apoptosis [309] and ABT-737, which 
binds preferentially to BCL-2 and BCL-XL and induces cell death through the intrinsic 
apoptotic pathway [310]. In various cultured leukemic cells and acute myeloid leukemia 
cells obtained from patients, the BH3 mimetic 072RB demonstrated mitochondrial 
localization followed by cell death [311]. Other examples of BH3 mimetics are ABT-263, 
gossypol (AT-101) and Obatoclax (GX15-070), which, similarly to gossypol, antagonizes 
BCL-2 and BCL-XL [312]. Obatoclax is currently undergoing phase I/II trials against 
myelofibrosis [153], advanced chronic lymphocytic leukemia [313], solid tumor 
malignancies [314] and advanced hematologic malignancies [315] with results that range 
from disappointing to promising. Moreover, the great majority of BH3 mimetic proteins 
have been described as having a differential cytotoxic effect on cancer treatment and 
normal counterparts [316]. 
As described above the PBR has been implicated in mitochondrial-mediated apoptosis. 
This role in conjunction with the overexpression of PBR in some cancer cells has been 
exploited by developing specific ligands which induce cell death [308]. These ligands, 
such as PK11195, Ro5-4864 and FGIN-1-27, have been identified as anticancer modulators, 
and may either induce apoptosis directly, or through inhibition of BCL-2 antiapoptotic 
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effects [308]. The overexpression of PBR in neoplastic tissues combined with selective 
binding of high affinity PBR ligands has also led to the development of PBR ligands as tools 
for tumor imaging and diagnosis [317]. 
The chemotherapeutic properties of curcumin, the major constituent of tumeric powder, 
have been reported as inducing lung cancer cell death through BAX upregulation and 
BCL-2, BCL-XL downregulation, causing AIF and cytochrome c release [154]. Several other 
intracellular targets for curcumin have also been described, including suppression of 
TP53 and inhibition of cyclooxygenase-2 (COX-2) [318]. Curcumin is currently 
undergoing phase II/III clinical trials in different types of cancer, including colon and 
cervical, with promising results in some cases [318]. 
Sanguinarine, a natural benzylisoquinoline alkaloid, was shown by our group to interfere 
with mitochondrial calcium loading capacity and to cause an increase in TP53 [319]. 
Barreto et al demonstrated that complex II is a mitochondrial target for sanguinarine, 
which may explain the effects on respiration [162]. Other studies confirmed that 
sanguinarine causes apoptosis via mitochondrial depolarization and cytochrome c release 
[320, 321], ROS-induced DNA damage [322], glutathione depletion, and cleavage of poly 
(ADP-ribose) polymerase and beta-catenin [323]. Berberine, an alkaloid derived from 
plants of the Berberidaceae family, has also been described to act as an anticancer agent, 
exerting several direct effects on mitochondria function, including inhibition of 
mitochondrial complex I and interaction with the ANT [279, 324]. Inhibition of mouse 
liver mitochondrial respiratory activity by berberine was confirmed by other 
experimental results [162, 325]. Berberine also induced apoptosis through alterations in 
the BCL-2/BAX ratio, ROS production, TP53 upregulation, a decrease in ΔΨ, cytochrome c 
release and activation of caspases [326-329]. Of particular interest is the fact that for low 
concentrations, berberine is accumulated by energized mitochondria in tumor cells [279] 
(see below). Clinical trials are still warranted for sanguinarine and berberine in order to 
confirm the promising efficacy shown in vitro. 
3.2 Autophagy 
Autophagy is an evolutionary conserved, tightly regulated lysosomal degradation 
pathway important in normal cell development and survival under changing 
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environmental conditions. This self-cannibalistic process is characterized by an extensive 
vacuolization of the cytoplasm and is generally activated in all cells at low basal levels 
[330].  
Autophagy is essential for homeostasis maintenance contributing to protein and organelle 
turnover, and it is rapidly upregulated upon stress conditions, such as starvation, growth 
factor deprivation, oxidative stress or whenever cells undergo situations that require high 
energy demands [331, 332]. Thus, autophagy is activated for structural remodeling and 
developmental transitions allowing cells to dispose of damaged cytoplasmic components 
in return of fresh building blocks. 
Due to its importance in cell-physiologic response, autophagy constitutes a method of 
cellular adaptation enabling cells to break down cellular organelles allowing the resulting 
catabolites to be recycled and used for biosynthesis and energy metabolism under new 
internal and external environments. Despite its role in survival, promoting cell flexibility 
to overcome environmental changes that ranges from adaptation to nutrient deprivation 
to severe cellular damage, autophagy can lead to the elimination of entire cells [333]. This 
occurs when adaptive mechanisms are insufficient to circumvent the damage caused to 
the cells. Consequently, autophagy molecular mechanism can be an alternative form of 
cell death, the so-called programed cell death type II [334]. Considering autophagy role in 
housekeeping, stress responses and cell death, defects in this cellular quality control 
process have been implicated in the development of several human diseases, including 
cancer (see Section 3.2.3) [332, 335]. 
So far three different autophagic routes have been identified, namely macroautophagy, 
microautophagy and chaperone mediated autophagy (CAM), which differ in their 
physiological function and mode of cargo delivery to lysosomal lumen (Fig.3.2) [332]. This 
section will focus on macroautophagy, regerred here as autophagy, and chaperone-
mediated autophagy. 
3.2.1 Macroautophagy 
The term autophagy often refers to macroautophagy processes. This form of autophagy is 
characterized by the formation of a double-membrane vesicle, which encapsulates 
cytoplasmic cargo and then fuses with lysosomes where the sequestered material is 
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degraded and recycled (Fig.3.2). Macroautophagy constitutes a high-capacity process that 
allows the simultaneous sequestration of multiple cytoplasmic components, including 
organelles, for degradation in the lysosomal lumen [336]. 
Although autophagosome formation occurs in close proximity to the endoplasmic 
reticulum (ER), the direct involvement of ER membrane in this process remains unclear. 
In addition to ER, recent works suggest that the Golgi complex, mitochondria, and plasma 
membranes may also provide a membrane source for autophagosome formation [337-
339]. In 1990, the identification of a series of autophagy-related (ATG) genes in yeast 
resulted in an increased understanding of the mechanism and function of autophagy 
[340, 341].  
The first step of the autophagic pathway is the induction phase, which is initiated by 
cellular stresses mediated by signaling cascades. Thus, stress stimuli, such as starvation, 
induce autophagy through inhibition of mTOR, which is the major autophagy inhibitory 
signal. Conversely, in response to growth factors or other autophagy inhibitory signals 
that stimulate the class I phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway, 
mTOR negatively regulates autophagy. mTOR inhibition allows the activation of the 
complex consisting of UNC-51–like kinase 1 (ULK1), ATG13, FIP200, and ATG101, crucial 
for autophagy initiation. Once activated, the ULK1 complex regulates the class III 
phosphatidylinositol 3-kinase (PI3K) complex, which includes BECLIN-1, the class III 
phosphatidylinositol 3-kinase (VPS34), and ATG14L [342]. Antiapoptotic BCL-2 homologs 
exert an antiautophagic function through inhibition of VPS34-BECLIN-1 complex [343]. 
Stimulation of this complex generates phosphatidylinositol-3-phosphate (PI3P), which 
promotes vesicle nucleation and serves as signal to the recruitment of proteins required 
for vesicle elongation [343]. 
Moreover, autophagosomal elongation requires two ubiquitin-like conjugation pathways, 
the ATG5-ATG12 and the light chain 3 (LC3) conjugation systems (Fig.3.2). In the former, 
ATG12 protein is activated by the E1 ubiquitin-like enzyme ATG7, and then is further 
transferred to the E2 ubiquitin-like enzyme ATG10 to be finally conjugated with ATG5. 
The ATG12-ATG5 complex is important for the elongation of the isolation membrane 
during autophagosome formation and is required for efficient LC3 lipidation [344]. In the 
second conjugation system, LC3 is first proteolyzed in its C-terminus by the cysteine 
protease ATG4 and activated afterwards by the E1 ubiquitin-like enzyme ATG7 to be 
further transferred to the E2 ubiquitin-like enzyme ATG3 allowing phosphatidyl-
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ethanolamine (PE) connection to LC3-I (18KDA) and finally giving rise to LC3-II (16KDa) 
that stably associates to the autophagosomal membrane [345]. The next step involves 
autophagosome fusion with lysosomes, called autophagolysosomes, and consequent 
degradation of autophagic cargos by lysosomal proteases, such as cathepsins D, and B 
[346]. Cathepsins are considered an important class of lysosomal enzymes and are 
characterized by a cysteine at the active group, which may be susceptible to oxidative 
modification and redox regulation [347]. After fusion with lysosomes, both 
autophagosome cargo and inner limiting membrane are degraded and the resulting 
monomeric structures are exported to cytosol for reuse in biosynthesis or energy 
production [348]. Upon degradation, autolysosomes may either become lysosomes that 
are able to undergo another fusion with autophagosomes or, if the degradation of the 
cargo was not complete, autolysosomes may become residual bodies containing 
indigestible material [348]. 
Although this quality control process may occur in a non-selective manner increasing 
evidence indicates selectivity in the recognition of autophagic substrates, through which 
misfolded or aggregate-prone proteins (aggrephagy), organelles (e.g. mitophagy), and 
invading microorganisms (xenophagy) are degraded [349]. The identification of 
autophagic adaptors, such as p62/SQSTM1 (sequestosome 1) and neighbor of BRCA1 
(NBR1), provided new insights on autophagy selectivity. These adaptors are both selective 
autophagy substrates and cargo receptors for degradation of ubiquitinated substrates by 
autophagy [350]. 
A particular case: Mitophagy  
As mentioned in Section 2, mitochondria are highly central organelles for energy 
production and critical in the regulation of numerous signaling cascades. Consequently, 
the accumulation of dysfunctional mitochondria results in significant damage to the cell. 
Thus, mitochondrial biogenesis and degradation must be tightly regulated allowing an 
appropriate mitochondrial response to stress stimuli. 
In response to environmental stress, ATP synthesis is disrupted, with excessive 
production of ROS by mitochondria and loss of ΔΨm which can precede autophagy 
induction [351]. Elimination of aberrant mitochondria through both non-selective and 
selective autophagy pathways (mitophagy) constitutes a critical process as it allows 
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mitochondrial quality control, and cell viability maintenance. Damage to mitochondria 
often leads to the activation of apoptosis (Section 3.1.1). In an attempt to prevent cell 
death, mitochondria are sequestered by autophagosomes and degraded before cell death is 
triggered. In fact, increased ROS production plays an important role in autophagy 
activation through regulation of ATG4 activity [352]. Although there is an extensive 
similarity between general autophagy and mitophagy pathways, mitochondrial-specific 
mechanisms have been identified. 
One mechanism of mitochondrial clearance involves the autophagy ubiquitin-binding 
adaptor p62, which recruits autophagic membranes to mitochondria by binding to LC3. In 
this model, dysfunctional mitochondria are recognized by the E3 ubiquitin ligase Parkin 
which ubiquitinates specific protein substrates in the mitochondria to which p62 binds. 
Subsequently, this complex is selectively tethered to the autophagosome through p62 
binding to LC3. Although this model is supported by numerous studies [353, 354], others 
show that depletion of p62 by RNAi has no effect on mitophagy [355] suggesting the 
involvement of other adaptor proteins in mitochondrial autophagy pathway. 
Recent works led to the identification of AMBRA1 as a mitophagy regulator [356, 357]. 
AMBRA1 is a BECLIN-1 interacting protein, which positively regulates autophagy. Under 
normal conditions, AMBRA1 binds preferentially to mitochondrial BCL-2, after autophagy 
induction AMBRA1 is released from BCL-2 and is recruited to BECLIN-1 promoting its 
activity and leading to mitophagy initiation [356]. Moreover, AMBRA1-mediated 
mitophagy was shown to be dependent on its interaction with Parkin [357]. The activation 
of the phosphoinositide 3-kinase complex (see Section 3.2.1) by AMBRA1 in mitochondria, 
allows the formation of the autophagosome directly around depolarized organelles, 
contributing for the selective nature of mitophagy.  
Considering that LC3 only associates with already formed autophagosomes, and p62 
inability to induce the formation of new autophagosomes, these two Parkin-mediated 
mitophagy models seem to have complementary effects; AMBRA1 induces autophagosome 
formation at mitochondria, which, after incorporation of LC3, may be then linked to 
ubiquitinated mitochondria via p62 [351]. 
The identification of ATG11 and its receptor ATG32 as important factors for mitochondrial 
degradation in yeast [358] led to the understanding that damaged mitochondria can also 
be eliminated via an ubiquitin-independent pathway involving the direct binding of LC3 
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to autophagy receptors on the mitochondria. In mammalian cells, mitochondrial NIX 
(mammalian ATG32 homolog) and BNIP3 (BCL-2 /E1B 19KDa-interacting protein 3-like 
protein) are known to promote mitophagy [359, 360]. Both of these proteins target 
mitochondria for degradation by directly binding to LC3 on the autophagosome and 
BNIP3-mediated autophagy is associated with Parkin translocation to mitochondria.  
Other key player in the regulation of mitophagy is the serine/threonine kinase PTEN-
induced putative kinase 1 (PINK1), which plays a central role in communicating the loss of 
ΔΨm to Parkin [361, 362]. In healthy mitochondria, PINK1 is preferentially located in the 
inner membrane at low levels as it is rapidly cleaved by mitochondrial proteases. After 
ΔΨm loss, PINK1 accumulates in the outer membrane, where it is protected from 
degradation, and is involved in Parkin recruitment to mitochondria [363]. Parkin is then 
able to polyubiquitinate proteins residing in the OMM, namely VDAC, and mitofusins 
MFN1 and 2 [364].  
Additionally, segregation of mitochondria by fission and inhibition of their fusion 
machinery is thought to be a pre-requisite for mitophagic degradation. Accordingly, 
PINK1 and Parkin were shown to play an essential role in mitochondrial dynamics [365] 
supporting the idea of a close relation between mitochondrial dynamics and mitophagy. 
Mitofusins MFN1 and 2 degradation as result of Parkin activation prevents damaged 
mitochondria to fuse with functional mitochondria and constitutes an essential step in 
their clearance through mitophagy [351]. Furthermore, mitochondrial depolarization was 
shown to cause loss of OPA1 (optic atrophy 1) and MFN1 and 2, proteins necessary for the 
fusion of mitochondrial inner and outer membranes. Consequently, overexpression of 
these proteins results in excessive fusion, which in turn protect mitochondria from 
degradation. In accordance with the essential role of fission in mitophagy, inhibition of 
mitochondrial fission mediated by dynein-related protein 1 (DRP1) prevents 
mitochondrial degradation through autophagy [366]. 
Basal levels of mitophagy are important for maintenance of cellular homeostasis and 
protection against accumulation of dysfunctional mitochondria. During cellular stress, an 
activation of mitophagy occurs, which consists in an early response to promote survival. 
However, the pathways of mitochondrial quality control are limited in their capacity and 
eventually become overwhelmed by an accumulation of damaged mitochondria, which 
ultimately culminates in cell death. 
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Figure 3.2 - Different types of autophagy and autophagosome formation during 
macroautophagy. Macroautophagy occurs at basal levels and can be induced upon 
environment alterations. The regulatory pathway includes mTOR, which inhibits 
macroautophagy. Under macroautophagy induction, the ULK1 complex (includes ULK1, 
ATG13, FIP200, and ATG101) is activated regulating the class III PI3K complex (includes 
ATG14, VPS34, and AMBRA) and BECLIN-1 recruitment. Under nutrient-rich conditions 
BECLIN-1 is associated with BCL-2 and is released after BCL-2 phosphorylation by JNK. 
Stimulation of this complex generates PI3P, which promotes vesicle nucleation and serves as 
signal to the recruitment of proteins required for vesicle elongation. The elongation process 
requires two ubiquitin-like conjugation pathways, the ATG12-ATG5 complex, and LC3-PE. 
The ATG12-ATG5 is required for efficient LC3 lipidation. In the cytoplasm, p62 interacts 
with polyubiquitinated proteins and this complex binds to LC3 in the autophagosome. 
Autophagy receptors on the mitochondria such as BNIP3 and NIX interact directly with LC3. 
This is followed by fusion of the autophagosome with a lysosome, autolysosome, where 
captured material and inner membrane are degraded. Chaperone mediated autophagy 
involves cytosolic HSC70 recognition of a KFERQ motif presented by unfolded substrate 
proteins. Then these are translocated into lysosomal lumen after binding to LAMP-2A, this 
process requires lysosomal HSC70 (lys-HSC70). Mircoautophagy refers to sequestration of 
cytosolic components directly into the lysosome through invagination of lysosome 
membrane. Abbreviations: ATG – autophagy related gene; BCL-2 – B-cell CLL/lymphoma; 
BNIP3 – BCL-2 /E1B 19KDa-interacting protein 3-like protein; HSC70 – 70KDa heat shock 
cognate; LAMP-2A – lysosome-associated membrane protein type 2A; LC3 – light chain 3; 
mTOR – mechanistic target of rapamycin (serine/threonine kinase); NIX – BCL2/adenovirus 
E1B interacting protein 3-like; PE – phosphatidylethanolamine; PI3K – Phosphatidylinositol 
3-kinase; PI3P – phosphatidylinositol-3-phosphate; ULK1 – UNC-51–like kinase 1. 
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3.2.2 Chaperone-Mediated Autophagy 
Chaperone-mediated autophagy (CMA) constitutes a type of selective autophagy that 
differs from other subtypes due to the unique way through which substrates, mainly 
cytosolic proteins, are recognized for lysosomal delivery and enter this organelle 
(Fig.3.2). The proteins internalized in lysosomes through CMA contain in their aminoacid 
sequence a pentapeptide motif, KFERQ, which selectively targets proteins to the lysosome 
[367]. This motif is then recognized by a cytosolic chaperone, the heat shock cognate 
protein of 70KDa (HSC70), which, along with its modulatory co-chaperones (BAG1, HIP, 
HOP, and HSP40), delivers the substrate protein to the surface of lysosomes. Unlike other 
degradation tags, such as ubiquitin, that are added to substrates targeting them for 
degradation, the KFERQ motif is always present. However, in properly folded proteins 
this sequence is “hidden” from its recognition by CMA machinery. Conformational 
alterations may favor the recognition of the KFERQ motif and consequently target 
unfolded proteins to degradation through CMA [368]. Other mechanisms that mask tag 
motifs may involve interaction with other proteins and binding to intracellular 
membranes. Moreover, further studies revealed that post-translational modification of 
some proteins might also be necessary to complete the CMA-targeting motif [369]. 
After the recognition step, the substrate protein-chaperone complex docks at the 
lysosomal membrane where it interacts with the lysosome-associated membrane protein 
type 2A (LAMP2A), which functions as a receptor for CMA pathway [370]. One-by-one 
translocation of the substrate protein into the lysosomal lumen requires its unfolding in a 
process through which cytosolic HSC70 and its co-chaperones are thought to be involved 
[371]. Substrate binding to LAMP2A is a limiting step for CMA through which proteins are 
translocated one-by-one to the lysosomal lumen [372].  
LAMP2A organizes in dynamic defined protein complexes at the lysosomal membrane and 
was shown to undergo conformational changes along CMA process. Substrates bind 
preferentially to LAMP2A monomers while their translocation across the lysosomal 
membrane requires the formation of LAMP2A complexes. HSC70 plays a role in the 
disassembly of LAMP2A complexes whereas HSP90, at the lysosomal membrane, is 
important for the maintenance of LAMP2A stability [373]. 
Translocation to the lysosome lumen also requires the presence of a luminal from of 
HSC70 (lys-HSC70), which assists in this process [374]. In fact, lys-HSC70 levels increase 
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in response to stressors leading to an increase of CMA fluxes, and its presence or absence 
in lysosomal lumen allows the identification of CMA-active lysosomes [375]. Finally, in 
the lysosomal lumen, a wide range of lysosomal hydrolases rapidly degrades substrate 
proteins. 
Overall, CMA contributes to maintenance of energy homeostasis, by providing 
aminoacids resultant from protein degradation, and protein quality control, by 
elimination of damaged and prone-to-aggregate proteins [370]. 
3.2.3 The “Janus-faced” role of autophagy in cancer 
Disturbance in the autophagy flux has been associated with cancer development and 
progression [332]. Numerous lines of evidence point out to an anticancer role for 
autophagy. The tumor suppressive role of autophagy was first established from studies 
with BECLIN-1 [376]. Experiments revealed that mice with heterozygous disruption of 
BECLIN-1 exhibited decreased autophagy and were more susceptible to develop tumors 
[377], further studies showed that BECLIN-1 is monoallelically depleted in several human 
cancers [378]. Similarly, the antiapoptotic BCL-2 and BCL-XL proteins, which are often 
overexpressed in human cancers, inhibit autophagy by binding to BECLIN-1 (see Section 
3.2.1) [379]. Consequently, BECLIN-1 overexpression leads to increased autophagy and 
inhibition of tumor development [380]. Additionally, loss of the autophagy gene ATG5 
was shown to promote tumorigenesis [381]. Moreover, tumorigenesis and autophagy 
share several signaling pathways. The activation of the signaling pathway involving PI3K 
and the mTOR is one of the most common events in cancer cells and leads to autophagy 
inhibition [332]. Another example is related with the TP53 tumor suppressor, which was 
shown to positively regulate autophagy in DNA-damage cells through mTOR inhibition 
[382].  
All of the above works establish a role of autophagy as a mechanism of tumor suppression; 
however, the question of how autophagy depletion leads to cancer development remains 
debatable. A possible link between tumorigenesis and autophagy impairment may involve 
the accumulation of protein aggregates, damaged mitochondria, and misfolded proteins 
which in turn leads to increased ROS production and consequently to DNA damage [383]. 
Furthermore, defective autophagy may also contribute to tumor formation via decreased 
cell death. As previously mentioned in Section 3.2, autophagy has been proposed as a cell 
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death mechanism; in fact autophagy and apoptosis share regulatory circuits, namely the 
signaling pathway involving PI3K, AKT and mTOR which blocks apoptosis and inhibits 
autophagy [332]. In addition, BECLIN-1 is a member of BH-3–only  subfamily of 
antiapoptotic regulatory proteins whose expression is decreased in tumor cells [343]. 
Moreover, autophagy prevents necrotic death reducing the risk of inflammatory 
responses which can be actively tumor-promoting [384, 385]. Another possibility is that 
autophagy negatively regulates cell growth by degrading specific organelles and/or 
proteins essential for growth regulation. This hypothesis is supported by studies 
demonstrating that overexpression of BECLIN-1 slows the proliferation of tumor cell lines 
[386]. 
Conversely, autophagy activation in advanced cancer was shown to facilitate tumor 
progression by providing nutrients during starvation [332]. Similarly to what happens in 
normal cells, autophagy is activated in tumor cells by stress. Accordingly, autophagy 
activation in these cells potentiates cell survival in some cases [387], as it promotes a cell 
death escape by conferring superior stress tolerance in tumor cells. CMA was also shown 
to be upregulated in several human cancers allowing cell proliferation and tumor growth 
[388]. Moreover, autophagy induction by hypoxia-inducible transcription factor 1α 
(HIF1α) enables tumor cells to tolerate hypoxic conditions [389]. Autophagy activation 
under prolonged stress conditions may enable a state of dormancy in cancer cells, which 
contributes to tumor relapse and progression [390]. 
Taking all the above information into account, autophagy seems to have a “Janus-faced” 
role in neoplastic development. Although the importance of autophagy modulation in 
tumor cells is clear, the question of whether the promotion or inhibition of autophagic 
pathways is an effective cancer therapy, remains a challenge. The role of autophagy in 
cancer development is complex and seems to depend on cell type, stage and genetic 
context [391]. 
Recently, an important role was attributed to autophagy activation in tumor 
microenvironment by epithelial cancer cells. The importance of tumor microenviroment 
in tumorigenesis has been a topic of great discussion in the last years, revealing that 
tumor biology can no longer be understood solely by the enumeration of traits acquired by 
cancer cells alone [45]. Accordingly, the autophagic tumor stromal model of cancer was 
proposed based on the observation that epithelial cancer cells induce oxidative stress in 
neighboring cancer-associated fibroblasts (CAFs), and in other stromal cell types which 
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results in autophagy activation [392]. Autophagy activation in these cells works as a 
“battery” providing tumor cells with energy sources favoring tumorigenesis. In addition, 
increased oxidative stress also potentiates mutagenesis. Thus, ROS production in CAFs 
was shown to induce DNA damage and aneuploidy in adjacent epithelial cancer cells 
constituting an important driving force to tumor evolution as it potentiates random 
mutagenesis [392]. Furthermore, autophagy in CAFs was also seen to protect cancer cells 
from apoptotic cell death through the maintenance of a constant flow of energy-rich 
nutrients that help to fulfill their high metabolic demands [393].  
Although not consensual, these findings can provide great alterations in our 
understanding of tumor metabolism. Contributing to these advances, Lisanti and 
collaborators showed that CAFs are forced to undergo aerobic glycolysis due to loss of 
their mitochondria through mitophagy [394]. This phenomenon was termed “The Reverse 
Warburg Effect” through which substrates resulting from the Warburg effect occurring in 
CAFs can be transferred to adjacent tumor cells and used as fuels for oxidative 
mitochondrial respiration [394]. The autophagy stroma model of cancer and the reverse 
Warburg effect are characteristic of tumor microenvironment, providing new insights for 
autophagy role on cancer progression as well as a new target for cancer therapy. 
3.2.4 Targeting altered autophagy pathways in tumor cells 
Autophagy inducers were shown to have the potential to induce tumor cell death and may 
therefore be a potential strategy for cancer therapy [395]. Rapamycin, a natural occurring 
inhibitor of the autophagy regulator mTOR, along with its analogs temsirolimus (CCI-
779), everolimus (RAD-0014), and deforolimus (AP-23573) selectively inhibit mTOR 
resulting in autophagy stimulation [396]. However, rapamycin and its analogs have had 
limited successes in the treatment of neuroendocrine carcinomas and lymphoma, which 
results from their inability to inhibit mTORC2 [397]. These limitations led to the 
development of ATP-competitive mTOR inhibitors of both mTORC1 and mTORC2 and the 
dual PI3K-mTOR inhibitor NVP-BEZ235 [398]. 
Moreover, the anti-diabetic drug metformin was shown to modulate autophagy through 
activation of the mTOR upstream mediator AMPK [399]. However, in prostate cancer 
cells, metformin inhibited 2-DG-induced autophagy, decreased BECLIN-1 expression and 
led to cell death [400], suggesting that AMPK autophagy induction might depend on the 
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cell type. Other autophagy inducers include the BCL-ABL tyrosine kinase inhibitor, 
imatinib, which modulates autophagy through regulation of lysosomal components and 
was shown to be effective in chronic myeloid leukemia treatment [401]. In addition, some 
antidepressants, such as fluoxetine and maprotiline, were shown to induce autophagy in 
chemoresistant Burkitt lymphoma cell lines [402]. Furthermore, several conventional 
cytotoxic drugs showed autophagy induction as an important anticancer effect [398]. 
Conversely, autophagy inhibitors may provide the means to overcome treatment 
resistance caused by the induction of a post-treatment dormancy state in cancer cells that 
often contributes to cancer recurrence and metastasis [403]. Additionally, enhanced 
autophagy can target hypoxic tumors, which are usually more resistant to therapy [404]. 
Autophagy inhibitors can be divided in early- and late-stage inhibitors depending on the 
stage of the autophagic pathway they target. Early-stage inhibitors include 3-
methyladenine, wortmannin, and LY294002 that target class III PI3K (VPS34) interfering 
with its recruitment to the membranes [405]. Late-stage inhibitors include chloroquine 
(CQ), hydroxychloroquine (HCQ), and monensin that prevent acidification of lysosomes 
impairing cargo degradation by digestive hydrolases [405]. Another late-stage inhibitor is 
bafilomycin A1, which is a specific inhibitor of vacuolar-ATPase [406]. The use of 
microtubule-disruption agents, such as taxanes, and colchicine, was shown to inhibit 
autophagosome fusion with lysosomes [407]. 
Considering the dual role of autophagy as a tumor suppressor and as an adaptive stress 
response in tumor cell, discussed in Section 3.2.3, the understanding of autophagy 
function in different tumor cells is critical to improve therapy. Autophagy modulation for 
cancer therapy should take into account that tumors with enhanced autophagy will 
respond differently to therapy when compared to those with suppressed autophagy. 
Consequently, the question of whether to activate or inhibit autophagy remains a 
challenge and implies a better knowledge of how this process works in neoplastic versus 
normal cells. 
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Chapter 4  
 
Heat Shock Proteins in cancer 
 
 
4.1 HSP90 family 
4.1.1 TRAP1: the mitochondrial HSP90 
4.1.2 Targeting the mitochondrial complex of HSP90, TRAP1 and CypD in cancer 
cells 
 
 
As described in Section 3.2, accumulation of misfolded proteins and aggregates results in 
a cytotoxic effect in cells and is associated with the development of numerous diseases. 
Consequently, protein quality control is essential for homeostasis and cellular integrity 
maintenance. In normal cells, proteins often misfold as a result of stochastic insults, 
presence of destabilizing mutations, stress conditions, and metabolic challenges. In order 
to overcome these deleterious effects, cells developed different mechanisms to monitor 
and maintain the viability of their proteome. HSPs are stress proteins that play essential 
roles in protein homeostasis maintenance. 
Heat shock proteins assist the folding of newly synthesized polypeptides, avoid the 
formation of aggregates and promote the refolding of stress-denature proteins [408]. 
Besides these functions, HSPs also aid the translocation of proteins to their correct 
intracellular localization and target misfolded proteins for degradation [409]. Under 
normal conditions, HSPs are expressed at low levels. However, when exposed to cellular 
stressors, which leads to impaired proteome, damaged proteins bind to chaperones and 
induce the release heat shock factor (HSF) that consequently induces HSP expression 
[410]. 
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Mammalian HSPs have been categorized in two groups depending on their size, the high 
molecular weight HSPs, and small molecular weight HSPs. The former includes three 
major families, HSP90, HSP70, and HSP60, which localize in different cellular 
compartments. These high molecular weight HSPs are ATP-dependent and require co-
chaperones to function. Conversely, small weight HSPs, such as HSP27, are ATP-
independent [411]. HSPs are often overexpressed in several human carcinomas [412] as an 
adaptive response to promote cell survival under an unfavorable environment. Increased 
HSPs expression allows tumor cells to tolerate stress levels participating in alterations 
that define cancerous growth [45]. 
4.1 HSP90 family 
HSP90 proteins are highly conserved molecular chaperones that comprise up to 1-2% of 
all cellular proteins and their expression can be further stimulated under stress conditions 
[413]. The human HSP90 family includes seventeen genes from which only six (HSPAA1, 
HSP90AA2, HSP90N, HSPAB, HSP90, and TRAP1) are considered to be functional 
whereas the remaining eleven are thought to be pseudogenes. HSP90 members can be 
divided into four different classes, the cytosolic HSP90AA (or HSP90α), and HSP90AB (or 
HSP90β), the HSP90B (or GRP94) from ER, and mitochondrial TRAP1 [213]. These 
isoforms are closely related sharing high structural homology [213]. There are two major 
cytosolic HSP90 isoforms, the inducible HSP90AA1 and the constitutive form HSP90AB1, 
which are usually not differentiated in most works being generally referred to as HSP90 
[414].  
Heat shock protein 90 is an ubiquitously expressed molecular chaperone essential for the 
correct folding, maturation, stability, and function of a wide range of client proteins. 
HSP90 client proteins, namely protein kinases (HER2, AKT, Raf-1, CDK4, SRC) and 
transcription factors (steroid hormone receptors, TP53, HIF1α) are involved in many 
cellular processes such as cell signaling, growth and/or survival, angiogenesis, 
metastasis, and play important roles in tumor development and progression. HSP90 also 
escorts mitochondrial pre-proteins synthesized in the cytosol to the TOM70 complex and 
assists in their translocation across the outer mitochondrial membrane [415]. 
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Heat shock protein 90 exists as a homodimer, which is constituted by three domains; the 
N-terminal domain contains an ATP-binding site, the middle domain, which is highly 
charged and has a high affinity for co-chaperones and client proteins, and the C-terminus 
the second ATP-binding site is located [416]. The dimeric structure of the chaperone is 
crucial for ATP hydrolysis, and the association of the amino-terminal domains during the 
ATPase cycle is required for maximum ATPase activity [417]. The inherent ATPase 
activity of HSP90 is essential for its function as protein folding mediated by this 
molecular chaperone is dependent on an “active” ATP-coupled mechanism [418]. 
Moreover, C-terminal mutations were found to influence ATPase activity, which suggests 
the involvement of these regions in the ATPase cycle [419]. 
Additionally, HSP90 alters its conformation depending on the nucleotide occupancy of its 
N-terminal nucleotide-binding pocket to attract different co-chaperone proteins, such as 
p23, and Cdc37. Co-chaperones are critical components of the HSP90 folding pathway as 
their functions include targeting client proteins and HSP90 ATPase activity modulation. 
When ATP is bound to the N-terminus, p23 and Cdc37 (p50) proteins bind to HSP90 
leading to the stabilization and protection of its client proteins. However, when ADP is 
bound, HSP70 and HOP (p60) bind to HSP90, which results in client protein degradation 
by the proteasome [420]. 
As previously mentioned (Section 1.2), genetic instability allows cells to acquire some 
capabilities that are characteristic of most cancer cells, such as self-sufficiency in growth 
signaling, insensitivity to anti-growth signaling, ability to evade cell death, sustained 
angiogenesis, tissue invasion and metastasis, and limitless replicative potential. The fact 
that HSP90 plays a pivotal role in the acquisition and maintenance of each of these 
capabilities makes it an excellent target for anti-cancer therapies.  
HSP90 inhibitors interfere with the chaperone activity of HSP90, and consequently client 
proteins are targeted to the proteasome where they are degraded [421]. However, if the 
proteasome is inhibited, client proteins accumulate in a misfolded, inactive form in 
detergent-insoluble subcellular complexes [422]. These evidences demonstrate the anti-
tumor clinical potential of these agents. 
The HSP90 inhibitor NVP-AUY922 has been shown to exhibit significant antiproliferative 
properties against human breast cancer cell lines [423] and in HCT116 colon carcinoma 
cells where it induced a G1 and G2-M arrest [424, 425]. NVP-AUY922 interferes with the 
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HSP90-p23 complex [423] and exhibits an extremely high affinity for the N-terminal 
nucleotide-binding site of human HSP90 [424]. IPI-504, another HSP90 inhibitor, 
significantly inhibits growth of a series of pancreatic tumors revealing that it might have a 
potent anti-tumor activity in pancreatic cancer [426].  
Moreover, HSP90 is required for the stability and function of multiple mutated, chimeric, 
and/or overexpressed signaling proteins that are involved in the oncogenic process. BCL-
ABL protein and mutated B-RAF as well as mutated epidermal growth factor receptor 
(EGFR) are some examples of chimeric HSP90 client proteins, which show sensitivity to 
its inhibitors [427]. 
The fact that HSP90 plays an essential role in the maintenance of many oncogenic client 
proteins stability and function, contributing to all of the hallmark traits of malignancy, 
makes this a good therapeutical target for the treatment of cancer. HSP90 inhibition 
constitutes a promising therapeutical approach. 
4.1.1 TRAP1: the mitochondrial HSP90 
TRAP1, an HSP90-like chaperone, was first identified by yeast-two-hybrid assay as a 
novel interacting partner of the tumor necrosis factor receptor 1 (TNFR1) [428, 429]. 
Additionally, an independent screening identified a 75KDa protein (HSP75) with 
structural homology to HSP90 family members that bound to the Rb protein [430]. This 
HSP75 was implicated in the maintenance of RB conformation during mitosis and after 
heat shock [430]. Later, sequence analysis determined that HSP75 and TRAP1 were 
identical molecules. Although these initial reports suggest its predominant extra-
mitochondrial localization, TRAP1 was shown to be primarily a mitochondrial matrix 
protein [431, 432]. Nevertheless, TRAP1 was found to localize at specific 
extramitochondrial sites, namely on the cell surface of blood vessel endothelial cells, 
insulin and zymogen granules in pancreatic cells, nuclei of pancreatic and heart cells, 
cardiac sarcomeres, and in the ER [432]. Regarding tissue distribution, TRAP1 was 
detected in normal tissues and, with higher expression, in tumor cell lines [304, 433]. 
  
 SECTION 4.1
PhD in Biology – Specialization in Cell Biology 67
TRAP1 structure 
Despite being a member of HSP90 family, sharing 34% sequence identity and 60% 
homology with members of the HSP90 family [429], TRAP1 has distinct functional 
properties [431]. Sequence analysis revealed that TRAP1, similarly to other members of 
the HSP90 family, contains an ATP-binding domain at its N-terminus [434]. Thus, TRAP1 
ATPase activity is affected by HSP90 inhibitors [431]. Moreover, TRAP1 molecule lacks a 
C-terminal MEEVD sequence, which is characteristic of cytosolic HSP90 and is critical for 
its binding to several tetratricopeptide repeat-containing co-chaperones [431, 435]. 
Consequently, TRAP1 does not bind to typical HSP90 co-chaperones p23 and HOP, and 
cannot substitute HSP90 in promoting the maturation of the progesterone receptor 
hormone-binding state [431]. TRAP1 was shown to form stable homodimers with melting 
temperature of 55 °C, and its ATPase activity is induced by 200-fold in response to heat 
shock [436]. Another functional difference between TRAP1 and other HSP90 members 
regards its ATPase cycle. ATP-binding results in conformational alterations, shifting to a 
more closed configuration, though with slower kinetics in TRAP1 when compared to 
HSP90 [436]. Despite the conformational trapping, ATP hydrolysis occurs at a slower rate 
than chaperone configuration re-opening, i.e. ATP-binding to TRAP1 is insufficient to 
commit to nucleotide hydrolysis revealing the lower ATPase activity of these chaperone 
[436]. 
TRAP1 subcellular localization 
TRAP1 subcellular localization was confirmed by the identification of a mitochondrial 
targeting sequence at its N-terminal [431]. Further work demonstrated that TRAP1 
predominantly accumulates in the mitochondrial matrix [432], although it has been 
recently suggested it may also be found in the intermembrane space [437]. TRAP1 
putative mitochondrial import sequence is removed upon organelle import. 
Notwithstanding, TRAP1 is also found in extramitochondrial sites, suggesting that a pool 
of mitochondrial TRAP1 is exported out of the organelle matrix allowing chaperone 
interaction with proteins in other subcellular compartments. The presence of an LxCxE 
motif allows this chaperone binding to RB, being absent in other members of the HSP90 
family [430]. 
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TRAP1 functions and regulators 
With respect to its cellular functions, TRAP1 was first shown to be involved in the 
protection against apoptosis, through regulation of both intrinsic and extrinsic pathways 
[438]. Masuda and colleagues found that treatment of tumor cells with the ATP non-
competitive inhibitor of protein-tyrosine kinases, β-Hydroxyisovalerylshikonin (β-
HIVS), or with the DNA-damaging chemotherapeutic VP-16, resulted in suppression of 
TRAP1 expression and enhanced mitochondrial apoptosis [438]. These results suggest the 
important role of TRAP1 in the protection against apoptosis. Similar conclusions were 
achieved in studies regarding Granzyme M mediated apoptosis in Natural Killer cells 
[439]. Granzyme M, a serine protease stored in granules of immune system effector cells, 
causes mitochondrial swelling, loss of ΔΨm, generation of ROS, and cytochrome c release 
in a TRAP1-dependent manner [439]. 
In addition to its antiapoptotic function, TRAP1 also exerts an antioxidant function, 
allowing cells to cope with oxidative stress. Accordingly, several lines of evidence support 
the important role of ROS in TRAP1 regulatory network [438-440]. Moreover, Im and 
colleagues demonstrated that TRAP1 overexpression attenuated the effects of 
deferoxamine, through the reduction of ROS production [440]. An independent study 
identified TRAP1 as one of the target genes upregulated by the MYC oncogene [441]. The 
concept of TRAP1 as a stress-responsive chaperone that protects cells against oxidative 
stress and apoptosis following DNA damage, ROS production, or oncogene expression, 
gained further support [442-444]. TRAP1 cytoprotective effects seem to be important for 
cells to overcome oxidative stress through inhibition of ROS-mediated cell death. 
Further evidences of the role of TRAP1 in tumorigenesis came from studies regarding the 
role of TNFα/TNFR1 signaling in cell adhesion of neuronal cells. TRAP1 was shown to 
modulate the expression of N-cadherin cell adhesion molecule, through the regulation of 
the signal transducer and activator of transcription 3 (STAT3) phosphorylation status 
[445]. These observations seemed to point-out the involvement of TRAP1 in the processes 
of cell invasion and motility. Later, the identification of TRAP1-regulated pathways in an 
hypoxic model, demonstrated that TRAP1 regulates the expression of genes involved in 
cell cycle and metastasis [446]. In this study, TRAP1 depletion in lung cancer cells resulted 
in an increase of genes involved in cell motility and metastasis suggesting that TRAP1 
activates proliferation while inhibiting cell invasion [446]. In addition, Leav and 
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collaborators identified TRAP1 as a novel molecular target in localized and metastatic 
prostate cancer [433]. 
As previously mentioned, TRAP1 expression is increased in numerous cancer cells and 
tissues when compared with their normal counterparts [433, 447, 448]. TRAP1 
overexpression in cancer cell lines is associated with multi-drug resistance phenotype 
[442, 447]. However, the full mechanism for such resistance remains to be elucidated. For 
instance, Montesano and colleagues demonstrated that TRAP1 upregulation is associated 
with cell resistance to H2O2-induced DNA damage and apoptosis upon cisplatin treatment 
[442]. These observations were later supported by independent works showing a link 
between TRAP1 overexpression and the acquisition of a multi-drug resistance phenotype 
in colorectal cancer cells [447]. 
Studies in Parkinson Disease (PD) brought great contributions to the knowledge of some 
TRAP1 regulation mechanisms [437]. Pridgeon and colleagues found that phosphorylation 
of TRAP1 by PINK1 protects against ROS-mediated cell death whereas variants of PINK1 
exhibiting loss of function mutations in PD patients were unable to reverse cell death 
[437]. TRAP1 phosphorylation by PINK1 seems to be required to enable its cytoprotective 
effect and preserve mitochondrial integrity, at least in neuronal cells. 
Despite these advances in the understanding of TRAP1 role in apoptosis protection, the 
mechanisms behind TRAP1 cytoprotective effect in tumor cells are still unknown. 
Following this line of thought, recent studies regarding HSP90 protective role in tumor 
cells led to the identification of a mitochondrial chaperone network implicated in this 
process [304]. TRAP1 directly interacts with CypD, inhibiting mPTP opening and 
consequent cytochrome c release upon apoptotic stimuli [304]. The authors also identified 
a pool of HSP90 localized in mitochondria and demonstrated that both of these two 
chaperones physically associate with CypD and are required to oppose its function [304]. 
Later, works developed by Ghosh and collaborators led to the identification of HSP60 as 
an additional CypD interacting partner [302]. Altogether, CypD modulation seems to 
occur through its interaction with a multi-chaperone complex comprising HSP60, HSP90, 
and TRAP1 (Fig.4.1). Furthermore, the antagonistic functions of these chaperones 
regarding mPTP opening require their ATPase activity suggesting that protein 
folding/refolding is critical in regulating CypD functions [304]. These data support the 
mPTP model proposed by Lemasters [449] composed of clusters resulting from oxidized 
and misfolded proteins, which would expose hydrophilic residues to the lipid membrane 
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creating therefore the channel. Accordingly, pore closure would be determined by 
chaperone proteins, which would bind to the cluster blocking channel conductance [449]. 
In addition to CypD and PINK1, Sorcin, a mitochondrial localized low molecular weight 
(18KDa) calcium-binding protein, was recently identified as a novel TRAP1-interacting 
molecule [450]. In this work, the authors propose that Sorcin interaction with TRAP1 is 
implicated in stabilization of this chaperone through post-translational mechanisms. 
Functionally, this interaction was shown to be important for Sorcin-induced multidrug 
resistance phenotype and antiapoptotic activity whereas Sorcin mitochondrial 
localization and stability seems to be crucial for TRAP1 regulation of cell survival [450]. 
The crucial role of this 18-KDa Sorcin isoform in mitochondrial Ca2+ homeostasis 
maintenance, contributing to the regulation of mPTP opening, and the relevance of the 
TRAP1/Sorcin complex in TRAP1 cytoprotective pathway contribute for a better 
understanding of TRAP1 mPTP modulation. 
The most recent function attributed to TRAP1 is its involvement in ER stress protection 
[451]. TRAP1 expression regulates ER stress levels, i.e. TRAP1 expression decreases upon 
strong ER stress, resulting in the activation of the ER stress-induced unfolded protein 
response (UPR) pathway protecting cells against ER stress-induced cell death [451]. 
However, these results were quite inconclusive regarding the mechanisms through which 
TRAP1 is involved in ER stress protection. Nevertheless, Altieri’s group showed that 
selective targeting of mitochondrial HSP90 chaperones in tumor cells triggers 
compensatory autophagy and an UPR based on the upregulation of CCAAT enhancer 
binding protein (C/EBP) transcription factor and its dimerization partner C/EBP 
homology protein (CHOP) [452]. Simultaneous works led to the identification of TBP7, an 
AAA-ATPase component of the 19S proteasome subunit, as a TRAP1-interacting partner 
whose role is determinant in protein quality control (Fig.4.1) [452]. Moreover, 
TRAP1/TBP7 was shown to regulate ubiquitination of the 18KDa Sorcin isoform. 
4.1.2 Targeting the mitochondrial complex of HSP90, TRAP1 
and CypD in cancer cells 
The above data highlight TRAP1 cytoprotective functions in cells [438]. These results 
together with TRAP1 differential expression in cancer as opposed to normal tissue [447] 
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suggests TRAP1 involvement in tumor maintenance and the ability of tumor cell growth 
and survival under stress conditions, making it a potentially attractive target for cancer 
therapy. Moreover, the identification of a mitochondrial chaperone network, comprising 
HSP90, TRAP1 and CypD, brought new insights on TRAP1 mitochondrial integrity 
maintenance function [304]. As previously mentioned (Section 4.1.1), HSP90 and TRAP1 
bind to and antagonize CypD allowing cancer cells to circumvent apoptosis. Therefore, 
inhibition of this complex seems to provide an efficient approach of targeting cancer cells. 
Two types of drug candidates have shown high efficacy, shepherdin and gamitrinibs. 
Shepherdin was the first drug designed to target HSP90-like mitochondrial pool, and it 
Figure 4.1 - TRAP1 cytoprotective functions in tumor cells. The differential expression of
TRAP1 in tumor cells as opposed to normal cells has been associated with the acquisition of
resistance to chemotherapeutic agents, inhibition of apoptosis, and suppression of ROS
production, to which TRAP1 phosphorylation by PINK1 is thought to be required. A possible
mechanism through which TRAP1 exerts its protective functions may be by interacting with
CypD modulating mPTP. In addition, other molecular chaperones, namely HSP90 and
HSP60, also seem to be involved in this function. More recently, TRAP1 was described to
form a complex with TBP7 on the outside of the ER. This complex is involved in the control
of stability and ubiquitination of several mitochondrial proteins. Abbreviations: CypD –
cyclophilin D; HSP – heat shock protein; mPTP – mitochondrial permeability transition pore;
PINK1 – PTEN induced putative kinase 1; ROS – reactive oxygen species; TRAP1 – TNF
receptor-associated protein 1. 
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was shown to interact with the N-terminal region of HSP90 and TRAP1, which harbors 
their ATPase activity [453]. In the mitochondrial matrix of tumor cells, shepherdin 
rapidly induces apoptotic cell death in a CypD-dependent manner [454]. Further evidence 
of this inhibitor efficacy came from studies with TRAP1 overexpressing colorectal cancer 
cells. Treatment with shepherdin overcame cells resistance to chemotherapeutic agents 
[447]. 
A novel class of small molecule inhibitors of HSP90 that has been studied provide a less 
toxic alternative than the classic inhibitor Geldanamycin (GA) which binds to the ATP 
binding pocket, preventing ATP hydrolysis and revealed high hepatotoxicity in mammals 
[423, 424, 455]. Gamitrinibs (GA mitochondrial matrix inhibitors) are provided with a 
mitochondrial targeting sequence, which allows their accumulation in tumor 
mitochondria. Unlike gamitrinibs, non-GA derivatives such as NVP-AUY922 are not able 
to specifically accumulate in tumor mitochondria. Several studies show that gamitrinibs 
reveal a unique mechanism of action (revised in [454]). Within mitochondria, these 
mitochondria-targeted HSP90-like protein inhibitors lead to higher mitochondrial stress, 
namely the activation of the mitochondrial UPR, which in turn results in increased 
mitophagy [456]. In addition, tumor cell treatment with gamitrinibs causes a decline in 
mitochondrial and cytosolic energy production initiating the energy-sensing AMPK 
pathway and subsequent mTOR inhibition [457]. As a consequence of mTOR inhibition, 
there is an increase in the autophagy pathway in tumor cells. Importantly, these studies 
revealed high selectivity of gamitrinibs towards tumor cells showing no toxicity to their 
normal counterparts. 
Gamitrinibs effect on tumor cells has been widely studied and has revealed a high 
potential for anticancer therapy emphasizing the important role of TRAP1 and HSP90 in 
tumorigenesis. Furthermore, gamitrinibs potential tumor selectivity may be justified not 
only by the differences observed in TRAP1 expression between tumor and normal 
mitochondria, but also by a possible increase in ATPase activity in transformed cells 
similarly to what happens with HSP90 [458]. 
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Chapter 5  
 
Hypothesis and Aims 
 
As described in Chapter 4, TRAP1 is a highly expressed mitochondrial chaperone, in 
tumor cells, with antioxidant and antiapoptotic functions. The last decade of investigation 
added valuable information regarding TRAP1 network, unveiling the high complexity and 
wide range of mechanisms involved in TRAP1 role in tumorigenesis. However, despite the 
increasing knowledge on TRAP1 function in tumor cells there are still gaps that need to be 
filled for a better understanding of its mechanisms of action. Therefore, deeper 
investigation of TRAP1 role in mitochondria homeostasis and quality control is of great 
interest as it may contribute to the development of new therapeutic strategies. 
Hence, this work aspires to contribute with new insights on TRAP1 role in mitochondria 
protection and in quality control systems regulation. Based on previous observations 
indicating TRAP1 as a mediator of tumor homeostasis through protection against 
mitochondrial dysfunction we hypothesize that TRAP1 pro-survival actions are 
mediated by its interaction with critical cellular quality control systems  upregulating 
survival under stress conditions and preventing mitochondrial disruption. Thus, this 
study first aims the better understanding of the extent of TRAP1 role in mitochondrial 
integrity maintenance with special focus on the identification of the mitochondrial 
phenotype resulting from TRAP1 silencing. The second aim regards TRAP1 presumable 
involvement in the activation/suppression of quality control systems as a mechanism to 
achieve its cytoprotective role. In addition, this project intends to predict, the possible 
clinical significance of TRAP1 regulated quality control systems for tumor progression and 
maintenance. 
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This dissertation was divided in two independent chapters considering the two cell 
models used in our investigation. Alterations regarding mitochondrial function and 
morphology in TRAP1-depleted A549 lung cancer cells, a cell model which expresses high 
TRAP1 levels, are described in Chapter 7. Furthermore, the information which will be 
presented here will test whether TRAP1 impacts mitochondrial dynamics in this cell line. 
Also, studies concerning TRAP1 involvement in autophagy and apoptosis modulation are 
presented here, since stress-responses in the context of cancer are of high relevance for 
onco therapy. 
The same scientific approaches were independently performed in MRC-5 normal human 
lung fibroblast cell line, and are present in Chapter 8. As this cell line revealed low TRAP1 
content, this study aimed the deeper understanding of cell (in)dependence on TRAP1 in 
terms of mitochondrial dynamics and cell quality control. This work provided further 
information on TRAP1 function and effects of its inhibition in cells with low expression, 
which can mimic, saving the obvious differences, a pre-transformed cellular condition. 
Finally, Chapter 9 integrates all the obtained results with information previously 
provided in the literature. This dissertation provides relevant and new information on 
how TRAP1 exerts its cytoprotective functions in tumor cells. Moreover, this work also 
brings novel interesting information on TRAP1-silencing effect in cells with low TRAP1 
content providing new material for the eventual need of implementation of different 
therapeutic approaches. 
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Chapter 6  
 
Material and Methods 
 
 
6.1 Materials 
6.2 Cell Culture 
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6.4 Sulforhodamine B assay 
6.5 Material harvesting 
6.6 Protein Quantification 
6.7 Protein quantification and cellular localization 
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6.9 Evaluation of oxygen consumption 
6.10 Evaluation of mitochondrial membrane potential 
6.11 Evaluation of oxidative stress 
6.12 Evaluation of mitochondrial permeability transition pore opening 
6.13 Caspase-like activity assay 
6.14 Fluorescence detection of lysosomal bodies 
6.15 Statistics 
 
 
6.1 Materials 
6.1.1 Standard solutions and buffers 
All aqueous solutions and buffers were prepared with Milli-Q water. Whenever needed 
buffers’ pH was determined using a pH meter, which was regularly standardized with the 
following standard buffer solutions pH 7.0, 4.0, and 10.0. The solutions of siRNA 
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oligonucleotides to desired concentration were prepared in RNase DNase free water 
contained in the respective kits. All agents used in drug toxicity assays were diluted into 
the desired concentration directly in complete cell growth medium (see Section 1.2). 
6.1.2 Reagents and kits 
Reagents used in cell culture, such as 0.05% Trypsin-EDTA (Catalog# 25300-062), fetal 
bovine serum (FBS; Catalog# 16000-044), Penicillin-Streptomycin (Catalog# 15140-122), 
and Iscove's Modified Dulbecco's Medium (IMDM; Catalog# 12440-046), as well as 1x 
Opti-MEM (Catalog# 31985-047), and 10x Hank’s Balanced Salt Solution, calcium, 
magnesium (HBSS/Ca2+/Mg2+; Catalog# 14065-049) were purchased from Invitrogen 
(Carlsbad, CA, USA). 
The TRAP1 (Catalog# SI03066364) and the scrambled (Catalog# D-001810-03-20) siRNA 
oligonucleotides were obtained from Qiagen (Madrid, Spain) and Thermo Fisher Scientific 
(Lafayette, CO, USA) respectively, while Lipofectamine 2000 (Catalog# 11668-019) 
transfection reagent was from Invitrogen (Carlsbad, CA, USA). Additionally, 5x siRNA 
buffer (Catalog# B-002000-UB-100), used for oligonucleotide dilution during cell 
transfection protocol, was purchased from Thermo Fisher Scientific (Lafayette, CO, USA). 
Agents used in drug toxicity assays such as Doxorubicin (Catalog# D1515), 3-
Methyladenine (Catalog# M9281), and Rapamycin (Catalog# R8781) were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). Total RNA harvesting RNeasy mini kit (Catalog# 
74104) as well as the RNase-Free DNase set (Catalog# 79254) were acquired from Qiagen 
(Madrid, Spain), while the Recombinant RNasin ribonuclease inhibitor (Catalog# N2111) 
used was from Promega (Madison, WI, USA). 
Reagents used for total protein harvesting such as RIPA buffer (Catalog# 89900), and the 
protease inhibitor cocktail (Catalog# P83490) were purchased from Thermo Fisher 
Scientific (Lafayette, CO, USA) and Sigma-Aldrich (St. Louis, MO, USA) respectively. The 
protein quantification bicinchonic acid assay (BCA) was performed using the Pierce BCA 
assay kit (Catalog# 23250) from Thermo Fisher Scientific (Lafayette, CO, USA). 
Moreover, for Western Blot, precision plus protein dual color (Catalog# 161-0374) 
molecular weight standard and the blotting-grade blocker non-fat dry milk (Catalog# 170-
6404) from BioRad (Hercules, CA, USA) were chosen. In addition, membrane protein 
  
 SECTION 6.1
PhD in Biology – Specialization in Cell Biology 79
detection was achieved using the Enhanced Chemi-Fluorescence system (ECF; Catalog# 
RPN3685) from GE Healthcare (Buckinghamshire, UK). All primary antibodies used are 
listed in Table 6.2 as well as their respective catalog number and brand; the secondary 
antibodies used were all purchased from Santa Cruz biotechnology (Heidelberg, 
Germany). Moreover, when mounting coverslips during immunocytochemistry assay, 
ProLong Gold antifade reagent with DAPI (Catalog# P36935) from Invitrogen (Carlsbad, 
CA, USA) was used. 
All primers used were purchased from Integrated DNA Technologies (Coralville, IA, USA) 
and can be found listed in Table 6.3. Reverse transcription was performed using the 
iScript cDNA Synthesis kit (Catalog# 170-8891) while the SsoFast EvaGreen Supermix 
(Catalog# 172-5201) was chosen for quantitative PCR, all from BioRad (Hercules, CA, 
USA). For classic PCR the HotStarTaq Master Mix (Catalog# 203443) from Qiagen 
(Madrid, Spain) was used. 
In order to confirm primer specificity, agarose gel electrophoresis was performed using 
BlueJuice Gel loading buffer (Catalog# 10816-015) and a 100bp DNA ladder (Catalog# 
10380-012) all from Invitrogen (Carlsbad, CA, USA) while 10x Tris Acetate-EDTA buffer 
(TAE; Catalog# T9650) was obtained from Sigma-Aldrich (St. Louis, MO, USA). DNA 
amplification products were purified with the MiniElute PCR Purification kit (Catalog# 
28004) from Qiagen (Madrid, Spain). 
All probes used in the present work, which include the Tetramethylrhodamine, methyl 
ester (TMRM; Catalog# T-668), MitoTracker Green FM (MTG; Catalog# M-7514), 
H2DCFDA (Catalog# D-399), MitoSOX Red (Catalog# M-36008), LysoTracker Green 
(Catalog# L-7526), and the MitoProbe Transition Pore Assay kit (Catalog# M-34153), were 
purchased from Molecular Probes, Invitrogen (Carlsbad, CA, USA). 
Caspase 3/7 and 9-like activities were analyzed with caspase Glo 3/7 (Catalog# G8090) 
and caspase Glo 9 (Catalog# G8210) assay kits respectively, from Promega (Madison, WI, 
USA), whereas caspase 12-like activity was measured with the fluorimetric Caspase 12 
assay kit (Catalog# ab65664) from AbCam (Cambridge, UK). Caspase 8-like activity was 
accessed using the granzyme B substrate I (Catalog# 368057) from Millipore (Billerica, 
MA, USA).  
All general chemicals used were of the highest grade of purity commercially available. 
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6.2 Cell Culture  
6.2.1 Cell lines 
In the present work, the A549 lung cancer and MRC-5 normal lung fibroblast cell lines 
were used. The A549 cell line was first developed in 1972 by D.J. Giard, et al through 
explant culture of lung carcinomatous tissue from a 58-year-old Caucasian male [459]. 
A549 cells are a monolayer human adenocarcinomic alveolar basal epithelial hypotriploid 
representative with a modal chromosome number of 66 occurring in 24% of cells. 
Although most of the cells contain two X and two Y chromosomes, 40% of the cell 
population may have lost one or both Y chromosomes. 
The MRC-5 cell line was initially derived by J.P. Jacobs from normal lung tissue of a 14-
week-old male fetus aborted for psychiatric reasons from a 27-year-old physically 
healthy woman [460]. Cells show a fibroblast-like morphology and present normal diploid 
human cell line with 46,XY karyotype without any known alterations in the X and Y 
chromosomes. 
Both cell lines were purchased from ATCC (LGC Standards, Middlesex, UK), stored frozen 
in liquid nitrogen vapor phase and expanded following manufacturer’s instructions. For 
routine subculturing, cells were first rinsed with 1x Phosphate Buffered Saline (1x PBS; 
0.137 M NaCl, 2.7 mM KCl, 1.4 mM KH2PO4, 0.01 M Na2HPO4) and then incubated with 1 
volume of trypsin-EDTA for 3 min at 37°C. Trypsin activity was inhibited by the addition 
of 1 volume of complete growth medium and the final volume centrifuged at 300xg for 3 
min at room temperature. An appropriate aliquot of the cell suspension was added to new 
culture flasks to obtain cultures between 2x103 and 1x104 viable cells/cm2. This procedure 
was repeated when cultures reached 80-90% confluence. Cells were used between 
passages 5 and 25. 
Unless stated otherwise, the normal culture medium was Iscove's Modified Dulbecco's 
Medium (IMDM) supplemented with 5% FBS and 1% penicillin-streptomycin (all from 
Invitrogen) at 37°C in humidified air with 5% CO2  (all concentrations in vol/vol). 
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6.2.2 siRNA Transfection 
TRAP1 silencing was performed using a commercial available small interfering RNA 
(siRNA). siRNA are a class of double-stranded RNA, of short length (20-25 base pairs), 
present in nature as a mechanism to inhibit gene expression [461] The rationale behind it 
is that in normal cells, mRNA can only exist as a single strand. Because siRNA is 
complementary to the mRNA sequence, it binds to it and lead to its destruction. The RNAi 
pathway is depicted in Fig.6.1; briefly, the double-strand RNA is unwound through an 
ATP-dependent step by the RNA-induced silencing complex (RISC) where one of the 
strands is degraded and the other assists in the identification of RNAs that are 
complementary to this single stranded siRNA. Next, an endoribonuclease cleaves the 
referred RNA, which is then degraded by exoribonucleases [461]. 
Cells were transfected with 50nM of either TRAP1 siRNA oligonucleotide, antisense 
strand 5’- UGG AUG AGG ACU UUG CGG CTG -3’ (Qiagen), or with a scrambled siRNA 
(Thermo Fisher Scientific). Oligonucleotides were prepared following the manufacturer’s 
instructions in order to obtain a 20μM stock solution. 
Transfection was performed using Lipofectamine 2000TM transfection reagent 
(Invitrogen) according to the manufacturer’s instructions. Twenty-four hours prior to 
transfection, cells were seeded at a concentration of 1x105 cells/mL in standard 60mm 
dishes and incubated overnight under normal growth conditions. In the transfection day, 
two sets of three tubes were prepared, tubes 1 to 3, and 1’ to 3’, as represented in Fig.6.2. 
The TRAP1 and control oligonucleotides were diluted to the desired concentration (50nM) 
in 1x siRNA buffer (Thermo Fisher Scientific) in the first set of tubes, tubes 1 and 2 
respectively (see Fig.6.2), reaching the final volume of 250μL. In tube 3, only 250μL of the 
referred buffer was added. Additionally, in the second set of tubes, namely tubes 1’ and 2’, 
Lipofectamine 2000TM was diluted in Opti-MEM (Invitrogen) without serum to a final 
volume of 500μL.  Moreover, 500μL of Opti-MEM was added to tube 3’. Both sets of tubes 
were incubated for 5 min at room temperature before addition of 250μL of Opti-MEM to 
the first set of tubes (1 to 3).  
Next, the content of tubes 1 to 3 was combined with tubes 1’ to 3’ respectively and 
incubated for 20 min at room temperature allowing complexes to form. Once the 
incubation was complete, complexes were added to dishes containing cells and 1.5mL of 
Opti-MEM and incubated for 5 hours under growth conditions until the addition of 2.5mL  
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of complete growth medium. The cell culture medium was changed 24 hours after 
transfection to remove unloaded oligonucleotides and transfection reagent from solution 
and cells were allowed to grow for 48 hours before further experiments.  
6.3 Experimental design 
The overall experimental design is shown in Fig. 6.3. Twenty-four hours before the 
transfection protocol, cells were seeded in 60mm dishes. The time of transfection was 
designated as time zero and cells were kept in culture for 48 hours for an efficient 
transfection. However, at that time, and depending on the final objective of the 
experiment, cells were harvested and seeded into proper plastic ware or glass coverslips 
Figure 6.1 - siRNA pathway. The double-strand RNA (dsRNA) is unwound through an ATP-
dependent step by the RNA-induced silencing complex (RISC). Upon dsRNA loading onto
RISC the passenger (sense) strand is cleaved so that active RISC contains the guide
(antisense) strand. Consequently, the siRNA guide strand recognizes target sites to direct 
mRNA cleavage. Adapted from [460]. 
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24 hours before the assay (live imaging, immunocytochemistry, caspases 3/7 and 9-like 
activity and Sulforhodamine B, SRB assay), or otherwise kept in culture (mRNA and 
protein harvest, flow cytometer, caspases 8 and 12-like activity) until 72 hours post-
transfection.  
A relevant note should be made regarding the incubation times in SRB assay to clarify the 
reader. Although the results are expressed as percentage of time zero, this designation 
250 ! L 
siTRAP1 siOT3 CTL 
Oligonucleotides 
(50 nM) 
siRNA buffer 
(1x) 
1’ 2’ 3’ 
500 ! L 
Lipofectamide 2000 Opti-MEM 
RT 
5 min 
500 ! L 
siTRAP1 siOT3 CTL 
Opti-MEM 
1’ 2’ 3’ 
1000 ! L 
a 
b 
c 
d RT 
20 min 
Add to cell 
culture dishes 
Figure 6.2 - Cell transfection scheme. Two sets of three sterile RNase DNase free tubes
were prepared (tubes 1 to 3 and 1’ to 3’). Firstly, 250μL of 1x siRNA buffer was added to tubes
1 to 3 and 500μL of Opti-MEM to tubes 1’ to 3’. Moreover, 50nM of either TRAP1 siRNA or
scrambled RNA oligonucleotides were added to tubes 1 and 2 respectively while
Lipofectamine was added to tubes 1’ and 2’. Tubes were incubated for 5 min at room
temperature before addition of 250μL of Opti-MEM to tubes 1 to 3. After incubation time, the
content of tubes containing the diluted oligonucleotides was combined with the respective
tube containing the transfection reagent. Tubes were incubated for 20 min at room
temperature. In the mean time, cells were washed three times with pre-warmed 1x PBS and
1.5mL of Opti-MEM was added to each plate. After the incubation period, the content of each
tube was added in different cell plates and let incubate for 5 hours under normal growth
conditions. 
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does not refer to the time when transfection was performed but to 24 hours post-cell 
plating. In fact, the SRB time zero refers to 48 hours post-transfection (please consult 
Fig.6.3 to visualize the protocol). 
6.4 Sulforhodamine B assay 
Skehan introduced the sulforhodamine B (SRB) assay in 1990[462]. This method is based 
in the ability of the bright pink aminoxanthene SRB dye with two sulfonic groups to bind 
to cell proteins under mildly acidic conditions. Under these conditions, SRB binds to 
protein basic amino acid residues in acid-fixed cells to provide an estimate of total protein 
Cells  
seeding Transfection 
-24h 0h 24h 48h 72h 
mRNA and protein harvest 
flow cytometer 
caspases 8 and 12-like activity 
live imaging 
Immunocytochemistry 
caspases 3/7 and 9-like activity 
a 0h 
* 24h * 48h * 72h * 
SRB proliferation assay 
SRB drug toxicity assay 
Drugs (DOX, 3-MA, Rapamycin) 
b 
Figure 6.3 - Experimental design. Twenty-four hours prior to transfection 1x105 cells/mL 
were seeded in a standard 60mm dish and incubated overnight under normal cell culture 
conditions. Cells were then transfected with either a TRAP1 siRNA (siTRAP1) or a scrambled
siRNA (siCTL) for control, another control group of non-treated cells (CTL) was added to the 
experiment. The medium from cells used for mRNA and protein harvest as well as for flow 
cytometry assays was replaced twenty-four hours post-transfection and cells were leave to 
rest for 48 hours under growth conditions until used. However, when performing SRB
proliferation assays, transfected cells were transferred to a 48-well plate 24 hours post-
transfection. Moreover, at 48 hours post-transfection, these same cells were either drugged 
or allowed to grow and medium from cells corresponding to time zero was removed. The
experimental protocol was conducted until stopping cell growth at the pretended time point. 
To perform live imaging, immunocytochemistry and caspase 3/7 and caspase 9-like activity 
assays, transfected cells were transferred to the respective plates 48 hours post-transfection 
while assay was performed 72 hours post-transfection. 
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mass, which is related to cell number. Accordingly, this assay allows to indirectly access 
cell proliferation and viability. Moreover, once pH is alkalinized, basic amino acids 
became protonated and the SRB dye is released into the solution allowing its measurement 
through a conventional spectrophotometer.  
The protocol used in the present work follows the initial method with minor 
modifications. Since in most situations the experiment was performed in such a way that 
a single microplate contained wells for different time points, cells were first dried before 
being methanol fixed in order to stop cell growth. For that purpose and at the required 
time points, wells were washed twice with 1x PBS and allowed to dry in the incubator at 
37°C for the remaining time of the experiment. Once all wells were processed, cells were 
fixed with ice-cold 1% acetic acid in methanol overnight at -20°C and covered with 
parafilm. Microplates containing fixed cells were then dried at 37°C and 0.5% SRB in 1% 
acetic acid was added to each well and incubated for 30 min at 37°C and subsequently 
washed three times with 1% acetic acid to remove unbound staining. Plates were then 
allowed to dry before the addition of 10mM Tris (pH 10), which was incubated at room 
temperature for 15 min in an orbital shaking platform in order to solubilize bound-protein 
stain. Finally, 200μL of the solubilized solution was transferred to a standard 96-well 
plate and its absorbance read in a VITOR X3 microplate reader (Perkin Elmer, Waltham, 
MA, USA) working at room temperature with a 544/15 nm filter. 
Note that the volume of solution added was always the standard advised volume for the 
plate in use.3 
6.4.1 Cell proliferation assay 
For evaluation of cell growth, cells were seeded at a concentration of 2x105 cells/mL in 48-
well plates. Note that the referred seeding time corresponds to 24 hours post-transfection 
(see Fig.6.3). Twenty-four hours later, one of the wells was used as time zero to normalize 
cell proliferation and reduce inter-plate and inter-day variability associated with the 
assay. Then, every 24 hours, wells were processed as described in the previous section to 
estimate cell growth.  
                                                                
3 Recommended volumes for plastic labware material used can be found in the manufacturer’s 
website:  http://catalog2.corning.com/Lifesciences/media/pdf/an surface areas reco med vol for cc 
vessels.pdf. 
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Drug toxicity assay 
To evaluate cells susceptibility to different chemical compounds, the following setup was 
used: cells were seeded at a concentration of 2x105 cells/mL in 48-well plates, 24 hours 
post-transfection (see Fig.3). After 24 hours, one well was used as time zero and the agents 
were added to cells. For this purpose, a solution with the compound in study was prepared 
in complete growth medium and then added to wells. Every 24 hours, wells were 
processed as described before (Section 2) to estimate cell growth. Table 6.1 shows agent 
concentrations applied in this study as well as the time of addition. 
6.5 Material harvesting 
6.5.1 Total RNA 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) with minor alterations. In the 
day of the harvesting (72 hours post-transfection) cells grown in 60mm dishes were 
rinsed once with 1x PBS and incubated with 1 volume of trypsin during 3 min at 37°C to 
detach cells. Then, 1 volume of complete growth medium was added to stop the reaction 
and cells were centrifuged for 3 min at 300xg at room temperature, with the supernatant 
being discarded. 
Table 6.1 - Drug concentrations and combinations used in SRB proliferation assays. 
Name Concentration Incubation Time * 
Doxorubicin 0.5 μM 0 to 72 h 
Rapamycin 100 nM 0 to 72 h
3-methyladenine 5 mM 0 to 72 h
Doxorubicin + Rapamycin 0.5 μM + 100 nM 0 to 72 h
Doxorubicin + 3-methyladenine 0.5 μM + 5 mM to 72 h
*Note that incubation time is relative to SRB time zero and not post-transfection 
period, corresponding to 48h to 120h post-transfection. 
  
 SECTION 6.5
PhD in Biology – Specialization in Cell Biology 87
To disrupt cells and remove the nuclei, the pellet was resuspended in 350μL of RLN 
[50mM Tris pH 8.0, 140mM NaCl, 1.5mM MgCl2, 0.5% NP-40, 1mM DTT supplemented 
with 175 U RNAsin (Catalog# N2111, Promega)] and incubated on ice for 5 min. Tubes were 
then spun at 300xg for 2 min at 4°C and pellets discarded. 
RNA extraction was initiated with the addition of 600μL of Buffer RLT (supplemented 
with 1% of β-mercaptoethanol) and vigorously vortexing the tubes. Once mixing was 
complete, 430μL of 100% biomolecular grade ethanol was added to the tubes and the 
resulting solution was transferred to a RNeasy spin column placed in a 2mL microtube 
and centrifuged at 8,000xg for 15 sec. After discarding the flow-through, the column was 
washed with RW1 buffer at 8,000xg for 15 sec followed by an in-column DNase digestion 
performed by adding 80μL DNase I incubation mix (RNase-Free DNase Set, Qiagen) 
directly to the column and incubating for 15 min at room temperature. Finally, columns 
were washed once with RW1 buffer (8,000xg for 15 sec) and twice with RPE (firstly, 
8,000xg for 15 sec; secondly, 8,000xg for 2 min). 
RNA was eluted twice from the columns with 30μl RNase-free water to two separate new 
1.5mL RNase DNase-free microtubes. RNA was quantified using a NanoDrop 
spectrophotometer (Thermo Fisher Scientific) to measure the absorbance at 260nm 
(A260). Finally, RNA quality and purity was tested by spectral scan observation and 
considered when a single prominent A260 peak and an A260/A280 ratio with a minimum 
value of 2, was found. 
6.5.2 Total protein 
Two different buffers were used to extract total protein depending on its final 
applications. Extracts for western blot were collected with RIPA buffer (Thermo Fisher 
Scientific; 25mM Tris-HCl pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 
0.1% SDS) as it detergent composition allows efficient extraction of water-soluble and 
membrane-inserted proteins. On collection day, cells grown in 60mm dishes were washed 
once with 1x PBS, detached with 1 volume of trypsin followed by its inactivation with 1 
volume of complete growth medium. Cells were transferred to a 15mL tube and 
centrifuged at 300xg for 3 min; supernatant was discarded and pellet rinsed in 1x PBS. 
Cells underwent another centrifugation at 300xg for 3 min and the supernatant was 
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discarded. Finally, cells were lysed in 1mL of RIPA supplemented with protease inhibitors 
cocktail (Sigma-aldrich) and 1mM DTT. 
The suspension was kept on ice for 20 min, mixed with a pipette every 5 min. Lysates 
were then sonicated three times 1.5 sec at 60 A with 18 W output. Protein content was 
determined by BCA assay (Section 4) using Bovine Serum Albumin (BSA) as standard. 
Extracts for caspase 8-like activity assay (Section 11.2) were collected using a mild-
detergent buffer composition that allows proteins to retain their activity. On collection 
day, cells grown in 60mm dishes were washed once with 1x PBS, detached from the dishes 
with 1 volume of trypsin followed by its inactivation with 1 volume of complete growth 
medium. Cells were then transferred to a 15mL tube and centrifuged at 300xg for 3 min; 
supernatant was discarded and pellet rinsed in 1x PBS. Cells underwent another 
centrifugation at 300xg for 3 min and the supernatant was discarded. Finally, cells were 
lysed in a buffer containing 100mM NaCl, 0.1% CHAPS, 1mM DTT, 0.1mM EDTA, 50mM 
HEPES pH7.4, and kept on ice for 20 min. Protein was quantified by BCA assay (Section 
4), using BSA as standard. 
6.6 Protein Quantification 
6.6.1 Bicinchonic acid assay (BCA) 
Protein was quantified using the bicinchonic acid assay (BCA) as it is less prone to errors 
resulting from the high detergent concentrations found in RIPA buffer. The commercial 
Pierce BCA assay kit (Thermo Fisher Scientific) was used and the complete protocol was as 
follows. 
Working Reagent was prepared in a proportion of 50 parts of BCA reagent A to 1 part of 
reagent B. The reaction was initiated by adding 200μL of working reagent to 8μL of 
sample diluted 1:5 in ultrapure water, in a standard polystyrene flat bottom 96-well 
microplate. After 30 min incubation at 37°C, absorbance was read in a VICTOR X3 plate 
reader (Perkin Elmer Inc.) using a 544/15 nm filter. The standard curve ranging from 25 
to 2,000 μg/ml was made using a solution of BSA standard ampules included in the 
referred kit. Standards and unknown samples were performed in duplicates. 
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6.7 Protein quantification and cellular localization 
6.7.1 Immunoblotting 
After protein quantification, samples were diluted in a 5:1 ratio with a homemade 5x 
concentrated Laemelli Buffer [62.5mM Tris pH 6.8 (HCl), 2% SDS, 50% Glycerol, 5% β-
mercaptoethanol, 0.04% bromphenol blue] to achieve a working concentration of 
1μg/mL. Protein lysates were then boiled at 95ºC for 5 min. The previous steps led to 
protein denaturation and therefore loss of quaternary, tertiary and secondary protein 
structure. Moreover, proteins obtained a uniform negative charge, which masks the 
intrinsic charges on the amino acids side-chain. Consequently, after this point, proteins 
can be separated solely as a function of their molecular size [463]. 
To accomplish that, samples (15 to 25μg of protein) were loaded in a discontinuous vertical 
polyacrylamide gel electrophoresis system. Polyacrylamide gels were formed by 
copolymerization between acrylamide and bis-acrylaminde through a vinyl addition 
polymerization reaction initiated with the addition ammonium persulfate (APS) and 
catalyzed by tetramethylethylenediamine (TEMED). The separating gel consisted in 12% 
acrylamide/bis, 375mM Tris pH 8.8 (HCl), 0.1% SDS, 0.05% TEMED and 0.05% APS 
while stacking gel consisted in 4% acrylamide/bis, 126mM Tris pH 6.8 (HCl), 0.1% SDS, 
0.1% TEMED and 0.05% APS. Different final acrylamide/bis percentages were used 
depending on the molecular size of the proteins of interest allowing a maximum 
separation resolution (see Table 6.2). 
Casted gels were fitted in a Mini-PROTEAN 3 Cell (Bio-Rad) filled with running buffer 
(25mM Tris, 192mM glycine, 0.1% SDS) and connected to a PowerPac Basic Power Supply 
(Bio-Rad) outputting a constant voltage of 150V. Separation was carried out at room 
temperature and until the front of the run reached the bottom end of the gel. Note that in 
every gel, a molecular weight standard (Precision Plus Protein Dual Color Standards, from 
Bio-Rad) was included to allow molecular weight estimation. 
Once protein separation was complete, proteins were transferred to a thin surface layer of 
pre-activated (5 sec in 100% methanol followed by 15 min in 25mM Tris, 190mM glycine 
and 20% methanol) polyvinylidene difluoride membrane (PVDF, 0.45μm, Millipore, 
Billerica, MA, USA), by an electric current passed through the gel. For that, gels were 
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placed in a 'transfer sandwich' (filter paper-gel-membrane-filter paper), cushioned by 
pads and pressed together by a support grid/cassette. The supported gel sandwich was 
then placed vertically in a Mini Trans-Blot Cell (Bio-Rad) tank between stainless 
steel/platinum wire electrodes and filled with transfer buffer (25mM Tris, 190mM glycine 
and 20% methanol). Protein transference was performed at a constant voltage (100mV) 
during 90 min with a PowerPac Basic Power Supply (Bio-Rad). An ice pack was placed 
inside the tank to mitigate the heat produced during the transference. 
Once protein transfer was complete, the membrane was labeled for future identification 
and incubated with blocking solution, 5% non-fat dry milk (Bio-Rad) in Tris-buffered 
saline Tween-20 (TBS-T; 154 mM NaCl, 50 mM Tris pH 8.0 (HCl) and 0.1% Tween-20) 
overnight (<18 hours) at 4°C under continuous stirring (Stuart SRT6 tube roller, VWR, 
Leuven, Belgium), to block non-specific binding. On the next day, membranes were 
washed three times for 5 min each with TBS-T prior to incubation with a primary 
antibody directed against the respective protein (listed in Table 6.2) overnight (>18 hours) 
at 4°C under continuous stirring (Stuart SRT6 tube roller), except for anti-actin antibody 
which was incubated for 2 hours only at room temperature. All primary antibodies were 
prepared in 1% non-fat dry milk in TBS-T supplemented with 0.02% sodium azide to a 
final volume of 5 ml and stored at 4°C for no longer than 4 months or used for a maximum 
of 4 times. Alternatively, antibodies were prepared in 1% BSA solution in TBS-T 
depending on manufacturer’s instructions. 
Once incubation was complete, membranes were washed three times for 5 min with TBS-
T and incubated with alkaline phosphatase conjugated secondary antibodies (1:5,000 
dilution) for 1 hour at room temperature under continuous agitation (Stuart SRT6 tube 
roller). Finally, membranes were washed three times in TBS-T for 5 min before 
immunodetection. 
Membranes were dried and placed with the protein side down on a flat plastic plaque pre-
filled with small droplets of Enhanced Chemi-Fluorescence system (ECF; GE Healthcare) 
substrate ensuring no air bubbles were trapped and was incubated for no longer than 5 
min at room temperature. Alkaline phosphatase present in secondary antibody 
dephosphorylates the ECF substrate leading to the formation of a fluorescent product at 
540 to 560nm when excited at the appropriate wavelength (UV), which localizes at the 
site of catalysis. 
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Chemi-fluorescence data was collected using a UVP Biospectrum 500 Imaging System 
equipped with a BioChemi HR Camera (UVP, Upland, CA, USA) through UV (365 nm) epi-
illumination. Camera settings, namely exposure time, were set-up in preview mode to 
optimize exposure and determine the appropriate final exposure settings using 4x4 
Table 6.2 - List of primary antibodies used in Western Blot protein analysis. 
Code Dilution Host Species MWt
(KDa) 
Gel 
(%) 
Catalog Number Manufacturer
Actin 1:10,000 Mouse 43 var. MAB1501 Millipore 
ATG12 1:300 Rabbit 16.53 12 4180 Cell Signaling 
ATG3 1:500 Rabbit 40 10 3415 Cell Signaling 
ATG5 1:500 Rabbit 55 10 2630 Cell Signaling 
ATG7 1:300 Rabbit 78 10 2631 Cell Signaling 
ATP sub c 1:500 Rabbit 14 8 ab96655 abcam 
BAX 1:1,000 Rabbit 20 12 2774 Cell Signaling 
BCL-2 1:500 Rabbit 26 12 2870 Cell Signaling 
BCL-xL 1:1,000 Rabbit 30 12 2764 Cell Signaling 
BECLIN-1 1:600 Rabbit 60 10 3495 Cell Signaling 
CypD 1:10,000 Mouse 18 12 ab110324 abcam 
DRP1 1:500 Mouse 80 10 611113 BD Biosciences 
FIS1 1:500 Rabbit 17 14 IMG-5113A IMGENEX 
HSP90 1:600 Rabbit 90 10 4877 Cell Signaling 
LAMP2A 1:500 Rabbit 100 10 ab18528 abcam 
LC3 1:600 Rabbit 16/18 14 PD014 MBL 
MFN1 1:200 Rabbit 87 10 sc50330 Santa Cruz 
OPA1 1:200 Goat 132 9 sc30573 Santa Cruz 
p62 1:1,000 Rabbit 62 10 PM045 MBL 
PINK1 1:300 Rabbit 60 10 ab23707 abcam 
SHC1 1:1,000 Mouse 66/52/46 10 610878 BD Biosciences 
SOD-2 1:1,000 Rabbit 25 12 ab13533 abcam 
TOM20 1:500 Rabbit 20 14 sc11415 Santa Cruz 
TRAP1 1:750 Mouse 75 10 612344 BD Biosciences 
Ubiquitin 1:750 Rabbit 10 14 3933 Cell Signaling 
*also used in immunocytochemistry assay. Abbreviations: MWt – molecular weight; var. – 
variable. 
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binning with real-time exposure compensation. Data processing was performed with on-
chip integration ensuring maximum exposure without signal saturation. 
Densitometry analysis was carried out using Quantity One software (Bio-Rad 
Laboratories) where a rectangle with the maximum size similar to the band of greater 
length present in the blot was considered as the region of interest (ROI) which was then 
repeated for all the bands in the membrane. The parameter “adjusted volume”, which 
represents the sum of all pixels intensity in ROI corrected for the local mean background, 
was used for analysis. The software calculates “local mean background” as the intensities 
of added pixels in a 1-pixel border around ROI and divided by the total number of border 
pixels. For each blot, data was first normalized as the percentage of the sum of the total 
density of all bands and then normalized to its respective actin immunoreactivity to 
achieve even amounts of protein loading in gels.  
6.7.2 Immunocytochemistry 
Twenty-four hours prior to the beginning of the experiment, 1.5x105 cells/mL were seeded 
in 6-well plates containing sterile glass 18x18mm coverslips and were grown under 
normal culture conditions. For some experiments, mitochondria were first labeled using 
MitoTracker® Red CMXRos (MTR; Invitrogen) prior to fixation. The culture medium was 
removed and cells were washed with warm 1x PBS. Cells were then incubated with 125nM 
MTR for 45 min under normal growth conditions. After staining, cells were washed with 
fresh pre-warmed 1x Hank’s Balanced Salt Solution, calcium and magnesium 
(HBSS/Ca2+/Mg2+; Invitrogen) and fixed with 3.7% formaldehyde in 1x PBS for 15 min at 
37°C. 
After fixation, coverslips were washed three times for 5 min each with 1x Phosphate 
Buffered Saline Tween-20 (1x PBS-T; 0.137 M NaCl, 2.7 mM KCl, 1.4 mM KH2PO4, 0.01 M 
Na2HPO4, 0.1% Tween-20) followed by cell permeabilization with 0.2% Triton X-100 in 
1x PBS for 10 min at room temperature. Coverslips were washed again three times for 5 
min each with 1x PBS and blocked with 1% BSA in 1x PBS-T solution for 60 min at room 
temperature in an orbital shacking platform. The volume used was enough to cover the 
entire well surface to ensure an efficient blocking. After blocking, coverslips were again 
washed three times for 5 min each with 1x PBS-T and transferred to a humid chamber, 
consisting in a squared glass container (20 x 20 cm) with filter paper soaked in ultrapure 
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water underneath the tray, in where the coverslips were incubated with the primary 
antibodies at 37°C for 90 min. 
Primary antibodies (listed in Table 6.2) were used in a 1:250 dilution in 1% BSA in PBS-T 
solution. Coverslips were then washed three times for 5 min each with 1x PBS-T, and 
incubated with 1:250 diluted secondary antibodies in PBS-T containing 1% BSA solution 
in humid chamber for 60 min at 37°C. For dual immunofluorescence staining, antibodies 
were simultaneously incubated under the conditions described above. In this case, the 
only additional care was to make sure that the hosts of primary antibodies were distinct to 
allow fluorescent detection using different fluorophores (Texas Red or FITC).  
All samples were mounted in microscope slides using ProLong® Gold antifade reagent with 
DAPI (Invitrogen) according to manufacturer’s instructions. If visualization was not 
performed at the end of the protocol, slides were stored at -80C and analyzed as soon as 
possible. Slides were examined by confocal microscopy. Images were obtained in a Zeiss 
LSM510 META (Carl Zeiss Microscopy LLC, Thornwood, NY, USA) confocal scan head 
mounted on an inverted based-microscope Zeiss Axiovert 200M with a 63x objective. 
Sequential excitation at 350nm (DAPI), 490nm (FITC), 579nm (MTR) and 589nm (Texas 
Red) was provided by diode, argon gas and diode-pumped solid-state lasers, respectively. 
Emission filters BP500-550 and LP560 were used for collecting green and red channel 
images, respectively. After sequential excitation, all fluorescent images of the same cell 
were saved with LSM 510 software and then analyzed with ImageJ (NIH). The term 
colocalization refers to the simultaneous presence of green and red fluorescence in the 
same pixel, as measured by the confocal microscope. 
6.8 Quantitative RT-PCR 
6.8.1 Primer design 
All primers were designed using the web-based Primer–Basic Local Alignment Search 
Tool (Primer-BLAST) after obtaining nucleotide accession numbers from the database. 
Both services are public and supported by the National Center for Biotechnology 
Information (NCBI). 
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The accession numbers used for the transcripts of interest analyzed are shown in Table 
6.3. The default settings were used with the following exceptions: amplicon was set to a 
minimum of 70 bp and a maximum of 200 bp; primers should span an exon-exon junction 
and intron inclusion options were selected to allow specific amplification of mRNA over 
DNA or pre-mRNA. 
Although the algorithm aims to design the best primer set, the operator should always 
double-checked the top five entries for: priming towards the 3’ of the target, optimal 
melting temperature close to 60°C and primers specificity amplifying no off-target gene 
sequences in the targeting genome. Additionally, secondary structure of the primer set 
was checked in OligoAnalyzer 3.1 web-based software from IDT.  There, low intra-primer 
and between-primer complementary (low meting temperature and high ΔG) were 
preferred. 
All primers were synthesized by Integrated DNA Technologies (Coralville, IA, USA) and 
diluted in DNase RNase-free water to a working concentration of 10 μM upon arrival. 
Table 6.3 - List of primers used in the present work. 
Accession 
Number Code Sequence 
Amp. 
(bp) 
Tm 
(°C) 
NM_016292.2 TRAP1 5' - GTC GCG CAG GCT CAC GAC AA -3' 203 60 
5' - CGC AGC CAC TTG GGC AGG AT -3' 
NM_001017963.2 HSP90AA1 5' - CCC AGA GTG CTG AAT ACC CG -3' 191 60 
5' - GTG GAA GGG CTG TTT CCA GA -3' 
NM_001017963.2 HSP90AA1.1 5' - CAGT GAAG CATT TTTC AGTT GAAG G -3' 201 60 
5' - CCG AGT CTA CCA CCC CTC TA -3' 
NM_002156.4 HSP60 5' - TCT TTC GCC AGA TGA GAC CG -3' 191 60 
5' - ACT TCC CCA ACT CTG CTC AAT -3' 
NM_005729 PPIF 5' - CTC CGG GAA CCC GCT CGT GTA -3' 198 60 
5' - TCG CCC GCC TGG CAC ATG AA -3' 
NM_001130040.1 SHC1 5' - CTC ATT TGC ATC CGG CGG GGA -3' 111 60 
5' - GCA AGC CCT TCG GGA CAC TCC -3' 
 18S 5' - TCAA CTTT CGAT GGTA GTCG CCGT -3'  60 
5' - TCCT TGGA TGTG GTAG CCGT TTCT -3' 
Note: Amp -amplicon in base pairs; Tm - temperature of melting in Celsius. 
  
 SECTION 6.8
PhD in Biology – Specialization in Cell Biology 95
Primers were tested through a standard PCR and agarose gel and discarded if non-specific 
products were detected (none for the current design).  
Primers for the HSP90 family 
There are two subfamilies of the cytoplasmic HSP90A which differ by being constitutively 
or inducible expressed [213]. For the current study, the HSP90AA inducible family was 
chosen as the most relevant. This protein is encoded by two different genes, HSP90AA1 
and HSP90AA2, which generating 
 HSP90-α1 and HSP90-α2 isoforms respectively. Moreover, the HSP90AA1 mRNA can 
occur as two transcripts variants due to alternative splicing increasing therefore the 
complexity of this analysis. 
Running a blastn suite-2sequences to find similarity over the above mentioned sequences, 
besides the already expected 100% identity without gaps of HSP90AA1 variant 2, 
HSP90AA2 also shares 97% of homology with only 8 gaps in a total of 2868 bp when 
compared to HSP90AA1 variant 1. It was also evident from this screening that primers 
targeting position below the 711th bp would solely target the HSP90AA1 variant 1 
transcript. 
Therefore our strategy was to design one set of primers that would target both subfamilies 
and another that was able to detect specifically the HSP90AA1 variant 1 (HSP90AA1.1), 
following the above mentioned specifications. 
6.8.2 Step one: reverse transcription  
mRNA levels were analyzed through a two-step quantitative real-time polymerase chain 
reaction (PCR). The first step involves the reverse transcription of total mRNA into cDNA 
using the iScript cDNA Synthesis Kit (Bio-Rad). The kit contained a modified moloney 
murine leukemia virus (MMLV)-derived ribonuclease H plus (RNase H+)-type reverse 
transcriptase enzyme that synthesizes a complementary DNA strand up to 7 kb from 
single-stranded RNA. It also specifically degrades the RNA in RNA:DNA hybrids but not 
unhybridized RNA, also lacking endonuclease activity.  
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Additionally, the kit mix contained oligo(dT) and random hexamer primers to maximize 
the sensitivity (towards mRNA) and extension (increasing the probability that 5' ends of 
the mRNA would be converted to cDNA) of the reverse transcription reaction. Oligo(dT) is 
a short sequence of deoxy-thymine nucleotides that targets the poly-A tail only present in 
mRNA. The random hexamer priming consisted in the use of a mixture of oligonucleotides 
representing all possible nonamer sequences (5’–NNN NNN–3’ with 46 = 4096 
permutations). 
The iScript mix was diluted in 1:5 with nuclease-free water and 1μg of total RNA to a final 
volume of 20μL, which was then loaded in PCR strip tubes recommended by vendor. 
Reactions were performed in a Bio-Rad S1000 thermal cycler running a single cycle 
programmed as follows: 5 min at 25ºC, 30 min at 42ºC and 5 min at 85ºC. In order to dilute 
the total cDNA for downstream PCR but also to dilute the salts present in the RT mix, the 
final product was diluted to one-tenth of the reaction volume. 
6.8.3 Step two: real-time PCR 
mRNA transcript levels were quantified in real-time PCR using 2μl of the cDNA samples 
and amplified with SsoFastTM EvaGreen® Supermix (Bio-Rad) in 20μl total reaction 
volume using 500nM of genetic-specific forward and reverse primers. SsoFast supermix 
uses Bio-Rad’s Sso7d fusion protein technology in which the antibody-mediated hot-start 
feature sequesters the enzymatic activity prior to the initial PCR denaturation step and 
the dsDNA-binding protein stabilizes the polymerase:template complex and provides 
greater speed reducing reaction time [464]. 
Amplification and quantification of generated products were performed in a Multiplate® 
low-profile 96-Well unskirted PCR plate (Bio-Rad) sealed with an optically clear Microseal 
'B' adhesive seal (Bio-Rad) and then loaded in a CFX96 Real-time PCR detection system 
(Bio-Rad) under the following cycling conditions: a single step of 95°C for 30 sec, 30 to 40 
cycles of 95°C for 5 sec followed by another 5 sec at 60°C with single-point fluorescence 
acquisition at the end. Finally, a melting curve program was performed at the end of the 
amplification program in order to ascertain that only the expected products were 
generated. The melting curve program ranged from 65°C to 95°C for 5 sec per step with 
increments of 0.5°C. 
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Samples were run in duplicates, together with a standard curve for that respective 
transcript across 5 log10, which covered the range in the sample unknowns without 
extrapolating. This allowed calculating the efficiency of the reaction, which is of extreme 
importance in expression analysis. Additionally, a non-template control (NTC) and a 
negative control lacking cDNA template (NRT) were also included to ensure no 
contamination. None of the runs showed expression on these conditions and none was 
discarded. 
6.8.4 DNA standards preparation 
Standard curves were prepared by serial dilutions of a characterized DNA standard 
prepared from cDNA from either A549 or MRC-5 cells amplified through a simple PCR 
reaction using the HotStartTaq Master Mix Kit (Qiagen) and genetic-specific primers. For 
this purpose, the master mix was diluted with 0.3μM of forward and reverse primers and 
10μL of cDNA template to a final volume of 50μL. The reaction was amplified in a Bio-Rad 
S1000 thermal cycler running a pre-incubation step at 95°C for 15 min, followed by 35 
cycles of denaturation at 94°C for 30 sec, annealing at 60°C for 30 sec and extension at 
72°C for 20 sec plus an additional final extension step at 72°C for 10 min. 
In order to check primer set specificity and temperature reaction efficiency, the 
amplification product (10μL) was first diluted 4:1 with BlueJuiceTM Gel loading buffer 
(Invitrogen) and then loaded in a 4% agarose (Invitrogen, Catalog# 16520-050) gel 
prepared in 1x Tris Acetate-EDTA buffer (TAE; Catalog# T9650, Sigma, St Louis, MO, 
USA) supplemented with 0.02% of ethidium bromide together with 5μL 100bp DNA 
ladder (Invitrogen). DNA fragments were separated through a horizontal electrophoresis 
system consisting in a multiSUB Midi (Cleaver Scientific Ltd, Rugby, Warwickshire, UK) 
connected to a PowerPac Basic Power Supply (Bio-Rad) running at 100mV for 1 hour at 
room temperature. In the end, the gel was imaged by UV (365nm) transillumination using 
a UVP Biospectrum 500 Imaging System equipped with a BioChemi HR Camera (UVP, 
Upland, CA, USA).  
If a single product was detected the remaining PCR reaction product was purified using 
the MinElute® PCR Purification Kit (Qiagen) for efficient recovery of DNA fragments and 
removal of contaminants such as enzymes, primers, unincorporated nucleotides and salts. 
Briefly, the remaining PCR reaction was diluted 1:5 with PBI buffer, transferred to a 
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MiniElute column and centrifuged at 8,000xg for 1 min. The column was then washed 
with PE buffer by being first spin at 8,000xg for 1 min and then at 10,000xg for 1 min 
after discarding the flowthrough. The DNA standard was eluted by applying 10 μL of EB 
buffer to the center of column and incubation for 1 min at room temperature before 
centrifugation at 10,000xg for 1min and thereafter quantified in a NanoDrop 2000 
(Thermo Fisher Scientific). 
A standard stock solution of 5x109 copies/mL was prepared using the following equation: 
݊ݑܾ݉݁ݎ	݋݂	ܿ݋݌݅݁ݏ ൌ 	ܥ݋݊ܿ݁݊ݐݎܽݐ݅݋݊ௌ௧௔௡ௗ௔௥ௗ 	ൈ ܣݒ݋݃ݎܽ݀݋′ݏ	݊ݑܾ݉݁ݎ݈݁݊݃ݐ݄௔௠௣௟௜௖௢௡ 	ൈ 650  
and stored at -20°C where number of copies is in copies/mL, the concentration of DNA 
standard in g/mL and 650 is the average molecular weight of a DNA base pair in g/mol. 
6.8.5 mRNA expression analysis 
Expression analysis was performed in CFX Manager Software (version 2.1) to normalize 
the relative differences in a target concentration between samples, where a reference 
gene was used to account for loading differences or other variations represented in each 
sample, thus used to normalize the expression levels of the gene of interest. In the present 
study 18S was used as the reference gene. 
The software was set to calculate the normalized expression using the ‘delta-delta Ct’ 
(∆∆Ct) [465]. This is an efficiency corrected calculation model based on multiple samples 
and a single reference gene and is expressed by the following equation: 
ݎܽݐ݅݋ ൌ 	 ሺܧ௧௔௥௚௘௧ሻ
୼஼೟ሺ	஼௢௡௧௥௢௟ಾ೐ೌ೙	ି	்௥௘௔௧௠௘௡௧ಾ೐ೌ೙	ሻ
ሺܧ௥௘௙௘௥௘௡௖௘ሻ୼஼೟ሺ	஼௢௡௧௥௢௟ಾ೐ೌ೙	ି	்௥௘௔௧௠௘௡௧ಾ೐ೌ೙	ሻ	 
where E is the efficiency of the reaction and Ct is the crossing-point value of the sample. 
Efficiencies were automatically calculated using the amplification rate, which is calculated 
on the basis of a linear regression slope of a serial dilution of standards: 
ܧ݂݂݅ܿ݅݁݊ܿݕ ൌ 	10ష భೞ೗೚೛೐	
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Additionally, the software was set to normalize expression relative to siOT3 control 
group. Depending on the comparison being made, the control group was defined as siOT3 
for intra-cell line comparisons and A549 for between-cell line comparisons.  
6.9 Evaluation of oxygen consumption 
In the present work, cellular oxygen consumption was measured using a novel oxygen-
sensitive fluorescent probe. While Clark-type electrodes sensors detect a current flow 
caused by oxygen reduction, this new optical oxygen sensors operate on the principle of 
fluorescence quenching of the excited-state lifetime of a fluorescent indicator dye. A 
complete comparison of both methodologies and their inherent pros and cons has been 
previously described [466]. 
The oxygen-sensitive Oxoplate (model numb. OP96U) microplates were obtained from 
PreSens (Regensburg, Germany). The oxygen sensor is based on the use of the 
luminescent probe Pt(II)-pentafluorophenylporphyrine which is incorporated in 
hydrophobic oxygen-permeable particles containing sulforhodamine B as a reference 
fluorophore. These oxygen-sensitive microspheres are dispersed in a hydrogel matrix 
with thickness of about 10μm and fixed at the bottom of each well of a round bottom 96-
well plate [467]. 
For the assay, cells were washed once with 1x PBS, trypsinized and centrifuged. The 
supernatant was discarded and the pellet resuspended in complete growth medium in 
order to count cells using a Bio-Rad TC10 automated cell counter (Bio-Rad). Preliminary 
studies showed that a final concentration of 3.75x103 cells/mL was found to give the best 
oxygen consumption rates for A549 cells. For this purpose, 8.25x105 cells were pippeted to 
a microtube, centrifuged (300xg, 3 min) and resuspended in 220μL of DMEM (no phenol 
red and no FBS). Then, 200μL of cell suspension was added to each well and covered by 
100μL of pre-warmed heavy mineral oil (Sigma-aldrich) to prevent oxygen from air to 
diffuse back to the reaction medium. 
Plates were read in a SpectraMax Gemini EM multiplate reader (Molecular Devices, 
Sunnyvale, CA, USA) working in time-resolved fluorescence dual kinetic mode. The 
complete setup program comprised the following entries: 49 reads every 1 min and 15 sec 
up to 1 hour, excitation and emission wavelengths set to 540/650nm for the indicator dye 
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and 540/590nm for the reference dye. To increase the resolution of the assay, integration 
start was set to 0μsec and integration time to 500μsec, for both wavelength pairs 
combination. Each condition was run at least in duplicate. 
A two-point calibration was also performed using air-saturated and oxygen-free water 
using 1mg/mL of sodium sulphite to deplete oxygen. This calibration allowed the 
conversion of absolute fluorescence values to oxygen partial pressure (pO2) given as % of 
air saturation, following manufacturer’s instructions. 
6.10 Evaluation of mitochondrial membrane potential 
The ΔΨm was evaluated using different fluorescent probes and different methods, which 
differed at a cell manipulation extent and end-point measurement after fixation or live 
imaging. 
6.10.1 Microplate assay 
For this protocol, tetramethylrhodamine methyl ester (TMRM; Invitrogen) was used in 
quench mode, i.e. higher dye concentrations were applied so accumulation within 
mitochondria is enough to form aggregates, thus quenching some of the fluorescent 
emissions of the aggregated dye. Under these conditions, mitochondrial depolarization is 
followed by probe release and thus increasing fluorescent signal [468]. 
Forty-eight hours post transfection cells were seeded in 24-wells plate at a concentration 
of 2.5x104 cells/mL. In the next day, cells were washed with 1x PBS and loaded with 1μM 
of TMRM dissolved in warm 1x HBSS/Ca2+/Mg2+ and incubated for 30 min at 37°C in cell 
culture incubator. Then, plates were read in a SpectraMax Gemini EM multiplate reader 
(Molecular Devices, Sunnyvale, CA, USA) working with 573nm emission and 549nm 
excitation wavelengths with a time course of 45 min read every 5 min at 37°C. In the end, 
2μM of the uncoupler FCCP was added to each well and fluorescence read as previous 
described. Mitochondrial membrane potential was indirectly calculated as the difference 
between TMRM fluorescence after FCCP addition and dye fluorescence before the addition 
of the uncoupler. 
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6.10.2 Flow cytometer 
For this protocol, TMRM was used in non-quenching mode, i.e. low dye concentrations 
were applied so accumulation within mitochondria does not allow dye aggregation and 
quenching. Under these conditions, depolarized mitochondria contain lower dye 
concentration and therefore display a lower TMRM signal [468]. 
On the day of the assay, transfected cells were harvested by trypsin treatment and 
resuspended in microscopy medium (120mM NaCl, 3.5mM KCl, 0.4mM KH2PO4, 20mM 
HEPES, 5mM NaHCO3, 1.2mM NaSO4, 10mM sodium pyruvate at pH 7.4) supplemented 
with 1.2mM MgCl2, 1.3mM CaCl2 and incubated with 150nM TMRM (Invitrogen) for 30 
min at 37°C in cell culture incubator. A sample of non-labeled cells was also analyzed in 
order to calibrate the system, taking cell self-fluorescence into account. 
Samples were kept on ice until use and 10,000 cells were analyzed on a FACSCalibur flow 
cytometer (BD Biosciences, San Jose, California, USA) at a low (12 μL/min) sample flow 
rate. The blue laser was used for excitation and the filter 3 for red was used for emission; 
for forward scatter detection, a photodiode with 488/10nm bandpass filter was used. 
During preliminary tests, all cell groups were incubated with FCCP in order to ascertain 
the sensitivity, reliability and best analysis to perform. Data was analyzed using BD 
CellQuest Pro software package (version 5.2). 
6.10.3 Confocal microscopy 
Mitochondrial transmembrane potential changes were also analyzed through live imaging 
confocal microscopy by co-labeling cells with TMRM and MitoTracker® Green (MTG). In 
contrast to TMRM that is accumulated by polarized mitochondria, MTG stains 
mitochondria independently of membrane potential [469]. When co-labeled TMRM 
reversibly quenches MTG fluorescence of functional mitochondria. Furthermore, the 
addition of an uncoupler, such as FCCP, results in mitochondria depolarization and 
consequent loss of TMRM but not MTG fluorescence. At this point, MTG fluorescence 
becomes visible allowing the identification of all mitochondria in the cell. 
Twenty-four hours prior to the assay, 1.5x105 cells/mL were seeded in μ-Slide 8 well 
ibiTreat (ibidi Martinsried, Germany) (Fig.3). At the time of experiment, the medium was 
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removed from all wells and cells were washed with warm 1x PBS. Cells were then 
incubated with 100nM MTG in warm 1x HBSS/Ca2+/Mg2+ for 30 min under normal growth 
conditions followed by labeling with 1μM TMRM for 30 min under the previously referred 
conditions. Note that control samples stained with either TMRM or MTG were also 
analyzed in order to assure correct probe staining and concentrations. Moreover, ΔΨm was 
monitored by serial imaging before and after depolarization with 2 μM FCCP. Samples 
were examined by confocal microscopy using Zeiss LSM510 META and image analysis 
performed in the LSM 510 software. An argon/2 laser was used for MTG fluorescence 
detection, and a DPSS 561-10 laser for TMRM. 
6.11 Evaluation of oxidative stress 
Oxidative stress evaluation was addressed through flow cytometry and confocal 
microscopy by using two different probes, H2DCFDA (Invitrogen) and MitoSOXTM Red 
(Invitrogen). The probe H2DCFDA is used as a general indicator for reactive oxygen 
species (ROS) as the probe can be oxidized by different radicals while MitoSOX is 
specifically accumulated in mitochondrial matrix and allows the unique identification of 
superoxide generated in mitochondria in live cells [470]. 
6.11.1 Flow cytometry 
On the day of the assay, transfected cells were harvested by trypsin treatment and 
resuspended in a solution of 5μM H2DCFDA (Invitrogen) in 1x HBSS/Ca2+/Mg2+ for 60 min 
at 37°C in a CO2 incubator. A sample of non-labeled cells was also analyzed in order to set 
up the assay settings considering cells self-fluorescence. Samples were kept on ice until 
use and 10,000 cells were analyzed in a FACSCalibur flow cytometer (BD Biosciences, San 
Jose, California, USA) at a low (12 μL/min) sample flow rate. When measuring DCFDA 
fluorescence, the red laser was used for excitation together with filter 1 for detection of 
green emission. For MitoSox fluorescence, the blue laser was used for excitation together 
with filter 3 for detection of red emission. Data was analyzed using BD CellQuest Pro 
software package (version 5.2). 
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6.11.2 Confocal microscopy 
Twenty-four hours prior to live imaging assay, 1.5x105 cells/mL were seeded in μ-Slide 8 
well ibiTreat (ibidi Martinsried, Germany). At the time of experiment, medium was 
removed from all wells and cells were washed with warm 1x PBS. Cells were then 
incubated with either 7.5μM of H2DCFDA or 5μM MitoSOX in warm 1x HBSS/Ca2+/Mg2+ 
for 30 min under normal cell culture conditions. Regarding H2DCFDA, a positive control 
was performed by incubating cell with 50μM of tert-butylhydroperoxide (tBHP) in 1x 
HBSS/Ca2+/Mg2+ for 60 min under normal cell culture conditions before incubation with 
the probe. The pro-oxidant compound tBHP is commonly used as an oxidative stress 
inducer [471].  
Finally, samples were examined by confocal microscopy using a Zeiss LSM510 META 
device and image analysis performed in the LSM 510 software. More detailed information 
about the microscope is presented in Section 5.2. An argon/2 laser was used for H2DCFDA 
fluorescence detection, and a DPSS 561-10 laser for MitoSOX. 
6.12 Evaluation of mitochondrial permeability 
transition pore opening 
The mPTP opening was measured using the MitoProbeTM Transition Pore Assay Kit 
(Invitrogen) with slight alterations to the manufacturer’s instructions. This assay includes 
calcein-AM, a non-fluorescent esterase substrate, and CoCl2, a quencher of calcein 
fluorescence [472]. Briefly, calcein-AM passively diffuses across cell membranes 
accumulating in cytosolic compartments including mitochondria. Once inside the cell, 
calcein acetoxymethyl esters are cleaved by intracellular esterases releasing the 
fluorescent dye calcein that does not cross cellular membranes. Moreover, CoCl2 quenches 
calcein cytoplasmic fluorescence while mitochondrial fluorescence is maintained due to 
the fact that CoCl2 is not able to cross the mitochondrial inner membrane. As a control, 
cells were treated with ionomycin, a calcium ionophore which allows Ca2+ accumulation 
in cell and, in triggering pore opening and consequent loss of mitochondrial calcein 
fluorescence due to CoCl2 influx. Additionally, cells were also treated with cyclosporin A 
(CsA), a mPTP inhibitor through its interaction with Cyclophilin D (CypD) [473]. 
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To perform the assay, cells were first trypsinized and centrifuged 300xg for 3 min. Pellets 
were resuspended in pre-warmed 1x HBSS/Ca2+/Mg2+. Cells were counted using a Bio-Rad 
TC10 automated cell counter (Bio-Rad) and 1mL of 1x HBSS/Ca2+/Mg2+ containing 3.5x105 
cells was transferred to a FACS tube. For each treatment group, five aliquots were 
prepared as follows: one containing 10nM calcein-AM only; one containing calcein-AM 
plus 0.4mM CoCl2; one containing calcein-AM, CoCl2 and 0.5μM ionomycin; one 
containing calcein-AM, CoCl2 and 2μM cyclosporin A (CspA); and one containing calcein-
AM, CoCl2, ionomycin and CspA. Cells were incubated under one of the referred 
conditions for 15 min at 37°C protected from light followed by removal of excess staining 
through addition of 1x HBSS/Ca2+/Mg2+and centrifuged 300xg 3 min at room temperature. 
Finally, the pellet was resuspended in 400μL 1x HBSS/Ca2+/Mg2+and samples were 
analyzed on a FACSCalibur flow cytometer. 
6.13 Caspases-like activity 
6.13.1 Caspase 3/7 and Caspase 9-like activities 
Caspase 3/7 and Caspase 9-like activities were measured using the Caspase Glo® 3/7 and 
Casapse Glo® 9 Assay Kits (Promega, Madison, WI, USA) respectively. Both kits provide a 
simple, sensitive and one-step only approach to measure caspase-like activity based on 
cell lysis followed by caspase cleavage of the substrate (DEVD and LEDH derivatives for 
caspase 3/7 and 9, respectively) and generation of a “glow-type” luminescent signal.  
Four hours prior to the assay, 2x104 cells/well were seeded in a cell culture compatible 
white-walled 96-well plate in 100μL of complete growth medium. Prior to initiating the 
assay, the 96-well plate containing the cells was removed from incubator and equilibrated 
at 25°C. Cells were then incubated with 100μL of either Caspase Glo® 3/7 or Caspase Glo® 9 
Reagent for 60 min at 25°C. A negative control consisting of non-transfected cells and a 
background control to measure luminescence associated with the culture medium and 
caspase-reagent was included to each assay and subtracted from experimental values. 
Luminescence was read in a VICTOR X3 plate reader (Perkin Elmer) working in 
luminometer mode. Caspase-like activity was expressed as relative units of luminescence 
(RLU). 
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6.13.2 Caspase 8-like activity 
Caspase 8-like activity was accessed using a colorimetric assay base on the proteolytic 
cleavage of granzyme B substrate I (Calbiochem, Millipore) composed by the 
chromophore, p-nitroanilide (pNA), and a synthetic tetrapeptide, IETD. The assay is 
sensitive to caspase 8 and other proteases that recognize the amino acid sequence, IETD 
(Ile-Glu-Thr-Asp). Upon cleavage of the substrate, free pNA light absorbance can be 
quantified at 400 or 405 nm following manufacturer’s instructions. 
Cells extracts were collected as previously described in Section 3.2. The reaction was 
performed in a standard 96-well plate equilibrated at 37°C with 40μg cell extract per well 
and assay buffer (100mM NaCl, 0.1% CHAPS, 10mM DTT, 0.1mM EDTA, 10% glycerol, 
50mM HEPES pH 7.4) supplemented with 200μM Granzyme B Substrate I. For 
quantitative measurement, a pNA standard curve and a control with no cell extract were 
included in the experiment. Absorbance was measured at 405nm in VICTOR X3 plate 
reader (Perkin Elmer) after 2 hours incubation at 37°C and capase 8-like activity was 
expressed as μM of pNA. 
6.13.3 Caspase 12-like activity 
Caspase 12-like activity was accessed using a fluorimetric Caspase 12 assay kit (Abcam, 
Cambridge, UK). Cells were trypsinized, centrifuged at 300xg for 3 min as previously 
described in Section 3.2, the supernatant was discarded and cells were resuspended in 
complete cell culture medium. Thereafter, either 4x106 A549 or 2x106 MRC-5 cells were 
transferred to a new microtube and centrifuged 300xg for 3 min at room temperature. 
The supernatant was once again discarded and the pellet was resuspended in 50μL cell 
lysis buffer following manufacturer’s instructions. The lysates were then transferred to a 
standard 96-well plate where 1x Reaction Buffer containing 10mM DTT and 50μM ATAD-
AFC substrate were added to each sample. Samples were read in a fluorimeter under 
kinetic conditions bottom read every 10 min to a total of 120 min at 37°C with 400nm 
excitation filter and 505nm emission filter with cut off at 475nm. Caspase 12-like activity 
was expressed as relative units of fluorescence (RFU). 
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6.14 Fluorescence detection of lysosomal bodies 
Twenty-four hours prior to live imaging assay, 1.5x105 cells/mL were seeded in μ-Slide 8 
well ibiTreat (ibidi Martinsried, Germany). At the day of the experiment growth medium 
was removed and cells were incubated with 75nM Lysotracker® Green (Molecular Probes), 
a weakly basic amine that selectively accumulates in cellular compartments with low 
internal pH, in pre-warmed growth medium for 45 min under growth conditions. After 
incubation period, medium was replaced by fresh growth medium. Cells were examined 
by confocal microscopy using Zeiss LSM510 META and image analysis performed in the 
LSM 510 software. Argon laser was used for lysotracker detection. 
6.15 Statistics 
For statistical analysis of two means, including for comparison of control groups between 
both cell lines, the Student’s t test was used while for comparisons of more than two 
groups an analysis of variances (ANOVA) with matched-pairs was used instead. In both 
cases, data was checked for normality using the Kolmogorov-Smirnorv with Dallal-
Wilkinson-Lillie for correction and equality of variances using the F test or Bartletts’s test 
in order to apply the statistical tests. If data deviated from normality, a simple squared or 
log transformation was applied and normality checked once again. If transformed data 
revealed to be normal, the parametric statistical test was applied. Otherwise the 
respective non-parametric test was chosen: Mann-Whitney for t test and Friedman test 
for ANOVA. For ease of comprehension, data is presented to the reader as non-
transformed. 
In situations where one wanted to evaluate the effect of two variables, namely 
transfection effect and time points, a two-way ANOVA was applied following the same 
assumptions as mentioned earlier. Differences were considered significant at 5% level and 
p value was categorized accordingly to their interval of confidence. For one- and two-way 
ANOVA, corrections for multiple comparisons were made using Bonferroni post-hoc test 
using predefined comparisons, in order to decrease both type I and type II errors. 
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Chapter 7  
 
TRAP1 regulates of mitochondrial 
function and dynamics, as well as 
cellular quality control systems in A549 
lung cancer cells 
 
 
 
 
 
Tumor necrosis factor receptor associated protein 1 (TRAP1) is a mitochondrial heat shock 
protein with antioxidant and antiapoptotic functions determined to be overexpressed in 
several tumor cells. Although our knowledge on TRAP1 functions has been increasing, the 
mechanisms of TRAP1 cytoprotective effect still remain to be fully defined. In the present 
work, we have used transient TRAP1 silencing in A549 lung cancer cells to show how TRAP1 
modulates mitochondrial function and how its depletion influences different quality control 
pathways. This work brings new insights on TRAP1 regulation of ROS production and mPTP 
modulation, as well as it describes, for the first time, TRAP1 involvement in the regulation of 
autophagy pathways. Overall, the preferential mitochondrial localization of TRAP1 in A549 
cells appears to be important in the maintenance of normal mitochondrial physiology, 
morphology and organelle quality control. 
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7.1 Introduction  
TRAP1 is a member of HSP90 family with prevalent mitochondrial localization, and 
whose cytoprotective role has been widely documented. Several studies suggest that 
TRAP1 preserves cellular function by decreasing ROS-mediated oxidative stress [439, 
440, 442], and by regulating mPTP opening through its interaction with HSP90 and CypD 
[304, 474]. Together, these functions seem to contribute for TRAP1 protective effect 
against mitochondrial apoptosis. Additionally, TRAP1 expression increases in numerous 
human malignancies [433, 447, 475] and its antiapoptotic functions confer tumor cells 
resistance against several chemotherapeutic agents [447, 450]. For these reasons, TRAP1 
has been proposed as a cancer biomarker and consequently a potential target for 
anticancer therapies. In this context mitochondrial-targeted agents have been developed 
to selectively inhibit HSP90-like chaperones inducing cell death and reverting tumor cell 
multi-drug resistant phenotype [454]. 
Despite the increased information regarding its cytoprotective functions, the 
characterization of TRAP1 antiapoptotic effects is far from being complete. Research on 
TRAP1 role in tumorigenesis led to numerous pieces of evidence whose conections are, in 
our opinion, still not well established. For example, although several papers suggest 
TRAP1 involvement on mPTP modulation [304, 474], none of these works directly 
evaluated the basal state of the mPTP through any of the available techniques [472, 476, 
477], which can cloud the established concept of TRAP1 as a protective heat shock protein. 
Moreover, although TRAP1 cytoprotective functions in cancer cells have been largely 
attributed solely to its mitochondrial functions, recent reports indicate its involvement in 
the extramitochondrial control of cell death [452, 478]. These evidences point out for a 
higher complexity of TRAP1 functions. 
Recent findings point out new tumor protective role for TRAP1, focusing on the regulation 
of the unfolded protein response (UPR) in the ER [451, 452, 456]. Therefore, inhibition of 
mitochondrial HSP90-family proteins induces an organelle-specific UPR triggering 
compensatory autophagy and activates ER stress responses [456]. Further evidence came 
from the demonstration that TRAP1 downregulation increases caspase-4 expression and 
activates UPR-related signaling molecules [451]. As a mitochondrial protein, TRAP1 
regulation of ER stress was soon thought to constitute evidence for the relationship 
between the two organelles, which was later demonstrated by the identification of TRAP1 
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localization at the interface between ER and mitochondria [452]. These works constituted 
the first link to TRAP1 involvement in the regulation of protein quality control 
mechanisms. 
While these studies focused on TRAP1 role in the crosstalk between ER and mitochondria, 
the relationship between TRAP1 mitochondrial maintenance and quality control is still 
unknown. In this work we hypothesize that TRAP1 contributes to mitochondrial function 
maintenance through regulation of the main mechanisms of cell quality control, namely 
autophagy and apoptosis. This hypothesis was investigated in A549 lung cancer cells, 
which overexpress TRAP1 [446]. Hence, we first aimed the identification of TRAP1 
silencing-induced mitochondrial alterations and, additionally, we aimed at obtaining for 
the first time a functional assessment of mPTP opening resulting from manipulating 
TRAP1 levels. Finally, we addressed TRAP1 role in mitochondrial dynamics and its 
silencing repercussion on autophagy pathways and expression and activity of several 
apoptosis regulators. 
7.2 Results 
7.2.1 TRAP1 silencing efficiency 
TRAP1 silencing efficiency was evaluated by assessing TRAP1 mRNA content by qRT-PCR. 
After 72 hours post-transfection, the results showed an 18-fold decrease on TRAP1 mRNA 
content normalized to 18S upon silencing when compared to the two control (siCTL and 
CTL) groups (Fig.7.1A). In addition, no differences were found in TRAP1 mRNA content 
between siCTL and CTL groups demonstrating the lack of effect resulting from the 
transfection reagents per se. In order to address silencing efficiency at the protein level, 
TRAP1 content was semi-quantified through western blot. In accordance with mRNA 
analysis, TRAP1 protein content, normalized to actin as loading control, was significantly 
decreased (p<0.001) in A549 siTRAP1 cells when compared with the siCTL and CTL 
control groups (Fig.7.1B), with the two latter groups again showing no differences 
between themselves. 
The above mentioned effects were assessed only at 72 hours post-transfection, the time 
point chosen for the characterization of TRAP1-silenced effects in the present work. 
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However, considering that siRNA-mediated gene knockdown consists in a transient 
silencing method, TRAP1 silencing stability was also evaluated. After cell transfection, 
protein was harvested every 24 hours up to 144 hours post-transfection. As can be seen in 
Fig. 7.1 panel C, 24 hours post-transfection were not sufficient to observe a decrease in 
TRAP1 at the protein level; however, 48 hours after the silencing protocol, a clear and 
dramatic decrease in TRAP1 expression in siTRAP1 cells was observed. This difference 
remained stable up to 144 hours post-transfection (Fig.7.1C). Consequently, the effects to 
be described in the upcoming sections were evaluated during the early stages of TRAP1 
low expression/content (72 hours). 
7.2.2 TRAP1 silencing effect on cell growth and susceptibility to 
DOX-induced toxicity 
In order to characterize TRAP1 silencing effect on A549 cell growth, cell mass was 
evaluated through the SRB dye-binding assay, used as an indirect method to infer cell 
proliferation. Cell growth was assessed every 24h up to 72h post-seeding. As described in 
the previous section, this time frame corresponds to the period when TRAP1 transcript 
and protein are permanently decreased. As can be seen in Panel A of Fig. 7.2, the growth 
profile of TRAP1-silenced cells is clearly slower when compared to the control groups. 
TRAP1 silencing led to a decrease in cell growth within 24 hours post-seeding 
(corresponding to 72 hours post-transfection, see Section 6.2.3, Material and Methods) 
(Fig.7.2A). These differences in cell proliferation were more visible for 48 and 72 hours 
post-seeding time points. Thus, TRAP1 silencing resulted in a maximal 62% reduction of 
cell mass during the 72 hours the assay lasted (Fig.7.2A). Note that no differences were 
observed regarding cell proliferation between siCTL and CTL groups. 
Because TRAP1 overexpression confers tumor cell resistance against several 
chemotherapeutical agents [447], we next addressed TRAP1 silencing effect on the 
susceptibility of A549 cells to DOX-induced toxicity. DOX is a chemotherapy drug used in 
the treatment of numerous types of cancer, inducing tumor cell death through multiple 
mechanisms, including induction of DNA damage [479]. A preliminary experiment was 
performed in order to address the optimal DOX concentration for the assay. The aim here 
was to obtain the highest DOX concentration that would still allow for some cell 
proliferation. CTL cells were incubated with different drug concentrations (0μM, 0.1μM, 
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0.2μM, 0.5μM, and 1μM of DOX) for up to 48 hours. Fig. 7.2B summarizes the obtained 
results and shows that except for the concentration of 0.5 μM DOX, all other 
concentrations resulted in unaltered growth rates. Therefore, 0.5 μM of DOX was used in 
the following assays. 
After TRAP1 silencing, cells were plated as previously described (Section 6.3, Materials 
and Methods), incubated with 0.5 μM DOX, and allowed to grow up to 72 hours. DOX 
Figure 7.1 - TRAP1 silencing efficiency in A549 cells. A549 cells were either transfected
with a TRAP1 siRNA oligonucleotide (siTRAP1) or a scrambled siRNA as a control (siCTL),
CTL cells correspond to non-transfected cells. Silencing efficiency was confirmed through
qRT-PCR and western blot. (A) Results show a significantly lower TRAP1 content in siTRAP1
cells when compared with the controls groups. mRNA levels were normalized to 18S (N=12)
and results were calculated by ΔΔCT method. Bars show mean ± SEM (*** p<0.001 to siCTL,
one-way ANOVA followed by Dunnett’s post-hoc test). (B) TRAP1 protein content analysis
shows a large decrease in TRAP1 protein upon silencing when compared with the controls.
Protein levels were normalized to actin (N=4), bars show mean ± SEM (*** p<0.001 to siCTL,
one-way ANOVA followed by Dunnett’s post-hoc test). (C) Transfection stability was
evaluated by using western blot in a time period ranging from 24 hours to 144 hours post-
transfection. Data shows that silencing is efficient at 48 hours post-transfection remaining
stable at least up to 144 hours post-transfection (a – siTRAP1 cells, and b – siCTL control
cells). 
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effect on siTRAP1, siCTL, and CTL cell proliferation was analyzed through the SRB assay. 
All cell groups were susceptible to DOX toxicity, showing a decreased cell proliferation 
pattern when compared with non-treated cells described in Fig.7.2B. Despite these 
observations, cell proliferation seems to be more inhibited in TRAP1-depleted cells than in 
control groups suggesting that TRAP1 loss results in a higher cell predisposal to DOX-
induced toxicity (Fig.7.2C). Comparing the two control groups (siCTL and CTL), no 
differences in cell proliferation in any of the analyzed time-points were found, confirming 
that the variations regarding TRAP1-depleted cell growth were not due to the transfection 
protocol (Fig.7.2C). 
Although the above results seem to indicate a link between TRAP1 depletion and increased 
DOX susceptibility, siTRAP1 cells previously showed decreased proliferation rates under 
non-treatment conditions (Fig.7.2A), which may be masking the real effects of DOX in cell 
growth. In order to overcome this issue, an alternative data analysis approach in which 
variances in cell proliferation between the different groups were considered was 
performed. For this, the percentage of difference between each cell group non-treatment 
growth and DOX-treatment growth was calculated. The new data analysis revealed that 
both siTRAP1 and siCTL cell groups are statistically equally susceptible to DOX toxicity, 
showing a 75.5±2.2 % (N=6) decrease in siTRAP1 cell growth against the 78.7±1.0 % (N=6) 
observed for siCTL cell group (p>0.05). 
7.2.3 TRAP1 modulation of mitochondrial function 
After general evaluation of TRAP1 effects on cell growth, we moved on to analyze its 
cellular effects. Considering its subcellular localization we hypothesize that TRAP1 
silencing might affect mitochondrial physiology. This section aims to assess this issue with 
a special interest on ΔΨm, oxygen consumption, global and mitochondrial oxidative stress 
and mPTP regulation. 
TRAP1 preferentially localizes to mitochondria 
TRAP1 subcellular localization was verified through immunocytochemistry by co-staining 
cells with both TRAP1 and OMM marker TOM20 antibodies, and imaging cells by confocal 
fluorescence microscopy. In agreement with the literature [431], immunofluorescence 
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showed TRAP1 co-localization with TOM20 in both siCTL and CTL groups suggesting 
TRAP1 preferential mitochondrial localization (Fig.7.3A). Nevertheless, both controls 
showed TRAP1 staining that did not co-localize with TOM20 fluorescence and was 
disperse throughout the cell, also in accordance with previously reported non-
mitochondrial TRAP1 localization [432]. Interestingly, it appears that the remaining 
TRAP1 staining upon chaperone silencing may reside in those non-mitochondrial targets. 
These results also reinforced the efficiency of our transfection by showing a significant 
decrease in TRAP1 staining in siTRAP1 cells when compared with the control groups 
(Fig.7.3A). Additionally, the immunofluorescence analysis did not show decreased 
staining (either signal and/or extension) for TOM20, suggesting that mitochondrial 
network content appear to remain constant despite TRAP1 silencing. This idea was 
Figure 7.2 - TRAP1 silencing effect on cell growth and susceptibility to DOX treatment.
(A) Cell growth curves show a decrease in TRAP1 silenced cells proliferation when compared
with control groups (N=6). (B) Control cell susceptibility to different DOX concentrations.
(C) DOX-treated TRAP1-silenced cells show lower cell proliferation when compared with the
controls (N=6). Data are presented as mean ± SEM (* p<0.05, ** p<0.01, and *** p<0.001 to
siCTL; two-way ANOVA followed by Bonferroni post-test). 
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further assessed by measuring the levels of TOM20 through western blot, which showed 
no change in this protein levels in TRAP1-silenced cells (Fig.7.3B). 
These findings indicate that TRAP1 localizes to A549 mitochondria, and that its depletion 
has no effect on overall mitochondrial mass. 
TRAP1 silencing results in ΔΨm depolarization 
To assess the possible impact of TRAP1 depletion on mitochondrial function, alterations in 
ΔΨm were evaluated in all experimental groups through flow cytometry using the probe 
TMRM, which is accumulated by polarized mitochondria. TRAP1-silenced cells showed 
lower TMRM fluorescence, suggesting a decrease in ΔΨm when compared with siCTL cells 
(Fig.7.4A). The same experimental conditions were repeated using TMRM in quenching 
[468] and further analyzed fluorimetrically in a microplate reader. Once again, siTRAP1 
cells showed decreased ΔΨm when compared with the control group (Table 7.1).  
A third technique based in the co-labeling of cells with Mitotracker Green (MTG) and 
TMRM was also performed. The former probe stains mitochondria in a ΔΨm- independent 
fashion whereas TMRM loads into polarized mitochondria. When co-labeled, TMRM 
reversibly quenches MTG fluorescence to obtain a relative balance between total 
mitochondrial content and depolarized mitochondria [469]. Results showed higher TMRM 
fluorescence and consequent MTG quenching in siCTL cell group in contrast with TRAP1-
depleted cells (Fig.7.4B), suggesting once more the higher depolarization status of 
siTRAP1 cells. To further confirm the sensitivity of the technique, cells were then 
incubated with 2 μM FCCP to collapse ΔΨm. As expected, a higher uncoupler-related 
difference was found in control cells while no significant alterations were observed in 
siTRAP1 cells, demonstrating once again the lower mitochondrial polarization in this cell 
group (Fig.7.4B). It should also be noted that since MTG stains mitochondria in a ΔΨm-
independent fashion it provides an indirect measurement of mitochondrial mass, which 
once again appears to be similar to control. 
The fact that TRAP1 depletion results in decreased ΔΨm supports the hypothesis of a wider 
role for this chaperone in mitochondrial physiology maintenance. 
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TRAP1 silencing results in a higher closed-conformation of the mPTP 
Considering that mitochondrial depolarization constitutes one of the end-point effects of 
mPTP opening [291], and that TRAP1 has been described to modulate mPTP by binding to 
and antagonizing CypD function conferring tumor cells protection against apoptosis 
[304], we next aimed the understanding of whether the observed mitochondrial 
depolarization (Section 7.2.2) was associated with alterations in mPTP flickering. Thus, 
the effect of TRAP1 silencing was for the first time investigated using the calcein-cobalt 
quench assay [480]. Transfected A549 cells were co-loaded with calcein-AM and cobalt 
chloride and either incubated with CsA, ionomycin (Io) or both. Calcein-AM readily 
crosses cellular and mitochondrial membranes whereas cobalt is spatially restricted to the 
cytosol. In the cell cytosol, cobalt quenches cytoplasmic calcein fluorescence revealing the 
mitochondrial calcein fluorescence staining and thus an intact IMM. 
Figure 7.3 - TRAP1 subcellular localization. (A) Red fluorescence labels TRAP1 while green
fluorescence labels TOM20 (mitochondrial outer membrane marker), nuclei were
counterstained with DAPI and are shown in blue. The merged figures show a large overlap
between TRAP1 and TOM20 labeling in siCTL and CTL cell groups while TRAP1 silenced
cells show decreased red fluorescence when compared with controls. Images were acquired
by confocal microscopy using a 63x objective, scale bar = 8μm. (B) TRAP1 silencing did not
affect TOM20 expression levels (N=4). Bars show mean ± SEM (one-way ANOVA). 
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When co-loaded with calcein-cobalt, TRAP1-silenced cells showed higher mitochondrial 
calcein fluorescence than siCTL control (Fig. 7.5A, first group of bars) whereas treatment 
with Io led to a decrease in calcein fluorescence, with no differences between cell groups 
being observed (Fig.7.5A). When the assays were performed in the presence of the mPTP 
inhibitor CsA, although the fluorescence increased in all groups as expected, it was higher 
in siTRAP1 cells compared with the control (Fig.7.5A). In order to determine the 
percentage of mPTP closure, we normalized the values obtained after CsA as 0% open 
probability and after Io as 100% open probability. Surprisingly, TRAP1 depletion resulted 
in a higher percentage of mPTP closed state than siCTL group (Fig.7.5A right graph). In 
Figure 7.4 - Mitochondrial membrane
potential alterations upon TRAP1
silencing. (A) Mitochondrial membrane
potential (ΔΨm) alterations were
evaluated using TMRM probe and
analyzed through flow cytometry. Cells
showed a significant decrease in TMRM
fluorescence when compared with siCTL
(N=10). Bars show mean ± SEM (*p<0.05,
two-tailed t-students test). (B)
Quenching of MTG by TMRM in siCTL
and siTRAP1 cell groups (two upper
panels). A549 siCTL cells show a large
MTG quenching (upper left panel) while
no MTG quenching was observed in
siTRAP1 group. In addition siCTL cells
show higher TMRM fluorescence when
compared with siTRAP1 cells.
Mitochondrial de-energization with
FCCP caused red TMRM fluorescence
(two lower panels) to disappear and
green MTG fluorescence to recover in
siCTL cells whereas no alterations were
seen in siTRAP1 cells. Images were
acquired by confocal microscopy using a
40x objective, scale bar = 22μm. 
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fact, siTRAP1 cells showed that 70% of their mitochondria had the mPTP in a closed state 
comparing to 50% in the control group. 
To elucidate about TRAP1 regulation of mPTP modulation, CypD mRNA content was 
analyzed in all cell groups. Data showed a significant increase in PPIF mRNA (CypD) 
content in A549 siTRAP1 cells after 72 hours post-transfection when compared with siCTL 
cell group (Fig.7.5B). However, for the same time-point and despite the increase in CypD 
mRNA, protein expression analysis by western blotting showed no differences in CypD 
content between cell groups (Fig.7.5C). Recent findings point out the possible role of 
subunit c of the ATP synthase in mPTP structure [481]. Considering this novel 
information, expression of the subunit c of the ATP synthase was evaluated, showing 
similar protein levels between both groups (Fig.7.5D). 
As referred in Section 4.1.1, TRAP1 is part of a mitochondrial chaperone network. 
Therefore, we investigated whether TRAP1 silencing leads to the activation of 
compensatory mechanisms which may result in increased HSP90 and HSP60 levels. Thus, 
transcript content of the both chaperones was measured. Regarding HSP60 mRNA 
content, no alterations were observed between siTRAP1 and siCTL cell groups after 72 
hours post-transfection (Fig.7.6A). Similarly, TRAP1 silencing had no effect on HSP90AA1 
(HSP90) mRNA content (Fig.7.6B). In addition, the mRNA content for the HSP90 splicing 
variant 1 (HSP90AA1.1, see Section 6.7.1.1 Material and Methods), often described as the 
canonical sequence, was analyzed. Although no differences were found when analyzing 
HSP90 mRNA, where primers were constructed to target both splicing variants 
(HSP0AA1.1 and HSP90AA1.2), TRAP1 silencing resulted in an increased HSP90AA1.1 
mRNA content (Fig.7.6C). Subsequently, HSP90 protein content was evaluated by 
western blotting, with no alterations in its expression between cell groups being found 
(Fig.7.6D). 
In conclusion, the data showed a transient mPTP opening in all cell groups, however, a 
normalization with pore inducer/inhibitor, suggests that TRAP1 silencing seems to induce 
a more closed mPTP conformation without alterations in the expression of the analyzed 
modulators/components of mPTP: CypD and subunit c of the ATP synthase. Moreover, 
data also suggest that mitochondrial HSPs are not upregulated upon TRAP1 silencing. 
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Figure 7.5 - TRAP1 expression and mitochondrial permeability transition pore (mPTP) 
modulation. The mPTP was monitored by quantifying calcein fluorescence in cell 
mitochondria by flow cytometry. The cells were loaded with calcein AM and cobalt, a 
cytosolic calcein quencher, in order to determine the basal calcein fluorescence in 
mitochondria. The cells were also incubated with Ionomycin (Io) which triggers calcium 
overload and pore opening and consequent loss of mitochondrial calcein fluorescence. 
Additionally, cells were incubated with cyclosporin A (CsA) which blocks pore opening. (A) 
siTRAP1 cells show higher basal calcein fluorescence when compared with siCTL cell group. 
No alterations were observed in calcein fluorescence between all cell groups upon treatment 
with Io only, and Io and CsA. siTRAP1 cells incubated with CsA also showed higher 
mitochondrial calcein fluorescence than the one observed for siCTL control (N=6). In the 
panel, we calculate the % of mPTP closure based on the values for CsA (0% mPTP opening), 
and Io (100% mPTP opening). (B) PPIF content was increased in siTRAP1 cells when 
compared to siCTL. mRNA levels were normalized to 18S (N=12), results were calculated by 
ΔΔCT method. (C) Evaluation of CypD protein expression showed no differences between 
cell groups. Protein levels were normalized to actin (N=8). (D) No differences were found in 
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the subunit c of the ATPsynthase expression levels between siTRAP1 and siCTL cells. Bars 
show mean ± SEM (***p<0.001, two-tailed t-students test). 
Table 7.1 - Mitochondrial membrane potential and basal O2 consumption in A549 cell 
groups. 
 Units siTRAP1 siCTL CTL n 
ΔΨm RUF 0.023*±0.0034 0.032±0.0056 0.032±0.0040 5 
O2 basal cons. RUF/min 0.0065*±0.0008 0.0186±0.0004 0.0179±0.0016 2 
ΔΨm values were calculated as the difference between TMRM fluorescence after FCCP 
addition and dye fluorescence before the addition of the uncoupler. Data is presented as 
mean ± SEM (*p<0.05, one-way ANOVA followed by Dunnets’ post-hoc test). 
TRAP1 silencing decreases oxygen consumption 
Another possible explanation for the decreased ΔΨm (Section 7.2.2) may reside in 
alterations in the mitochondrial ETC, resulting in inhibition of electron transfer. This was 
addressed by evaluation of oxygen consumption. Therefore, oxygen consumption was 
evaluated for all A549 cell groups using fluorescent based oxygen-sensitive Oxoplates (see 
Section 6.8, Materials and Methods). The basal oxygen consumption assay was performed 
in two independent cell groups. TRAP1-silenced non-permeabilized cells respiring using 
endogenous substrates showed lower basal oxygen consumption rates (about 65% 
decrease) when compared with siCTL cells (Table 7.1). Data strongly suggests that TRAP1 
silencing may decrease electron transfer in the respiratory chain, which may result in 
decreased ΔΨm. 
TRAP1 silencing results in increased ROS production 
Possible inhibition of respiratory chain suggested by the results obtained in the previous 
sections (Sections 7.2.2 and 7.2.4) may results in an increased ROS production. Since, the 
role of TRAP1 in oxidative damage has been previously described [439], we aimed at 
identifying whether TRAP1 silencing would alter the redox state in A549 cells. Cells were 
first labeled with the general oxidative stress indicator CM-H2DCFDA to verify the effect 
of TRAP1 silencing on ROS generation. Differences in CM-H2DCF fluorescence were 
evaluated using confocal microscopy and also quantified through flow cytometry. TRAP1 
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depletion resulted in a small increase in CM-H2DCF fluorescence and a more punctuated 
staining pattern as can be seen in the representative micrograph in Fig.7.7A. A549 CTL 
cells were incubated with the pro-oxidant compound tert-butyl hydroperoxide (tBHP), 
which promotes lipid peroxidation and which was used as a positive control. As expected, 
control cells treated with tBHP showed higher fluorescence indicative of probe oxidation 
(Fig.7.7A). Confirming microscopy results, flow cytometry analysis showed higher CM-
H2DCF fluorescence in A549 siTRAP1 cells when compared with siCTL cells. 
Figure 7.6 - Mitochondrial HSP90 and HSP60 chaperone content. HSP60 and HSP90 
mRNA content was analyzed by qRT-PCR. Results show no alterations in either HSP60 (A) 
or HSP90AA1 (B) mRNA content in siTRAP1 cells when compared with control cells. (C)
siTRAP1 cells showed higher HSP90AA1 variant 1 mRNA content than siCTL cells. mRNA 
levels were normalized to 18S (N=12), results were calculated by ΔΔCT method. (D) HSP90 
protein expression analysis by western blotting, showed no alterations in this protein
expression between siTRAP1 and siCTL cells. Protein levels were normalized to actin (N=8). 
Bars show mean ± SEM (*** p<0.001, two-tailed t-students test). 
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However, because CM-H2DCFDA is a general marker of oxidative stress it is not suitable 
for discriminating between ROS types or site of origin. Therefore, considering that 
mitochondria constitute an important intracellular source of ROS [482], the next question 
raised was whether TRAP1 silencing in A549 cells led to a higher mitochondrial 
superoxide anion generation. Thus, A549 cell groups were loaded with the mitochondrial 
superoxide anion indicator MitoSOX Red. Confocal microscopy imaging performed 72 
hours post-transfection demonstrated significant increase in MitoSOX fluorescence  
Figure 7.7 - TRAP1 silencing effect on intracellular and mitochondrial reactive oxygen
species (ROS). Detection of intracellular ROS was performed using the CM-H2DCFDA green
fluorescence probe through both live imaging confocal microscopy (A) and flow cytometry
(B) in A549 cells. (A) A549 siTRAP1 cells show higher DCFDA fluorescence when compared
with siCTL. siCTL control cells incubation with tert-Butyl hydroperoxide (tBHP) led to an
increase in probe fluorescence. (B) Results were then confirmed by flow cytometry, showing
higher cell fluorescence in siTRAP1 when compared with siCTL cells (N=4). Bars show mean
± SEM **p<0.01, two-tailed t-students test. (C) Mitochondrial superoxide anion was
monitored using the red fluorescent MitoSOX Red probe. A549 siTRAP1 cells show a higher
MitoSOX fluorescence comparing with siCTL cells. Images were acquired by confocal
microscopy using a 63x objective, scale bar = 8μm. 
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intensity in A549 TRAP1-silenced cells when compared with siCTL cell group (Fig.7.7C). 
As for CM-H2DCFDA, MitoSOX fluorescence evaluation by flow cytometry was also 
attempted; however, the use of this technique with this particular probe proved to be 
unreliable (data not shown). Overall, TRAP1 silencing appears to induce a higher 
oxidative stress status with a probable mitochondrial origin; still, the entity behind the 
increased ROS production upon TRAP1 silencing still remains elusive, even in the 
literature. 
Figure 7.8 - TRAP1 silencing effects on SHC1 gene and p66Shc and SOD2 protein content.
SHC1 mRNA content alterations were analyzed by qRT-PCR. (A) A549 siTRAP1 cells show 
lower SHC1 content than siCTL cells. mRNA levels were normalized to 18S (N=12), and
results were calculated by ΔΔCT method. (B) Protein expression of p66SHC showed a
decrease in siTRAP1 when compared to siCTL cells. (C) TRAP1-depleted cells showed 
increased pSer36-p66SHC content. (D) No differences in SOD2 protein measured by western
blotting were detected between cell groups. Band densities were normalized to actin (N=4).
Bars show mean ± SEM (*p<0.05, **p<0.01, two-tailed t-students test). 
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Considering p66SHC role in oxidative stress modulation and its regulation of SOD2, SHC1 
mRNA content as well as the expression of these two proteins were evaluated. SHC1 gene 
encodes three main isoforms designated according to their molecular weights, p66SHC, 
p52SHC, and p46SHC, and which differ in activity. P66SHC translocates to mitochondria 
upon phosphorylation of its Serine 36 residue and increases mitochondrial oxidative 
stress through an impairment of mitochondrial antioxidant responses [184]. Interestingly, 
despite the increase on mitochondrial ROS TRAP1 silencing led to a decrease in SHC1 
mRNA levels (Fig.7.8A). These results were then confirmed at protein level with A549 
siTRAP1 cells showing a significant decrease in p66SHC content when compared with 
siCTL group (Fig.7.8B). Interestingly, the expression of p66SHC phosphorylated in Serine 
36 residue was increased in TRAP1-depleted cells establishing a possible correlation 
between ROS increase in these cell group and p66SHC activation and possible 
translocation to mitochondria (Fig.7.8C). In fact, the ratio between the phosphorylated 
form over total p66SHC, which gives a better indication of protein activation, showed to 
be 4.2±1.43 (N=4) in siTRAP1 cells against 0.15±0.08 (N=4) in siCTL cell group (p=0.03). 
However, the expression of mitochondrial antioxidant protein SOD2 was not altered by 
TRAP1 silencing (Fig.7.8D). 
Therefore, described results are in accordance with TRAP1 antioxidant protection in 
tumor cells. Data supports the idea of TRAP1 role in mitochondrial ROS maintenance 
probably through a p66SHC-dependent mechanism. 
7.2.4 TRAP1 silencing affects mitochondrial morphology and 
dynamics 
Altogether, results described in the previous sections indicate that TRAP1 silencing results 
in mitochondrial dysfunction. As damage to mitochondria is often accompanied by the 
activation of fusion and fission processes, contributing for trigger mitochondrial quality 
control processes, we next aimed at the evaluation of TRAP1 silencing effect on 
mitochondrial morphology and dynamics. 
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TRAP1 silencing results in mitochondrial fragmentation 
To examine the effect of TRAP1 silencing in mitochondrial morphology, Mitotracker Red 
(MTR) and TOM20 labeling combination was used to stain for mitochondrial bodies, and 
results were analyzed by confocal microscopy. Similarly to TMRM, MTR is dependent on 
ΔΨm; however, mitochondrial morphology analysis with the former probe revealed 
inconclusive results due to the observed decrease in ΔΨm in A549 siTRAP1 cells (Fig.7.9A). 
Although MTR fluorescence was, as expected, decreased in siTRAP1 cells, analysis of 
mitochondrial morphology with this probe allowed a better assessment of polarized 
mitochondria than with TMRM by increasing the contrast of the image. 
Immunofluorescent microscopy showed that A549 siTRAP1 transfected cells contained 
highly fragmented, smaller, rounder and dot-like shaped mitochondira, whilst siCTL 
control cells exhibited more tubular shaped mitochondria with a longer interconnected 
networks (Fig.7.9B). The same pattern was observed with the OMM marker TOM20, 
which labels mitochondria in a ΔΨm-independent fashion, regardless of the cell-line in 
study. 
The results here obtained may indicate a role for TRAP1 in the maintenance of 
mitochondrial morphology, which is pertinent for cell homeostasis under stress, which 
occurs during the carcinogenic process. 
Effects of TRAP1 silencing on mitochondrial dynamics 
Considering the observed morphological alterations in TRAP1-depleted cell mitochondria 
(Fig.7.9), the identification of possible alterations on proteins involved in TRAP1 
mitochondrial dynamics modulation seemed pertinent. In this regard, the expression of 
proteins involved in mitochondrial fusion and fission was further investigated. 
 
Mitochondrial fusion proteins. Mitochondrial fusion is a process dependent on proteins 
from the MFN family, MFN1 and MFN2, located in the OMM, and OPA1 protein, located in 
the mitochondrial intermembrane space [483]. During mitochondrial fusion, MFN1 or 
MFN2 form homo-oligomeric or hetero-oligomeric complexes with juxtaposed 
mitochondria. This is followed by OMM and IMM fusion through a GTP dependent 
process and regulated by OPA1 [484]. Changes in MFN1 and OPA1 mitochondrial fusion 
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proteins were addressed by western blot analysis. TRAP1 silencing revealed no alterations 
in both MFN1 and OPA1 protein content after 72 hours post-transfection (Fig.7.10A and 
B). 
Mitochondrial fission proteins. Mitochondrial fission requires the recruitment of the DRP1 
from the cytosol to the OMM. In the OMM, DRP1 interacts with fission 1 protein (FIS1) 
leading to the constriction of mitochondria and consequent separation of the IMM and 
OMM [484]. Mitochondrial fission proteins FIS1 and DRP1 were evaluated in all cell 
groups. TRAP1 silencing did not alter expression of the fission protein FIS1 (Fig.7.10C). 
However, in the siTRAP1 group, significant increased DRP1 levels were observed when 
compared with control (Fig.7.10D). These findings suggest an important role for TRAP1 in 
maintaining mitochondrial morphology through regulation of DRP1. Interestingly, both 
increased fission and mitocondrial depolarization may signal mitochondrial for 
autophagic removal [485]. 
Figure 7.9 - Mitochondria morphology alterations upon TRAP1 silencing. (A)
Mitochondria were labeled with TMRM red fluorescent probe. Results were inconclusive
regarding A549 cells due to the decrease in siTRAP1 ΔΨm. Images were acquired by confocal
microscopy using a 40x objective, scale bar = 22μm (B) A549 mitochondria were stained
with Mitotracker Red (MTR) and with TOM20 (green) while nuclei were counterstained
with DAPI and are shown in blue. Images show mitochondrial morphology alterations in
A549 cells upon TRAP1 silencing. These cells show more fragmented mitochondria than
siCTL cell group. Images were acquired by confocal microscopy using a 63x objective, scale
bar = 8μm. Note that contrast in siTRAP1 MTR staining was increased in order to better
show the morphology alterations. The staining intensity was, in this case, not relevant for
the study. 
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7.2.5 TRAP1 silencing affects autophagy pathways 
Previous results show that TRAP1 silencing affects mitochondrial function (Section 7.2.3) 
and dynamics (Section 7.2.4). Taking the above observations into account and 
considering that mitochondrial damage often triggers the activation of autophagy 
pathways (Section 3.2.1.1) the next question regarded how TRAP1 silencing affects these 
processes of quality control in cells. 
TRAP1 silencing decreases macroautophagy levels 
Macroautophagy is initiated in the cytoplasm by the formation of an isolation membrane, 
the autophagosome, which is promoted by the class III PI3PK binding to BECLIN-1 and 
other cofactors [332]. Autophagosome expansion is mediated by two ubiquitin-like 
conjugation systems, the ATG12, and LC3 protein systems [332]. The first consists in a 
process that leads to ATG12 covalently binding to ATG5 and is mediated by the ubiquitin-
E1-like enzyme ATG7 and the E2-like enzyme ATG10. The second complex involves LC3-I 
activation by ATG7 and ATG3 through its conjugation with PE, originating LC3-II, which 
is intimately associated with autophagosome membranes [341]. 
In the present study, several autophagy markers were evaluated through western blot in 
all A549 cell groups. After 72 hours post-transfection, TRAP1 depletion resulted in a 
marked decrease in BECLIN-1 protein levels (Fig.7.11A). Next, alterations in the content of 
proteins from the ATG12 system were evaluated. TRAP1 silencing significantly decreased 
ATG5 levels when compared with siCTL group (Fig.7.11B). Similarly, ATG12 expression 
was decreased in TRAP1-silenced cells when compared with the control (Fig.7.11C). 
Additionally, as ATG12 antibody allows identification of the ATG12-ATG5 complex by 
means of different molecular weights, this complex content was also evaluated in both cell 
groups. Also, the ATG12-ATG5 complex content showed a significant decrease in siTRAP1 
cells when compared with control (Fig.7.11D).  
The following step was to evaluate the content of proteins from the LC3 conjugation 
system. It was observed that not only ATG3 (Fig.7.11E) but also ATG7 content were 
decreased in siTRAP1 cells (Fig.7.11F). Finally, total LC3 content was evaluated, showing 
that this protein was considerably decreased in siTRAP1 cells when compared to control 
(Fig.7.11G). In fact, both mature (high molecular weight; LC3-I) and cleaved form  
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 (low molecular weight; LC3-II) of LC3 were decreased to same extent, showing a LC3-
II/LC3-I ratio of 1.12±0.14 (N=3) in siTRAP1 cells against 0.94±0.06 (N=3) in siCTL 
(p=0.29). 
Analysis of the serine/threonine protein kinase PINK1 expression, which plays a key role 
in the removal of damaged mitochondrial through autophagy, showed no alterations 
Figure 7.10 - Measurement of mitochondrial dynamics-related proteins. Proteins
associated with mitochondrial fusion (MFN1 and OPA1) and fission (FIS1 and DRP1) were
evaluated by western blot. (A-B) There were no alterations in MFN1 and OPA1 proteins
between cell groups. (C) FIS1 protein analysis also showed no differences between siTRAP1
and control. (D) DRP1 protein levels were increased in siTRAP1 cells when compared with
siCTL. Protein levels were normalized to actin (N=4), bars show mean ± SEM (***p<0.001,
two-tailed t-students test). Abbreviations: MFN1 – mitofusin 1; OPA1 – optic atrophy 1; FIS1 –
fission protein 1; DRP1 – dynamin-related protein 1. 
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between siTRAP1 and control (Fig.7.11H). Similarly, no differences were observed 
between cell groups regarding the expression of NIX, a receptor protein for mitophagy 
(Fig.7.11I). 
Altogether, TRAP1 silencing results in a general decrease in the levels of several 
autophagy markers, indicating this chaperone involvement in the control of the 
autophagy flux.  
Autophagic flux. In order to confirm that TRAP1 silencing decreases autophagic flux, 
lysosome content and p62 protein levels were evaluated. Lysosomes constitute key 
executors of autophagy as they fuse with the autophagosome during the maturation 
process [348]. The p62 protein recognizes toxic cellular waste through its interaction with 
polyubiquitinated cargo. Furthermore, p62 is targeted to the autophagosome formation 
site where it directly interacts with LC3. Considering its role in autophagy, p62 is often 
analyzed as a marker for autophagy flux in cells. Suppression in autophagy leads to an 
accumulation of p62 as well as a large formation of ubiquitinated aggregates [486]. 
Lysosome content was evaluated by incubating cells with the Lysotracker Green probe 
and imaged through confocal fluorescent microscopy. As can be seen in Fig.7.12A (left 
panels), TRAP-silenced cells presented higher lysosomal content in comparison to siCTL 
group. Surprisingly, immunocytochemistry showed a decrease in p62 levels in TRAP1-
depleted cells when compared to both controls (Fig.7.12A right panels). The decreased p62 
content in siTRAP1 cells was further confirmed through protein analysis by western blot, 
which corroborated the confocal microscopy results by showing a significant decrease in 
p62 levels in siTRAP1 cells (Fig.7.12B). 
Figure 7.11 (Previous page) - Alterations in macroautophagy-related proteins during 
TRAP1 silencing. Proteins associated with autophagosome formation, namely in nucleation
(BECLIN1-) and elongation (ATG5, ATG12, ATG3, ATG7, LC3) were evaluated by western 
blot. (A) BECLIN-1 protein content in siTRAP1 cells was decreased. (B-D) ATG5, ATG12, 
proteins as well as ATG12-ATG5 protein complex content were decreased in siTRAP1 cells
when compared with the control. (E-F) TRAP1 silencing led to a decrease in both ATG3 and 
ATG7 protein expression. (G) LC3 protein content was also decreased upon TRAP1 silencing.
(H-I) No alterations were observed regarding the expression of PINK1 and NIX mitophagy
related proteins. Protein levels were normalized to actin (N=4), bars show mean ± SEM (* 
p<0.05, ** p<0.01 and *** p<0.001, two-tailed t-students test). 
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Although findings regarding the decreased expression of main autophagy markers 
together with the increased lysosomal content observed in siTRAP1 cells may suggest a 
reduced autophagy flux, p62 decreased levels indicate otherwise. One explanation for 
these apparently contradictory results may imply the activation of alternative autophagy 
pathways in these cells. 
TRAP1 silencing and macroautophagy modulation. In order to better understand the 
significance of the decreased macroautophagy pathway on cell proliferation, transfected 
cells were treated with either rapamycin or 3-methyladenine (3-MA) for up to 72 hours. 
Rapamycin constitutes an autophagy inducer as it inhibits the autophagy negative 
regulator mTOR [487]. In contrast, 3-MA inhibits the formation of the PI3K–BECLIN-1 
autophagosomal promoting complex leading to autophagy inhibition [488]. 
Figure 7.12 - p62 and lysosome content after TRAP1 silencing. (A, left panel series) Cells
were incubated with Lysotracker (green fluorescence) and imaged by confocal microscopy.
Increased lysosomal content was observed in siTRAP1. p62 protein content was evaluated
both by confocal microscopy (A, right panel) and western blot (B and C). Regardless the
methodology used, TRAP1 silencing always induced a decrease in p62 content. In
micrographs, nuclei are marked in blue (DAPI), images were acquired by confocal
microscopy using a 40x objective, scale bars = 22μm. Protein levels were normalized to
actin (N=4), bars show mean ± SEM (* p<0.05, two-tailed t-students test). 
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Figure 7.13 - Effect of macroautophagy modulators in the proliferation of TRAP1 silenced 
cells. Cell proliferation in the presence of the chemical compounds was accessed by SRB 
dye-binding assay during a period of 72 hours. (A) Data shows increased cellular 
proliferation for siTRAP cells compared to siCTL cell group with no differences in curves 
between the two control groups. (B) The same experiment was also conducted in the 
presence of the anticancer agent doxorubicin (DOX). No differences were observed in 
rapamycin and DOX-treated A549 cell mass between groups. (C) When treated with 3-MA 
siTRAP1 cells showed lower proliferation rates than control cells. (D) A549 siTRAP1 cells 
treated with 3-MA and DOX show a large decrease in cell mass when compared with siCTL 
control, with no differences being observed between CTL and siCTL cell mass. Data is 
presented as mean ± SEM (*p<0.05 and ***p<0.001 to siCTL for the respective time-point, 
N=5; two-way ANOVA followed by Bonferroni’s post hoc analysis for correction for multiple 
comparisons). (E) Summarized data from previous images for the 48 hours time-point in 
order to compare cell viability with and without treatment with the following agents: 
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rapamycin, DOX, and rapamycin and DOX. Bars show mean ± SEM, two-way ANOVA 
followed by Bonferroni’s post hoc analysis for correction for multiple comparisons (* 
represents comparison with non-treated, $ represents comparison with DOX-treated cells, # 
represents comparison with rapamycin and DOX-treated cells; all comparisons where made 
within the same cell group, symbol number represent statistical significance, i.e. one symbol 
– p<0.05, two symbols – p<0.01 and three symbols – p<0.001). 
As can be seen in Fig.7.13A, A549 cell proliferation analysis upon rapamycin treatment 
showed differences between siTRAP1 and control groups regarding cell growth at the 48 
and 72 hours post-seeding time points. In fact, when treated with rapamycin TRAP1-
silenced cells showed a surprisingly higher growth rate when compared to siCTL group. In 
order to better understand whether autophagy has a protective role in these cells, A549 
cell groups were incubated with both rapamycin and DOX (Rapamycin+DOX). In this case, 
data shows similar growth rates for all A549 cell groups with no statistically significance 
between them (Fig.7.13B). 
In contrast to the effect observed upon rapamycin treatment, cell incubation with the 
autophagy inhibitor 3-MA resulted in decreased cell proliferation in TRAP1-depleted cells 
(Fig.7.13C). Additionally, cell groups were also treated with 3-MA plus DOX (3-MA+DOX). 
The presence of both drugs in TRAP1-silenced cells resulted in lower cell proliferation 
when compared with siCTL for all the time points in study (Fig.7.13D). 
Based on the previous data, another analytic approach was used with the purpose of 
clarifying the alterations measured with rapamycin treatment. For this reason, results 
were analyzed in order to compare cell viability in untreated and treated conditions 
(rapamycin, DOX, and rapamycin+DOX) at the 48 hours post-transfection time point. 
Fig.7.13E summarizes this analysis and shows that rapamycin treatment in A549 siCTL nd 
CTL groups led to a decrease in cell mass similar to the one observed upon DOX treatment. 
Conversely, rapamycin-treated siTRAP1 cells showed higher proliferation than the one 
observed under both no-treatment and DOX-treatment conditions. In addition, no 
alterations were observed between DOX and rapamycin+DOX treatment in these cells. 
Moreover, treatment combination with the two agents, rapamycin+DOX, had synergistic 
suppression on cell growth in the control groups, which was significant in CTL group 
(Fig.7.13E). 
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Results suggest that autophagy levels in A549 control cells are maintained in a way that 
favors tumor progression. Additionally, the effect of rapamycin treatment in TRAP1-
silenced cells growth reinforces the role of this chaperone in autophagy maintenance.  
TRAP1 silencing decreases ubiquitin content and increases CMA 
Because p62 binds to polyubiquitinated cargos targeting them for autophagic removal, 
and TRAP1 as been reported to regulate cellular ubiquitination, we hypothesize that the 
observed decrease in p62 levels upon TRAP1 silencing results from differences in protein 
ubiquitination. Consequently, alterations in ubiquitin expression were analyzed in order 
to understand the previously observed differences in p62 content. Proteins were 
separated by SDS-PAGE and ubiquitin labeling was evaluated through western blot. 
Ubiquitin binds to several proteins and therefore it creates a smear-like pattern after 
western blot membrane imaging, as seen in Fig.7.14C. A semi-quantitative analysis of 
ubiquitin labeling, which comprised proteins from high to low molecular weight, showed 
that TRAP1 silencing resulted in a lower ubiquitin content when compared with siCTL 
group (Fig.7.14A and C). 
Considering the apparently contradictory results previously described regarding the 
decrease in macroautophagy markers and decreased p62 content in TRAP-depleted cells, 
the activation of alternative autophagy pathways, namely the chaperone-mediated 
autophagy (CMA), was evaluated. This constitutes a selective lysosomal mechanism of 
protein degradation through which proteins are singularly identified by a cytosolic 
chaperone, the HSC70, and delivered to the lysosome surface through binding to the 
LAMP2A [370]. Once bound to this receptor, proteins targeted for degradation unfold and 
cross the lysosomal membrane assisted by a lysosomal form of the HSC70 (lys-HSC70), 
with substrates being completely degraded by the lysosomal proteases in the lumen [370]. 
LAMP2A expression was analyzed revealing a higher content of this protein in A549 
TRAP1-silenced cells when compared with siCTL cells (Fig.7.14B and C). 
The results suggest that TRAP1 silencing leads to an activation of CMA pathway. In 
addition to these observations, the decreased ubiquitin content in this cell group is also in 
accordance with the decreased p62 content described previously.  
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7.2.6 TRAP1 silencing affects apoptosis regulators 
The previous sections showed that TRAP1 affects mitochondrial homeostasis and cellular 
quality control processes. The next question regarded the effect of TRAP1 silencing on yet 
another cell/tissue quality control mechanism, apoptosis. Apoptosis constitutes a highly 
regulated process of programed cell death in which caspases constitute central regulators. 
Initiator caspases, such as caspase 8, 9, and 12, are closely associated with pro-apoptotic 
signals. When activated, these caspases cleave and activate downstream effector 
caspases, namely caspase-3 and -7, which in turn execute apoptosis by substrate cleavage 
[489]. The decision to proceed with cell death upon intrinsic pathway activation is usually 
dependent on the balance between pro-apoptotic and pro-survival BCL-2 family proteins. 
Taking into account TRAP1 silencing effect on cell proliferation and mitochondrial 
physiology, it still remains to be known whether silencing of TRAP1 results in increased 
Figure 7.14 - Effect of TRAP1 
silencing in both ubiquitin and 
LAMP2A content. (A-C) The 
extent of protein ubiquitination 
was evaluated in total protein 
extracts. TRAP1 silencing 
decreased the overall ubiquitin 
content when compared to siCTL 
cell group. (B-C) Protein content of 
LAMP2A, a receptor for 
chaperone-mediated autophagy, 
showed increased levels on 
siTRAP1. Protein levels were 
normalized to actin (N=4), bars 
show mean ± SEM (**p<0.01; two-
tailed t-students test). Panel C 
show representative western blot 
for the above mentioned proteins 
together with their respective 
loading controls (actin). a –
siTRAP1 and b – siCTL. 
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apoptotic signaling. In order to elucidate this issue, caspase-like activity, as well as the 
content in proteins from the BCL-2 family were analyzed. 
TRAP1 silencing results in increased caspase 3-like activity while not affecting 
initiator caspases-like activities 
After 72 hours upon TRAP1 silencing, no alteration was observed on initiator caspases 8-, 
9- and 12-like activities, which are involved in the extrinsic-, intrinsic- and ER-related 
pathways (Fig.7.15A, B and C). However, suprisingly, effector caspase 3/7-like activity 
was dramatically higher in TRAP1-silenced cells when compared with siCTL control group 
(Fig.7.15D). 
TRAP1 silencing shifts the balance BAX/BCL-xL in favor of apoptosis 
Additionally, expression of BAX and BCL-xL pro-apoptotic and pro-survival proteins was 
analyzed. Note that it was not possible to evaluate BCL-2 protein content in this cell line 
because A549 cells do not express this protein [490]. TRAP1 silencing induced a slight yet 
significant increase in BAX content along with a marked decrease of BCL-xL (Fig.7.15E 
and F). Moreover, considering that the BAX/BCL-xL ratio was of 2.10±0.18 (N=6) for 
siTRAP1 cell group and 0.79±0.03 (N=6) for siCTL cells (p<0.001), TRAP1 seems to protect 
cells from apoptosis through regulating BCL-xL pro-apoptotic protein expression. 
7.3 Discussion 
Sustaining proliferative signaling is presumably the most fundamental trait of cancer 
cells [45]. Contrarily to normal cells, where growth is highly controlled by the release of 
growth-promoting signals, cancer cells overcome these controls and acquire the capability 
to circumvent these tight regulatory systems and show unlimited replicative capacity. 
Thus, A549 lung cancer cells are no exception, showing high cell proliferation rates and 
high TRAP1 content making A549 cells a good model for the study of TRAP1 role in 
tumorigenesis [446]. In this study, we initially showed that TRAP1 loss interferes with the 
high replicative capability of A549 cells, leading to a significant decrease in cell 
proliferation rates, therefore suggesting TRAP1 important role in tumor phenotype. 
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Figure 7.15 - TRAP1 silencing effect on caspase-like activities and BCL-2 family protein 
levels. The activities of initiator caspases (8, 9 and 12) and effector caspases (3/7) were 
evaluated. (A-C) There were no differences in activity of any initiator caspases between cell 
groups. (D) Alterations were only observed in caspase 3/7-like activity. Moreover, (E) BAX 
content was increased whereas (F) BCL-xL was decreased in siTRAP1 cells. Protein levels 
were normalized to actin (N=4). Bars show mean ± SEM (***p<0.001, two-tailed t-students 
test). 
Since several lines of evidence support a role for TRAP1 in tumor cell acquisition of a 
multi-drug resistant phenotype [447, 450, 478]. Although in our work all cell groups 
were equally susceptible to DOX-induced toxicity, TRAP1-depleted cells presented lower 
cell proliferation than controls. These findings may indicate that TRAP1 silencing 
synergizes with DOX-induced toxicity which agrees with the observations made by Wu 
and colleagues whose work shows that TRAP1 loss combined with DOX may constitute a 
useful therapeutic strategy [491]. 
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TRAP1 cytoprotective functions have been largely attributed to its mitochondrial 
localization. In agreement with previous studies [431] we found that TRAP1 co-localizes 
with A549 cell mitochondria labeled by TOM20. Cancer cell mitochondria undergo 
profound changes that often culminate in altered energy metabolism, hyperpolarization, 
increased ROS production, and resistance to apoptosis [492]. Considering its subcellular 
localization and cytoprotective roles, it did not take long for TRAP1 to be associated with 
mitochondrial function maintenance in tumor cells. Accordingly, TRAP1-depleted cells 
exhibit multiple markers of mitochondrial dysfunction, including loss of ΔΨm, increased 
ROS production, and low oxygen consumption. In the present dissertation, part of those 
hallmarks were evaluated in A549 cells in order to confirm the phenotype before 
exploring new mechanisms and roles of TRAP1 in tumor cells. During this 
characterization, new insights on previous reported alterations were detected and will be 
now further discussed. 
Several groups had previously demonstrated that TRAP1 plays an important role in 
inhibiting cell death caused by ROS and thus conferring tumor cells with a selective 
advantage [438, 439, 442]. Although TRAP1 role in mitochondria protection against 
oxidative stress is consensual, the mechanisms behind this protective function are still 
unclear [439, 440, 442]. The present work suggests the involvement of p66SHC on TRAP1 
regulation of mitochondrial ROS generation. 
p66SHC is a pro-apoptotic protein involved in mitochondrial ROS production and 
oxidative stress response [493]. Studies on p66SHC subcellular localization have 
identified it as a cytoplasmic protein able to translocate to mitochondria upon different 
pro-apoptotic stimuli (e.g. H2O2 and UV exposure) [494, 495]. The mechanism behind the 
signaling pathway includes p66SHC phosphorylation at Ser36 (pSer36-p66SHC) by 
protein kinase c beta (PKCβ). Although Ser36 phosphorylation is critical for its apoptotic 
potential, mitochondrial-translocated p66SHC is not phosphorylated [183]. In 
mitochondria, p66SHC was shown to operate as a redox enzyme that transfers electrons 
from reduced cytochrome c to molecular oxygen [183], although doubts remain whether 
p66SHC really crosses the OMM. 
The present study reveals that TRAP1 silencing increases Ser36 phosphorylation of 
p66SHC, which has been shown to exert a pro-apoptotic effect in different cell types 
[496]. Thus, it is plausible that TRAP1 controls ROS generation through regulation of 
p66SHC phosphorylation, thereby protecting mitochondria against oxidative stress-
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induced apoptosis. However, the question of whether the observed increase in pSer36-
p66SHC is cause or consequence of increased ROS production is still unclear and would 
require further investigation on this topic. In addition to increasing ROS generation in 
mitochondria, down-regulation of expression of antioxidant enzymes has been 
considered another mechanism for p66SHC-dependent increase in oxidative stress [497]. 
Because previous research has shown that p66SHC reduces SOD2 expression [498], we 
investigated the content of this antioxidant enzyme in TRAP1-depleted cells. Although our 
results showed no alterations in SOD2 expression in TRAP1-silenced cells, contradicting 
previous observations, several other publications support these observations by showing 
that p66SHC activity does not alter the levels of antioxidant enzymes [183, 499]. 
The increased intracellular ROS production can trigger cell death by the opening of mPTP, 
which in turn results in the ΔΨm loss. Moreover, mPTP opening has been reported to 
constitute a pre-requisite for induction of mitochondrial apoptosis [500]. Although mPTP 
exact structure is still debatable, a series of knockout studies demonstrated that CypD is 
indeed required for mPTP modulation, regulating mPTP opening in a positive manner 
[295, 501]. TRAP1, the HSP90 mitochondrial pool, and HSP60, were all described to 
physically interact with CypD modulating its activity resulting in mPTP inhibition [304, 
474]. Considering our observations regarding TRAP1 role in ΔΨm maintenance and 
oxidative stress regulation, we addressed this chaperone function in mPTP regulation in 
A549 cells. 
Surprisingly, our data revealed that TRAP1-depletion resulted in having the mPTP 
preferentially in the closed conformation under basal conditions. Although these results 
go against previously suggested mechanism of TRAP1-dependent mPTP inhibition in 
cancer cells, none of the referred works included studies on mPTP open/closed status after 
TRAP1 silencing and/or overexpression. In fact, in these previous works, the impact of 
TRAP1 on mPTP was extrapolated either by analysis of ΔΨm alterations [304] or by 
evaluation of cell viability [474] in the presence or absence of CsA. Although those 
methodologies are well established when using isolated mitochondrial fractions, the use 
of whole cells may result in other confounding factors. For example, CsA is not specific for 
mPTP inhibition (contrarily to NIM811) as it also inhibits calcineurin and multidrug 
resistance protein. Therefore, incubating the drug for long periods of time may impact 
mPTP-independent effects. In our assays, CsA was incubated solely during the assay and 
for a short period of time. Additionally, caution should be taken when using ΔΨm to 
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characterize mPTP status as mitochondrial depolarization can occur due to ETC inhibition 
or together with mPTP opening, giving rise to false positives. Although not explored in the 
present study, we hypothesize that if CsA was used in ΔΨm experiments, a higher value in 
siTRAP1 group would also be obtained, since CsA was shown in the calcein-cobalt 
technique to be able to fully close mPTP. Finally, one should understand the differences 
between the end-points used to characterize the mPTP status in intact cells. In the present 
work, the parameter used reports qualitatively the percentage of mitochondria/cells with 
closed mPTP under basal conditions, i.e. without cells experiencing any challenge (e.g. 
calcium increase) or exogenous stimuli. Therefore, it better depicts the mPTP opening 
extent in normal growth conditions. However, by using the same technique, but instead 
following the loss of mitochondrial calcein fluorescence over time after calcium 
challenging, it would be possible to observe that TRAP1-depleted cells show a faster 
calcein loss, suggesting a sensitized mPTP. Such outcome would suggest that TRAP1 
increases the threshold for mPTP opening protecting cells during stressful events, 
although the mPTP would be in a more closed conformation during basal conditions. 
Nevertheless, our observations corroborate the hypothesis that TRAP1 is somehow 
involved in mPTP modulation. Additionally, our results showed that TRAP1 silencing 
resulted in no alterations in overall HSPD1 (HSP60) and HSP90AA1 (HSP90) content while 
significantly increasing PPIF (CypD) levels. However, this increase was not observed at 
protein level suggesting that the time needed for CypD mRNA translation is higher than 
the time the assay lasted. Thus, differences at protein content level would only become 
visible at latter post-transfection times. This hypothesis can also help us understand the 
discrepancy in our results regarding previous observations of a more open state of the 
mPTP in TRAP1 depleted cells [304, 474]. In fact, in these previous works, studies on 
TRAP1 function in mPTP modulation were developed after longer periods of transfection 
time or incubation with HSP90-like inhibitors. However, further studies are needed to 
clarify the interplay between TRAP1 and the mPTP. Notwithstanding, our observations of 
a more closed mPTP state in cells lacking TRAP1 are interesting and suggestive of a more 
complex role of TRAP1 in mPTP modulation. 
In agreement with previous observations, our results suggest that TRAP1 contributes for 
tumor cell mitochondria homeostasis through regulation of ROS generation and ΔΨm 
maintenance, which is likely protective under stressful environments. TRAP1 
homeostatic role may involve indirectly controlling CypD levels, as a decreased 
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expression of CypD have been shown to desensitize cells to mPTP opening [502]. 
Accordingly, TRAP1 depletion, which results in mitochondrial impairment, would 
increase CypD levels and thus sensitizing the mPTP. Although our results support this 
hypothesis, they also suggest that alterations in CypD protein levels might only emerge 
after several days of TRAP1 silencing. However, further work would be required to 
understand whether the increased mPTP inhibition observed in TRAP1-depleted cells is 
directly related to TRAP1 loss or if it only reflects an early compensatory mechanism in an 
attempt of maintaining mitochondrial viability. 
Alternatively, loss of ΔΨm in TRAP1-depleted cells could reflect alterations in the 
mitochondrial ETC. Here we showed that TRAP1 depletion resulted in decreased oxygen 
consumption. Together, a reduced oxygen consumption and decreased ΔΨm, suggest 
inhibition of the ETC. In agreement with this hypothesis, several works suggest a key role 
for TRAP1 in the regulation of the ETC [444, 503]. TRAP1 has been reported to preserve 
complex IV activity under stress conditions with no effect on the activity of other ETC 
complexes [444]. Although these observations were later supported by the identification 
of TRAP1 interaction with complex IV [503], this study did not provide further detail 
regarding TRAP1-dependent complex IV regulation. Moreover, in contrast to Xu et al, 
Sciacovelli and co-workers showed that TRAP1 interacts with SDH, part of Complex II, 
inhibiting its activity, which in turn results in HIF1α stabilization and increased cell 
glycolytic potential [503]. Similarly, an independent work using the same cell lines 
showed that TRAP1 promotes a metabolic switch between mitochondrial respiration and 
aerobic glycolysis via c-Src activity modulation [504]. Therefore, our observations 
regarding oxygen consumption in TRAP1-depleted cells are discrepant from the ones 
reported by both Sciacovelli [503], and Yoshida [504]. Notwithstanding, the reduced 
oxygen consumption may possibly be explained by a decrease in complex IV activity 
supported by Xu and collaborators work [444]. Moreover, according to Sciacovelli and 
colleagues HIF1α stabilization resulting from increased succinate accumulation can 
inhibit PHD. However, HIF1α stabilization is far more complex and might be regulated 
through other mechanisms, namely HSP90 [505-507]) and ROS [508, 509] have also been 
implicated in HIF1α stabilization. TRAP1 depletion leads to an increment in ROS 
generation within the cell, which might be contributing for HIF1α stabilization and, if so, 
could also help justify the observed reduction of oxygen consumption. Moreover, it is 
becoming evident that different cancer cells are metabolic diverse [510]. This 
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heterogeneity may also explain the discrepancy in cell metabolic responses to TRAP1 
depletion. Altogether, these findings demonstrate that TRAP1 role in tumorigenesis is 
likely more complex than previously appreciated. TRAP1 function seems to be more 
nuanced and variable depending on the cell type and its basal TRAP1 levels and possible 
localization. 
As mentioned above, decreased oxygen consumption together with the observed decrease 
in ΔΨm suggests an inhibition of the ETC. Although these conditions may contribute, under 
specific circumstances, to ROS production [511], our data indicates p66SHC as the most 
probable mitochondrial ROS source. In fact, the published studies associate the increased 
oxygen consumption and mitochondrial depolarization with an increase in ROS [504], 
although other authors defended that mitochondrial uncoupling can decrease ROS 
produced by the ETC [512]. This apparent contradiction, further suggests that the source 
of ROS in TRAP1-depleted cells may result from activation of the p66SHC pathway upon 
TRAP1 depletion. 
Accumulation of depolarized mitochondria and oxidative damage has been associated 
with the occurrence of mitochondrial fusion and fission processes in an attempt to either 
restore homeostasis or eliminate mitochondria that are beyond repair [513]. In this report, 
TRAP1 silencing shifted the balance towards a fission-prone phenotype, characterized by 
the accumulation of smaller and rounder mitochondria. In order to assess whether TRAP1 
affected mitochondrial fusion or fission the expression of fusion and fission proteins was 
evaluated. TRAP1 was shown to have no effect on both MFN1 and OPA1 fusion proteins 
levels. Conversely, TRAP1 depletion led to a significant increase in DRP1 levels without 
affecting FIS1. This effect of TRAP1 depletion on mitochondrial morphology reported in 
our study is in accordance with the observations made by Butler and colleagues [514], and 
although not coherent with the tubular mitochondria observed by Takamura and 
colleagues [515], our findings also support the hypothesis that TRAP1 controls 
mitochondrial dynamics through DRP1 expression. In addition, Takamura and 
collaborators suggested that DRP1 is regulated by TRAP1 in a non-transcriptional manner. 
Post-translational modifications of DRP1, for example through ubiquitination, regulate its 
function in mitochondria by affecting DRP1 mitochondrial pool [516]. Considering that 
TRAP controls cellular ubiquitination and expression levels of mitochondrial proteins 
[452] it seems reasonable to think that it might also be involved in DRP1 regulation 
through this pathway. In fact, when analyzing overall protein ubiquitination, TRAP1-
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depleted cells showed considerably lower ubiquitin levels, which may explain DRP1 
stabilization in these cells. However, more specific assays are needed to verify to what 
extent DRP1 protein ubiquitination is affected by TRAP1 silencing.  
Increased mitochondrial fragmentation is often related with damaged-mitochondria 
elimination through autophagy (mitophagy) as defective mitochondria can become toxic 
to the cell [485]. Indeed, DRP1 inhibition resulted in inhibition of mitochondrial 
autophagy, suggesting that fission is required for mitophagy [485]. Moreover, loss of ΔΨm 
has been reported to induce mitophagy [517]. In this work, TRAP1 silencing resulted in a 
generalized decrease of the proteins involved in the autophagic pathway, such as BECLIN-
1, part of class III PI3K complex and important for vesicle nucleation, and proteins that 
make part of both ATG12 and LC3 ubiquitin-like systems, which play crucial role in 
autophagosome elongation and cargo engulfment [335]. 
Interestingly, although both soluble (LC3-I) and membrane-bound (LC3-II) LC3 forms, 
were decreased in siTRAP1, no differences were found regarding the LC3-II/LC3-I ratio, 
an indicator of autophagosome formation [518]. This approach suggests that there are no 
alterations in the autophagic flux, i.e. according to this analysis autophagy does not seem 
to be defective or blocked although it may occur in a lesser extent considering that the 
overall machinery is downregulated. Alternatively, due to the limitations associated with 
LC3 analysis to infer autophagy flux (reviewed in [519]), measurement of p62 degradation 
may constitute an important tool. p62 binds to LC3 and constitutes a selective substrate of 
autophagy [520]. Therefore, p62 decreases upon autophagy stimulation and increases 
when autophagy is suppressed. Our data demonstrated that TRAP1 silencing resulted in 
decreased p62 levels, thus indicating an increased autophagic flux. However, the 
expression levels of p62 can also be changed in an autophagy-independent manner, 
namely by alterations in the levels of ubiquitinated proteins [521]. As previously 
mentioned, TRAP1 plays a role in cellular ubiquitination through its interaction with the 
regulatory proteasome protein TBP7 [452]. In fact, we observed reduced global cellular 
ubiquitin levels in TRAP1-depleted cells, which suggests that the observed decrease in p62 
levels is not a consequence of a higher autophagy flux but is actually influenced by low 
cargo ubiquitination. 
In addition to being regulated by autophagy adaptor proteins, such as p62 binding to 
ubiquitinated proteins on mitochondria, mitophagy may also be mediated via autophagy 
receptors, namely the ubiquitin-independent pathway that includes the mitochondrial 
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NIX/BNIP3 receptors [351]. However, results showed that NIX protein levels were not 
altered in TRAP1-depleted cells, thus indicating that TRAP1 does not affect this pathway. 
Another pathway involved in damaged-mitochondria removal by autophagy involves the 
activation of the PINK1/Parkin pathway, which is extensively studied in neuronal 
systems. Following ΔΨm collapse, PINK1 accumulates in the OMM resulting in Parkin 
recruitment and activation [362, 363]. Parkin activation leads to ubiquitination of 
mitochondrial proteins signaling them for mitophagy [354]. In neuronal cells, TRAP1 was 
shown to be a downstream phosphorylation target of PINK1 [437]. Moreover, PINK1 was 
also shown to regulate TRAP1 levels [522]. However, while some studies developed in 
Drosophila indicate that TRAP1 expression compensates for the mitochondrial defects in 
Parkin mutant flies [523], others suggest that PINK1-dependent TRAP1 role in 
mitochondrial integrity maintenance is parallel or upstream of Parkin [524]. However, in 
this work, TRAP1 silencing did not affected PINK1 protein levels suggesting that the 
observed alterations regarding autophagy are independent of this pathway. 
Because, TRAP1 depletion resulted in a significant decrease in several key components of 
the autophagic machinery, it is thought that TRAP1 plays a role in the control of 
autophagy levels in tumor cells. In order to understand whether the regulation of 
autophagy by TRAP1 manipulation constitute an advantage to tumor growth, cells were 
incubated either with an autophagy inducer, rapamycin, or inhibitor, 3-MA, and 
alterations at cell proliferation level were measured. Interestingly, when incubated with 
rapamycin siTRAP1 cells showed higher proliferation rates than control cells, whereas 
autophagy inhibition with 3-MA led to a decrease in the growth of these cells. In fact, 
TRAP1-depleted cells proliferation after rapamycin treatment was higher than their basal 
growth, suggesting that autophagy stimulation confers a growth advantage to TRAP1-
silenced cells. Moreover, cell incubation with both rapamycin and DOX, with the purpose 
of understanding the advantage conferred by increased autophagy upon TRAP1 depletion, 
showed no differences in cell proliferation between groups indicating a lack of synergistic 
effect of autophagy stimulation and DOX in control cells.  
Altogether, these findings suggest that TRAP1 plays a role in the maintenance of 
autophagy levels possibly through regulation of the expression of several components of 
the autophagic machinery. Moreover, mitochondria permeability transition has been 
implicated in the signaling for the induction of mitochondrial autophagy [525, 526]. In 
accordance with these works, we observed lower autophagy levels and a more closed 
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mPTP conformation. Although the referred works suggested mitochondrial 
depolarization as a bridge between mPTP and autophagy our current data may suggest a 
ΔΨm-independent mPTP regulation of autophagy. In these cells, autophagy levels seem to 
be kept at an “optimal” level conferring growth advantage to tumor cells, as stimulation or 
suppression of autophagy in these cells leads to a significant drop in cell proliferation. 
In addition to the reduced autophagy levels, we showed in this work that TRAP1-depletion 
resulted in increased lysosomal content and increased LAMP2A. Similarly to previous 
studies showing a compensatory activation of CMA in response to autophagy impairment 
[527] our results suggest the activation of CMA pathway upon TRAP1 silencing. However, 
the activation of this compensatory mechanism presents its limitations as CMA lacks 
(macro)autophagy selectivity. Consequently, CMA would only be able to degrade cytosolic 
proteins and could not compensate for (macro)autophagy removal of organelles [527]. In 
the absence of (macro)autophagy, CMA can be responsible for enhanced oxidative stress 
resistance reflecting the advantage of its activation as a compensatory mechanism for 
autophagy impairment [528]. Moreover, substrate binding to LAMP2A transporter is a 
limiting step for CMA through which proteins are translocated one-by-one to the 
lysosomal lumen. Accordingly, levels of LAMP2A at lysosomal surface determine rates of 
CMA activity [373]. Despite the advantages conferred by CMA activation, when the 
gradual accumulation of damaged components overcomes cell repair/buffering capacity, 
cell death becomes inevitable. 
When protective/adaptative mechanisms fail, stressed cells trigger apoptosis. High levels 
of cell stress often result in mitochondrial fission and apoptosis. The process of 
mitochondrial fragmentation has been reported to occur almost simultaneously with pro-
apoptotic BCL-2 family member BAX translocation to mitochondria but before caspase 
activation [484]. Before caspase activation, BAX accumulates in the OMM in compacted 
foci that colocalize with DRP1 and mitofusin proteins [529]. Moreover, DRP1 stimulates 
BAX oligomerization and thus OMM permeabilization [530]. In addition to the increased 
mitochondrial fragmentation, TRAP1-depleted cells showed elevated BAX and reduced 
BCL-xL levels, thus indicating the higher sensibility of these cells to apoptosis. 
Surprisingly, caspase 3/7 was shown to be activated independently of caspase 8, 9, or 12. 
This further suggests that, in these cells, caspase 3/7 undergo activation through other 
alternative pathways or that we did not measure the right time-point for initiator 
caspases activation. Nevertheless, it was previously shown that caspase 3 activation 
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might occur independently of other initiator caspases, one example being through 
cathepsins’ cleavage [531, 532]. Although the current work did not address this issue, 
considering the observed increment in lysosomal content, the overall increase in cellular 
stress may contribute to enhanced lysosomal membrane permeabilization (LMP) 
therefore leading to cathepsin release resulting in caspase 3 activation [533]. In fact, 
although lysotracker fluorescent pattern is more prominent in TRAP1-depleted cells 
which would suggest that LMP is not occuring, previous reports have shown that LMP and 
selective cathepsins release may occur in a subset of lysosomes, still allowing organelle 
labeling [534]. Several cellular constituents can promote LMP: lysosomal free iron, ROS-
induced lysosomal lipid peroxidation, free fatty acids, sphingosine, oxidized cholesterol 
and BCL-2 family of proteins such as BAX or BAK [535]. In the context of the present 
work, ROS and BAX would be the most promising agents although the former appears to 
be of mitochondrial origin and with an inherent chemical character, which is not 
compatible with a high diffusion radius.  
7.4 Conclusions 
In agreement with previous reports, TRAP1 plays an important role in the mitochondrial 
physiology maintenance of A549 cells by decreasing oxidative stress, preserving ΔΨm, and 
modulating mPTP. Our present results suggest the participation of p66SHC in TRAP1 
mechanisms of ROS regulation in these cells, although p66SHC silencing would help 
clarify this. Here we confirmed that TRAP1 indeed modulates mPTP, however, on the 
contrary to what was expected, TRAP1 depletion led to a more closed mPTP conformation 
under basal conditions. Although the knowledge on the implication of these observations 
is still unknown, this finding suggests the re-evaluation of TRAP1 mPTP protective 
function indicating a far more complex involvement of this chaperone in this function. 
Nevertheless, the understanding of the mechanisms underlying TRAP1 modulation of 
mPTP requires further investigation. Moreover, our findings suggest that TRAP1 controls 
these mitochondrial functions by regulating mitochondrial morphology. Furthermore, 
here we describe for the first time TRAP1 involvement in the regulation of autophagy 
levels. In A549 cells, TRAP1 seems to maintain an adaptive autophagy flux conferring a 
growth advantage to tumor cells. Altogether, these findings provide new insights for 
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TRAP1 role in tumor cells and contribute to increase our understanding of the 
mechanisms behind this chaperone complex function. 
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Chapter 8  
 
TRAP1 regulates autophagy in MRC-5 
lung cells but has reduced effects on 
mitochondrial function 
 
 
 
 
TRAP1 is a mitochondrial chaperone of the HSP90 family which is differentially expressed 
in tumor versus normal cells. These differences in TRAP1 expression led to its 
characterization as an anticancer molecular target. However, current inhibitors available 
are not able to distinguish between TRAP1 and HSP90 making them not ideal drugs for 
targeting specifically TRAP1 in tumor cells. Furthermore, even if TRAP1 targeting is 
specific to this chaperone, it remains to be determined whether TRAP1 inhibition in non-
tumor cells would have deleterious effects to those non-target cells. To investigate this, we 
have used transient TRAP1 silencing in MRC-5, a model for non-tumor cell line. Our 
results from this and previous sections suggest that besides TRAP1 levels, differences in 
its subcellular localization might also be important to understand the differential effect of 
TRAP1 inhibition between normal and tumor cells. TRAP1 was shown to preferentially 
accumulate in extramitochondrial sites, which may explain the fact that its silencing did 
not greatly affect mitochondrial function. Nevertheless, as in previously studied lung 
cancer cell line, TRAP1 silencing in MRC-5 cells affected autophagy levels. 
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8.1 Introduction 
TRAP1 was first identified by yeast two-hybrid assay as a TNFR interacting partner. 
Although the presence of a mitochondrial targeting sequence at its N-terminus indicates 
TRAP1 primarily mitochondrial localization, further studies led to the identification of this 
chaperone in cytosol [430], nucleus [430], and more recently in the ER [452]. TRAP1 soon 
became high focus of study in cancer cells not only because of its high expression but also 
due to its cytoprotective functions (revised in [536]). Conversely, normal cells have been 
reported to have low TRAP1 expression [433]. To the author’s knowledge, TRAP1 function 
in non-tumor cells has not been yet fully described. Despite these observations regarding 
TRAP1 differential expression in tumor versus normal cells, further studies show that this 
chaperone expression is also variable in cancer cells [446]. Indeed, lower TRAP1 
expression levels observed in some cancers have been associated with the acquisition of a 
higher malignancy phenotype by increasing cell metastatic capability [441, 446]. Thus, 
TRAP1 functions in normal and transformed cells seem to be far more complex than 
initially thought. 
Recently, a novel generation of mitochondrial targeted HSP90 inhibitors were developed 
and are considered to constitute promising drugs for anticancer therapy due to their 
ability to efficiently inhibit TRAP1 within mitochondria (revised in [454]). In addition, 
such agents showed high efficacy in reducing tumor cell growth with no major effects on 
their normal counterparts. However, these inhibitors are not able to distinguish between 
TRAP1 and HSP90 making them less suitable for TRAP1-specific studies. 
TRAP1 expression and function in normal cell lines has been, in our opinion, highly 
disregarded, as most studies only focus on the therapeutic implications of HSP90-
inhibitors in these cells without an extensive evaluation of TRAP1 loss implications in 
these cells. However, judging by the increased information on TRAP1 in the last decade 
and considering that we cannot address TRAP1 function in such a linear and clear manner 
as previously appreciated, the study of this chaperone function in normal lung fibroblasts 
seemed pertinent. Therefore, this study aims to explore the consequences of TRAP1 gene 
inhibition on mitochondrial physiology and morphology in the human MRC-5 normal lung 
fibroblast cell line. We hypothesized that in this non-tumor cell line, TRAP1 does not play 
a crucial role in mitochondrial function and dynamics as well as in cellular and organelle 
quality control. Hence, we first aimed the identification of TRAP1 silencing-consequences 
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in terms of mitochondrial dysfunction including, loss of ΔΨm, mPTP induction, and 
oxidative status. Finally, we addressed TRAP1 role in mitochondrial dynamics and its 
silencing repercussion on autophagy pathways and expression and activity of several 
apoptosis regulators. The results have implications not only how we perceive TRAP1 roles 
in the different cell types but also to understand the consequences of off-targeting TRAP1 
in non-tumor cells. 
8.2 Results 
8.2.1 TRAP1 expression and silencing efficiency 
In order to address TRAP1 levels in MRC-5 human lung fibroblasts TRAP1 mRNA 
expression as well as its protein content were first investigated. Analysis of TRAP1 mRNA 
normalized to 18S showed that the transcript content was two-fold lower in MRC-5 
normal lung fibroblasts compared to A549 tumor cells, used in the previous section 
(Fig.8.1A). Moreover, TRAP1 protein expression normalized to actin confirmed its lower 
expression in MRC-5 cells (Fig.8.1B). It is important to mention that no differences 
regarding 18S mRNA content were found between both cell lines, indicating that this is a 
good internal reference for comparisons between cell lines (Fig.8.1C). However, in 
agreement with the fact that cell morphology differs, actin content was higher in MRC-5 
cells, suggesting that this protein may not be an ideal loading control to compare different 
cell lines (Fig.8.1D). Thus, these results show that MRC-5 cells have low TRAP1 
expression, making it a useful model for the understanding of the importance of TRAP1 
functions in normal cells where its expression is less noted than in tumor cells. 
The efficacy of TRAP1 inhibition by siRNA in MRC-5 cells was verified through qRT-PCR 
and results showed a 4-fold decrease in TRAP1 mRNA content when compared with both 
control groups with no differences observed in the latter (Fig.8.2A). Furthermore, 
silencing efficiency was verified at protein level showing that TRAP1 protein content, 
normalized to actin, was significantly decreased after 72 hours post-transfection in MRC-5 
siTRAP1 cells when compared with the siCTL and CTL control groups (Fig.8.2B), with the 
two latter groups showing no differences between themselves.  
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In order to evaluate TRAP1 silencing stability in MRC-5 cell line, cells were transfected 
and protein was harvested every 24 hours up to 144 hours post-transfection. Results 
showed no change in TRAP1 protein content 24 hours post-transfection; however, after 
48 hours post-transfection there is a decrease in TRAP1 expression in siTRAP1 cells (group 
a) compared with siCTL control (group b), which remains stable up to 120 hours post-
transfection (Fig.8.2C). Although at 144 hours post transfection siTRAP1 cells still show 
lower TRAP1 content this is not as clear as for the remaining time points revealing an 
apparent recovery of TRAP1 expression in these cells. 
Figure 8.1 - TRAP1 differential expression. TRAP1 mRNA content in A549 and MRC-5 cells 
was determined through qRT-PCR. (A) TRAP1 mRNA content was lower in MRC-5 
fibroblasts when compared with A549 cells. mRNA levels were normalized to 18S (N=12),
with results being calculated through the ΔΔCT method. (B) These differences were 
confirmed at protein level through western blot. (C) No differences were observed regarding
18S reference gene mRNA content between both cell lines. (D) A higher actin content was
found in MRC-5 cells when compared with A549 cells. TRAP1 protein content was 
normalized to actin (N=7). Bars show mean ± SEM (**p<0.01, ***p<0.001; two-tailed 
Student’s t-test). 
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8.2.2 TRAP1 silencing effect on cell proliferation and 
susceptibility to DOX-induced toxicity 
In order to assess TRAP1 role in MRC-5 cell growth in, cell proliferation was evaluated in 
TRAP1 naïve and silenced cells by the SRB method (see Section 6.2.3, Material and 
Methods). Results presented in Fig.8.3A show that TRAP1 silencing decreases cell mass 
Figure 8.2 - TRAP1 silencing efficiency in MRC-5 cells. Cells were either transfected with a
TRAP1 siRNA oligonucleotide (siTRAP1) or a scrambled siRNA as a control (siCTL), CTL cells
correspond to non-transfected cells. Silencing efficiency was confirmed through qRT-PCR
and western blot. (A) Results show a significantly lower TRAP1 content in siTRAP1 cells
when compared with the controls groups. mRNA levels were normalized to 18S (N=12) and
results were calculated by ΔΔCT method. Bars show mean ± SEM (*** p<0.001 to siCTL, one-
way ANOVA followed by Dunnett’s post-hoc test). (B) TRAP1 protein content analysis shows
a large decrease in TRAP1 protein upon silencing when compared with the controls. Protein
levels were normalized to actin (N=4), bars show mean ± SEM (*** p<0.001 to siCTL, one-
way ANOVA followed by Dunnett’s post-hoc test). (C) Transfection stability was evaluated
by using western blot in a time period ranging from 24 hours to 144 hours post-transfection.
Data shows that silencing is efficient at 48 hours post-transfection remaining stable at least
up to 144 hours post-transfection (a – siTRAP1 cells, and b – siCTL control cells). 
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within 24 hours post-seeding (corresponding to 72 hours post-transfection). These 
differences in cell growth continued for 48 and 72 hours post-seeding while controls 
showed a liner growth over the same period of time. Therefore, TRAP1 silencing led to a 
maximal 49% drop in MRC-5 proliferation (relative to siCTL cell group) during the 72 
hours of the assay. Overall, no differences were observed regarding cell proliferation 
between siCTL and CTL groups with the exception of the 72 hours time point where cell 
mass was shown to be higher in the CTL cell group (Fig.8.3A). 
We next addressed TRAP1 silencing effect on MRC-5 cell susceptibility to DOX-induced 
toxicity. After TRAP1 silencing, cells were plated as previously described, treated with 
0.5M DOX, and allowed to grow up to 72 hours. Doxorubicin-effects on cell proliferation 
were analyzed through the SRB assay and showed an overall growth inhibition in all cell 
groups and time points analyzed (Fig.8.3B). However, regarding inter-group 
comparisons, a high decrease in cell proliferation was observed in siTRAP1 cells within 
the first 24 hours of DOX incubation was shown, while no differences in both controls cell 
mass resulting from DOX treatment were detected. Although these findings reveal that all 
Figure 8.3 - TRAP1 silencing effect on cell 
growth and susceptibility to DOX 
treatment. (A) Cell growth curves show a 
decrease in TRAP1 silenced cells 
proliferation when compared with control 
groups (N=6). (B) DOX-treated TRAP1-
silenced cells show lower cell proliferation 
when compared with the controls (N=6). 
Data are presented as mean ± SEM (** 
p<0.01, and *** p<0.001 to siCTL; two-way 
ANOVA followed by Bonferroni post-test).
  
 SECTION 8.2
PhD in Biology – Specialization in Cell Biology 153
cell groups were similarly susceptible to DOX toxicity, they suggest a higher susceptibility 
in the siTRAP1 group. 
An additional analysis of the above data regarding DOX toxicity was performed taking 
into account the differences in cell proliferation between the different groups shown in 
Fig.8.3A. To achieve this, the percentage of difference between non-treatment growth 
and DOX-treatment growth for each correspondent cell group was calculated at 72 hours 
post-seeding. Interestingly, TRAP1-silenced cells showed a 59.4±0.61 % (N=3) inhibition 
of cell growth against the 78.2±3.84 % (N=3) inhibition in the siCTL group, which 
revealed to be statistically significant (p<0.01) and thus, indicating a higher susceptibility 
of siCTL cells to DOX toxicity.  
Figure 8.4 - TRAP1 subcellular localization. (A) Red fluorescence labels TRAP1 while green
fluorescence labels TOM20 (mitochondrial outer membrane marker), nuclei were
counterstained with DAPI and are shown in blue. The merged images show a sparse TRAP1
labeling, with no predominant co-localization with TOM20. In addition, siTRAP1 cells also
show a decrease in red fluorescence when compared with the controls. Images were
acquired by confocal microscopy using a 40x objective, scale bar = 22μm. (B) TRAP1
silencing did not affected TOM20 expression levels (N=4). Bars show mean ± SEM (one-way
ANOVA). 
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8.2.3 TRAP1 modulation of mitochondrial function 
After general evaluation of TRAP1 effects on cell growth, we moved on to analyze its 
silencing consequences on mitochondrial physiology. As a non-tumor cell line, and 
considering TRAP1 low levels in MRC-5 cells we hypothesize that mitochondrial function 
would not be extensively affected by TRAP1 depletion. This section aims to assess this 
issue with a special focus on ΔΨm, mPTP regulation, and cellular oxidative stress. 
TRAP1 is highly localized in extramitochondrial sites 
TRAP1 subcellular localization in MRC-5 cells was assessed through 
immunocytochemistry by co-staining cells with both TRAP1 and the OMM marker 
TOM20, followed by imaging trough using confocal fluorescence microscopy. TRAP1 co-
localized with TOM20 in siCTL and CTL MRC-5 cells although to a less extent than what 
would be expected taking into account what was described before [431] (Fig.8.4A). In fact, 
TRAP1 seems to have a sparse and diffused distribution within the cells instead of the 
expected specific mitochondrial localization. These results suggest that TRAP1 
preferentially localizes in extramitochondrial sites in MRC-5 cells. Mitochondrial mass 
was indirectly evaluated by measuring TOM20 protein content through western blot, the 
results showed that TRAP1 depletion had no impact on mitochondrial mass (Fig.8.4B). 
In order to investigate whether TRAP1 silencing results in increased compensatory 
expression of HSP90 and HSP60 transcript levels were measured. TRAP1-silencing led to 
a significant decrease in HSP60 mRNA content while not affecting HSP90AA1 (Fig.8.5A 
and B). Additionally the mRNA content for the HSP90 splicing variant 1 (HSP90AA1.1, see 
Section 6.2.3 Material and Methods) was also analyzed. Although no differences were 
found when analyzing HSP90 mRNA, in which primers were designed in order to target 
both splicing variants (HSP0AA1.1 and HSP90AA1.2), results showed an increase in 
HSP90AA1.1 mRNA content in siTRAP1 cells when compared with siCTL cells (Fig.8.5C). 
Despite these alterations, TRAP1 silencing had no effect on HSP90 protein expression 
levels (Fig.8.5D). 
In summary, cellular localization of TRAP1 in MRC-5 appear to be mostly 
extramitochondrial and chaperone silencing does not greatly affects other HSPs 
expression. 
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TRAP1 silencing does not affect ΔΨm 
To address the role of TRAP1 in mitochondrial function modulation in MRC-5 cells, 
alterations in ΔΨm were initially evaluated through flow cytometry using TMRM, a 
fluorescent probe which is accumulated by polarized mitochondria. TRAP1-silenced cells 
showed no differences regarding TMRM fluorescence when compared with the control 
Figure 8.5 - Mitochondrial HSP90 and HSP60 chaperones content. HSP60 and HSP90
mRNA content was analyzed by qRT-PCR. Results show a decrease in HSP60 content (A)
while HSP90AA1 content was not altered (B) in siTRAP1 cells when compared with control
cells. (C) siTRAP1 cells showed higher HSP90AA1 variant 1 mRNA content than siCTL cells.
mRNA levels were normalized to 18S (N=12), results were calculated by ΔΔCT method. (D)
HSP90 protein expression analysis showed no alterations in this protein expression
between siTRAP1 and siCTL cells. Protein levels were normalized to actin (N=8). Bars show
mean ± SEM (*p<0.05, *** p<0.001; two-tailed Student’s t-test). 
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(Fig.8.6A). In a second approach, cells were co-labeled with Mitotracker Green (MTG) and 
TMRM. The former probe stains mitochondria independent of ΔΨm whereas TMRM loads 
into polarized mitochondria. As described in the previous sections, when co-labeled, 
TMRM reversibly quenches MTG fluorescence to obtain a relative balance between total 
mitochondrial content and depolarized mitochondria [469]. Both cell groups (siTRAP1 and 
siCTL) showed similar TMRM uptake, MTG quenching and response to FCCP-induced 
mitochondrial depolarization (Fig.8.6B), supporting the notion that TRAP1 silencing in 
MRC-5 cells does not impact ΔΨm. 
TRAP1 silencing effect on mPTP modulation 
TRAP1 has been described to modulate mPTP by binding to and antagonizing CypD 
function [304]. With the purpose of further verify TRAP1 silencing effect on 
mitochondrial function we next evaluated mPTP status. Thus, the effect of TRAP1 
silencing was investigated using the calcein-cobalt quench assay, as described before 
[480]. Cells were co-loaded with calcein-AM and cobalt chloride and either incubated 
with CsA, Io or both. Calcein-AM readily crosses cellular and mitochondrial membranes 
whereas cobalt is spatially restricted to the cytosol. In the cell cytosol, cobalt quenches 
cytoplasmic calcein fluorescence revealing the mitochondrial calcein fluorescence 
staining. Calcein fluorescence in represented in Fig.8.7A showing that all cell groups 
equally responded to CsA and ionomycin by changing to a closed or open mPTP 
conformation, respectively. Normalization as described in previous section resulted in 
equivalent percentage of mPTP-closed state in both groups.  
Therefore, the above data suggests that mPTP is open/closed to the same extent in all 
treatment groups. Analysis of PPIF (CypD) mRNA level showed an increase in siTRAP1 
cells when compared to the control group (Fig.8.7.B). However, despite these differences 
in PPIF expression TRAP1 depletion did not affect CypD protein content (Fig.8.7C). 
Moreover, subunit c of the ATP synthase content, measured by western blotting, was also 
not affected by TRAP1 depletion (Fig.8.7D). 
Overall, cell groups showed similar transient mPTP opening with no alterations in CypD 
and ATP synthase subunit c expression. These observations emphasize the hypothesis 
that TRAP1, in these cells, does not have a preponderant role in the maintenance of 
mitochondrial function with respect to ΔΨm and mPTP. 
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TRAP1 silencing does not alter cellular oxidative stress 
Considering that mitochondria constitute an important intracellular source of ROS [482], 
and taking into account TRAP1 antioxidant role [442], the next question raised was 
whether TRAP1 silencing affected mitochondrial ROS generation. Consequently, MRC-5 
cells were loaded with the mitochondrial superoxide anion indicator MitoSOX Red. 
Confocal microscopy imaging demonstrated that cell groups showed very low levels of 
fluorescence staining with no variations between siTRAP1 cells and the control (Fig.8.8A). 
Figure 8.6 - Mitochondrial
membrane potential alterations
upon TRAP1 silencing. (A)
Mitochondrial membrane potential
(ΔΨm) alterations were evaluated
using TMRM probe and analyzed
through flow cytometry. No
differences were observed regarding
TMRM fluorescence. (B) Quenching
of MTG by TMRM in siCTL and
siTRAP1 cell groups (two upper
panels). Both cell groups showed
MTG quenching (upper left panel).
In addition no differences were
found in TMRM fluorescence
intensity. Mitochondrial de-
energization with FCCP caused red
TMRM fluorescence (two bottom
panels) to disappear and green MTG
fluorescence to recover in both cell
groups. Images were acquired by
confocal microscopy using a 40x
objective, scale bar = 22μm. 
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Figure 8.7 - TRAP1 expression and mitochondrial permeability transition pore (mPTP) 
modulation. The mPTP was monitored by quantifying calcein fluorescence in cell 
mitochondria by flow cytometry. The cells were loaded with calcein AM and cobalt, a 
cytosolic calcein quencher, in order to determine the basal calcein fluorescence in 
mitochondria. The cells were also incubated with Ionomycin (Io) which triggers calcium 
overload and pore opening and consequent loss of mitochondrial calcein fluorescence. 
Additionally, cells were incubated with cyclosporin A (CsA) which blocks pore opening. (A) 
Cell groups showed statistically similar basal calcein fluorescence. In addition, no 
alterations were observed in calcein fluorescence between all cell groups upon treatment 
with Io only, and Io and CsA (N=6). In the right panel, we calculated the % of mPTP closure 
based on the values for Io (100% mPTP opening) and CsA (0% mPTP opening). (B) PPIF 
content was increased in siTRAP1 cells when compared to siCTL. mRNA levels were 
normalized to 18S (N=12), results were calculated by ΔΔCT method. (C) Evaluation of CypD 
protein expression showed no differences between cell groups. Protein levels were 
normalized to actin (N=8). (D) No differences were found in the subunit c of the 
ATPsynthase expression levels between siTRAP1 and siCTL cells. Bars show mean ± SEM 
(***p<0.001, two-tailed Student’s t-test). 
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We further evaluated SHC1 mRNA expression as well as the content of p66SHC and SOD2 
proteins. SHC1 mRNA expression revealed no alterations in SHC1 gene expression 
between cell groups (Fig.8.8B). However, p66SHC protein content was significantly lower 
in siTRAP1 and CTL cell groups when compared with the siCTL cell group (Fig.8.8C). 
Interestingly, analysis of the active phosphorylated form of p66SHC (pSer-p66SHC) also 
showed a decrease in siTRAP1 cells when compared to the controls (Fig.8.8D). These 
alterations reflected a pSer36-p66SHC/p66SHC ratio of 1.10±0.06 (N=4) against the 
0.95±0.05 (N=4) observed in siCTL cells (p>0.05). Regarding SOD2 content no differences 
were found between siTRAP1 cells and siCTL group when measured by western blotting 
(Fig.8.8E). 
These findings indicate that MRC-5 cells have low oxidative stress levels which are not 
affected by TRAP1 silencing. Also, the p66SHC appears not to be activated in TRAP1-
silenced cells. 
8.2.4 TRAP1 silencing effect on mitochondrial morphology and 
dynamics 
Altogether, previous results indicate that TRAP1 silencing does not affect MRC-5 
mitochondrial function. To further confirm the lack of effect of TRAP1 silencing on 
mitochondrial function of MRC-5 cells, we next evaluated silencing effects on 
mitochondrial morphology and dynamics. 
TRAP1 silencing does not alter mitochondrial morphology 
To examine the effect of TRAP1 silencing in mitochondrial morphology, mitochondria 
were stained with TMRM and analyzed by confocal microscopy. Live-cell imaging showed 
an evenly spread tubular mitochondrial network in MRC-5 cells with no differences in 
mitochondrial shape between TRAP1-silenced cells and the respective controls (Fig.8.9A), 
revealing that TRAP1 loss does not affect MRC-5 mitochondrial morphology. 
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TRAP1 silencing does not affect the expression levels of proteins involved in 
mitochondrial dynamics 
Considering that TRAP1 silencing did not affect mitochondrial morphology, we next 
aimed to confirm these results by evaluating the expression of different mitochondrial 
dynamics markers. In this regard, the expression of proteins involved in mitochondrial 
Figure 8.8 - TRAP1 silencing and oxidative stress. (A) Mitochondrial superoxide anion was 
monitored using the red fluorescent MitoSOX Red probe. Both cell groups showed low
detectable levels of MitoSOX fluorescence. Images were acquired by confocal microscopy
using a 63x objective, scale bar = 8μm. (B) SHC1 content was not altered by TRAP1. mRNA 
levels were normalized to 18S (N=12), and results were calculated by ΔΔCT method. (C) 
Protein expression of p66SHC showed a decrease in siTRAP1 when compared to siCTL cells.
(D) TRAP1 depleted cells showed a decreased pSer36-p66SHC content. (E) There were no 
differences in SOD2 protein between cell groups. Band densities were normalized to actin
(N=4). Bars show mean ± SEM (*p<0.05, ***p<0.001, two-tailed Student’s t-test). 
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fusion and fission was investigated. Accordingly, the expression of mitochondrial fusion 
proteins, MFN1 and OPA1, was not altered in siTRAP1 cells when compared to the control 
(Fig.8.9B and C). In addition, expression of mitochondrial fission proteins FIS1 and DRP1 
was also evaluated in all cell groups showing no alterations in the expression levels of 
both fission proteins between cell groups (Fig.8.9D and E). These findings are in 
Figure 8.9 - Mitochondria morphology and dynamics in TRAP1-depleted cells. (A)
Mitochondria were labeled with TMRM red fluorescent probe. Results showed no
alterations in mitochondrial morphology between siTRAP1 and siCTL cells. Both groups
showed a complex interconnected mitochondrial network. Images were acquired by
confocal microscopy using a 40x objective, scale bar = 22μm. (B-E) Proteins associated with
mitochondrial fusion (MFN1 and OPA1) and fission (FIS1 and DRP1) were evaluated by
western blot. Protein levels were normalized to actin (N=4), bars show mean ± SEM
(***p<0.001, two-tailed Student’s t-test). Abbreviations: MFN1 – mitofusin 1; OPA1 – optic
atrophy 1; FIS1 – fission protein 1; DRP1 – dynamin-related protein 1. 
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agreement with the previous observations regarding the absence of mitochondrial 
morphology alterations after TRAP1 silencing. 
8.2.5 TRAP1 silencing effect on autophagy pathways 
Previous results corroborate the hypothesis that TRAP1 does not play an essential role in 
the maintenance of mitochondrial function in MRC-5 cells. However, we further 
investigated if TRAP1 silencing in this cell line would alter the mechanisms of regulation 
of quality control. 
TRAP1 silencing decreases macroautophagy levels 
The protein content of several autophagy markers was evaluated through western blot in 
all MRC-5 cell groups. Although TRAP1 depletion did not alter the protein levels of both 
BECLIN-1 and ATG5 autophagy-related proteins (Fig.8.10A and B), expression of ATG12 
was surprisingly decreased in siTRAP1 cells when compared with control groups 
(Fig.8.10C). Accordingly, levels of ATG12-ATG5 complex were also decreased in TRAP1-
depleted cells when compared with siCTL group (Fig.8.10D). The following step was to 
evaluate the content of proteins from the LC3 conjugation system. The expression of both 
ATG3 and 7 was not altered in TRAP1-depleted cells when compared with siCTL cell group 
(Fig.8.10E and F). However, total LC3 content was considerably decreased in siTRAP1 
cells (Fig.8.10G). In fact, both the mature (high molecular weight; LC3-I) and cleaved form 
(low molecular weight; LC3-II) of LC3 were decreased to same extent, showing a LC3-
II/LC3-I ratio of 1.01±0.06 in siTRAP1 cells and 1.01±0.03 in siCTL (p>0.05). 
Analysis of serine/threonine protein kinase PINK1 expression, which plays a key role in 
removal of damaged mitochondrial through autophagy, showed no alterations between 
siTRAP1 and the controls (Fig.8.10H). Similarly, no differences were observed between 
cell groups regarding the expression of NIX, a receptor protein for mitophagy (Fig.8.10I). 
To further evaluate TRAP1 loss implications on autophagy, lysosome content and p62 
protein levels were evaluated. Lysosome content was evaluated by incubating cells with 
the Lysotracker Green probe and imaged through confocal fluorescent microscopy. As can 
be seen in Fig.8.11A (left panels) no differences existed in lysosomal content between all 
cell groups. Although, immunocytochemistry analysis of p62 expression did not show 
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major alterations in this protein levels (Fig.8.11A right panels), protein analysis by 
western blot revealed a lower p62 content in siTRAP1 cells (Fig.8.11B). 
Although p62 decreased levels suggest an increased autophagic flux, autophagy markers, 
with the exception of ATG12 and LC3, did not suffer any alterations upon TRAP silencing 
indicating otherwise. 
 
TRAP1 silencing and macroautophagy modulation. In order to understand the significance 
of autophagy modulation on cell proliferation, transfected cells were treated with either 
rapamycin (autophagy inductor) or 3-MA (autophagy inhibitor) for up to 72 hours. 
Interestingly and contrarily to the effect observed in A549 cells, cell proliferation was 
shown to be statistically similar between all cell groups upon rapamycin treatment for all 
time points in study (Fig.8.12A). MRC-5 cell groups were also incubated with both 
rapamycin and DOX (Rapamycin+DOX), resulting in a higher decrease in cell proliferation 
of siTRAP1 group when compared with the siCTL control cells while no differences were 
found between the controls (Fig.8.12B). Moreover, treatment with the autophagy 
inhibitor 3-MA resulted in lower cell proliferation in siTRAP1 cells at 48 and 72 hours 
post-seeding (Fig.8.12C). Additionally, the response to co-incubation with 3-MA and DOX 
of MRC-5 cells was the same regardless of the applied treatment (Fig.8.12D). 
Based on the previous data, another analytic approach was used with the purpose of 
clarifying the alterations measured with rapamycin treatment. For this reason, results 
were analyzed in order to compare cell viability in untreated and treated conditions 
(Rapamycin, DOX, and Rapamycin+DOX) at the 48 hours post-transfection time point and 
are represented in Fig.8.12E. Rapamycin treatment in siCTL and CTL groups induced a 
decrease in cell mass when compared to the respective non-treated cell groups whereas 
siTRAP1 cell mass remained similar. Moreover, no differences were observed when 
comparing rapamycin-treated with DOX-treated cells for both control groups. In contrast, 
rapamycin treatment in siTRAP1 cells resulted in a higher cell proliferation than the one 
observed when treating this same cell group with DOX. In addition, rapamycin and DOX 
combination treatment appears to have a synergistic effect on decreasing cell mass when 
compared with DOX treatment alone, and it was statistically significant for both siCTL and 
CTL groups. Therefore, these results indicate that despite not affecting mitochondrial 
physiology, TRAP1 does play a role in autophagy levels maintenance in MRC-5 cells. 
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Figure 8.10 - Alterations in macroautophagy-related proteins during TRAP1 silencing. Proteins 
associated with autophagosome formation, namely in nucleation (BECLIN-1) and elongation 
(ATG5, ATG12, ATG3, ATG7, LC3) were evaluated by western blot. (A) BECLIN-1 protein content 
was not altered in TRAP1 silenced cells. (B-D) Although no differences were found in ATG5 levels, 
ATG12 content as well as ATG12-ATG5 protein complex were decreased in siTRAP1 cells when 
compared with the control. (E-F) No alterations were found in both ATG3 and ATG7 protein 
expression. (G) LC3 protein content was decreased upon TRAP1 silencing. (H-I) No alterations were 
observed regarding the expression of PINK1 and NIX mitophagy-related proteins. Protein levels 
were normalized to actin (N=4), bars show mean ± SEM (*** p<0.001, two-tailed Student’s t-test). 
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TRAP1 silencing does not affect ubiquitin content and CMA levels 
Because p62 binds to polyubiquitinated cargos targeting them for autophagic removal, 
and since TRAP1 has been reported to regulate cellular ubiquitination, we hypothesized 
that the observed decrease in p62 levels upon TRAP1 silencing results from differences in 
protein ubiquitination. Consequently, alterations in ubiquitin expression were analyzed 
in order to understand the previously observed differences in p62 content. Proteins were 
separated by SDS-PAGE and ubiquitin labeling was evaluated through western blot. 
Ubiquitin binds to several proteins, therefore creating a smear-like pattern after western 
blot membrane imaging, as can be seen in Fig.8.13C. A semi-quantitative analysis of 
ubiquitin labeling showed no alterations in ubiquitin content between cell groups 
(Fig.8.13A and C). 
In order to better clarify TRAP1 role in MRC-5 cells autophagy modulation, we next 
investigated its silencing effect on LAMP2A expression. TRAP1 did not affect LAMP2A 
expression levels (Fig.7.14B and C). 
8.2.6 TRAP1 silencing affects apoptosis regulators 
Considering the previously reported antiapoptotic TRAP1 role [450], we next investigated 
the effects of silencing this chaperone in the activity of different initiator and effector 
caspases, as well as TRAP1 silencing implications on the expression of pro- and anti-
apoptotic proteins from BCL-2 family. 
TRAP1 silencing results in increased caspase 3-like activity and decreased 
caspase 12-like activity 
After 72 hours upon TRAP1 silencing no alterations were observed on initiator caspases 8- 
and 9-like activities, which participate in extrinsic- and intrinsic- pathways respectively 
(Fig.8.14A and B). However, caspase 12-like activity decreased in siTRAP1 cells when 
compared with the control (Fig.8.14C). Moreover, effector caspase 3/7-like activity was 
dramatically elevated in TRAP1-silenced cells when compared with siCTL cells 
(Fig.8.14D). 
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TRAP1 silencing did not affect pro-apoptotic and pro-survival BCL-2 family 
proteins 
Additionally, expression of pro-apoptotic protein BAX and pro-survival BCL-2 and BCL-
xL proteins was analyzed. TRAP1 depletion was shown to have no effect on any of these 
proteins (Fig.8.14E-G). Moreover, BAX/BCL-2 ratio was of 1.06±0.07 (N=4) for siTRAP1 
and 1.00±0.15 (N=4) to siCTL group (p>0.05), further confirming that TRAP1 did not alter 
the balance between pro- and anti-apoptotic protein levels. 
8.3 Discussion 
Cell treatment with several HSP90 inhibitors inhibits cell proliferation and promotes cell 
death in several cancer cells without affecting their normal counterparts [454]. However, 
these inhibitors do not distinguish between HSP90 and TRAP1, making them not suitable 
Figure 8.11 - p62 and lysosome content after TRAP1 silencing. (A, left panel series) Cells 
were incubated with Lysotracker (green fluorescence) and imaged by confocal microscopy.
There were no differences in lysosomal content between cell groups. p62 protein content
was evaluated both by confocal microscopy (A, right panel) and western blot (B and C).
Regardless the methodology used, TRAP1 silencing was shown to induce a decrease in p62.
In micrographs, nuclei are marked in blue (DAPI), images were acquired by confocal
microscopy using a 40x objective, scale bars = 22μm. Protein levels were normalized to 
actin (N=4), bars show mean ± SEM (** p<0.01, two-tailed Student’s t-test). 
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for specific TRAP1-function studies. Also, there is still a lack of knowledge on the effects of 
targeting TRAP1 in non-tumor cells, which could be an off-target consequence of a 
possible anti-cancer strategy. In this chapter we evaluated TRAP1 silencing effect on 
MRC-5 mitochondrial physiology and morphology, as well as its involvement in cellular 
quality control mechanisms. 
MRC-5 cells are well-characterized normal human diploid fibroblasts with capability of 46 
population doublings and limited lifespan [537]. Several lines of evidence led to the 
observation that TRAP1 is differentially expressed in normal versus cancer cells [433]. In 
accordance, MRC-5 express low TRAP1 levels. TRAP1 silencing in this cell line did not 
affect ΔΨm, oxidative stress, or did sensitize cells to mPTP opening. In addition, TRAP1 
silencing resulted in a decrease in p66SHC expression levels, which was accompanied by a 
decrease in its activation through phosphorylation in Ser36 residue. Despite these 
differences between TRAP1-depleted cells and control, p66SHC activity, extrapolated 
with pSer-p66SHC/p66SHC ratio, was found to be statistically similar. Together, these 
results indicate that although TRAP1 somehow regulates p66SHC levels, it does not lead to 
p66SHC phosphorylation on its Ser36 residue confirming the lack of redox stress observed 
in these cells after TRAP1 silencing. 
Notwithstanding, despite not affecting mitochondrial function, TRAP1 silencing resulted 
in a significant decrease of cell proliferation rates. These observations were interesting 
considering that most works report that TRAP1 inhibition affects tumor growth with no 
detectable alterations in normal cells [434]. Although our results seem apparently 
contradictory to these observations, it is important to mention that these studies were 
performed using HSP90 inhibitors that specifically inhibit the mitochondrial pool of both 
TRAP1 and HSP90. However, we observed that TRAP1 seems to preferentially localize in 
extramitochondrial sites in MRC-5 cells; therefore, considering its low levels within 
mitochondria, TRAP1 organelle-specific inhibition would also have low impact on cell 
growth. Altogether, these findings suggest that different responses to HSP90 inhibitors 
may be due to TRAP1 distinct intracellular localization between tumor and normal cells. 
In support of this hypothesis several works showed that cytoplasmic TRAP1 regulates cell 
cycle by interacting with TNF pathway, thus promoting cell growth and proliferation 
[446]. Although MRC-5 cells do not express high levels of TRAP1, this protein is still 
present in these cells, and extramitochondrial TRAP1 seems to play an important role in 
MRC-5 cell proliferation probably through TNF pathway. 
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Figure 8.12 - Effect of macroautophagy modulators in the proliferation of TRAP1 silenced 
cells. Cell proliferation in the presence of the chemical compounds was accessed by SRB 
dye-binding assay during a period of 72 hours. (A) Data shows similar cellular proliferation 
for all cell groups analyzed. (B) The same experiment was also conducted in the presence of 
the anticancer agent DOX. In this case, siTRAP1 showed depressed cell growth throughout 
the 72 hours in comparison to controls. (C) When treated with 3-MA siTRAP1 cells showed 
lower proliferation rates than control cells. (D) MRC-5 siTRAP1 cells treated with 3-MA and 
DOX did not show significant decrease in cell mass in comparison to controls. Data is 
presented as mean±SEM (*** p<0.001 to siCTL for the respective time-point, N=5; two-way 
ANOVA followed by Bonferroni’s post hoc analysis for correction for multiple comparisons). 
(E) Summarized data from previous images for the 48 hours time-point in order to compare 
cell viability with and without treatment with the following agents: rapamycin, DOX, and 
rapamycin and DOX. Bars show mean±SEM, two-way ANOVA followed by Bonferroni’s post 
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hoc analysis for correction for multiple comparisons (* represents comparison with no-
treated, $ represents comparison with DOX-treated cells, # represents comparison with 
rapamycin and DOX treated cells; all comparisons where made within the same cell group, 
symbol number represent statistical significance, i.e. one symbol – p<0.05, two symbols – 
p<0.01 and three symbols – p<0.001). 
In addition to mitochondrial function, we also investigated possible mitochondrial 
morphology changes resultant from TRAP1 loss. Our data showed that TRAP1 silencing 
had no effect on mitochondrial morphology as all cell groups showed a filamentous 
mitochondrial network concomitant with the absence of alterations in the expression 
levels of different fusion and fission proteins. These results were coherent with our 
previous observations and further emphasize the idea of a less preponderant role of 
TRAP1 in regulating mitochondrial homeostasis in these cells. 
Interestingly, TRAP1 depletion resulted in a decrease of ATG12 and LC3 levels while not 
affecting any of the other analyzed autophagy proteins. Moreover, both soluble (LC3-I) 
and membrane-bound (LC3-II) forms were decreased to the same extent in TRAP1-
depleted cells. Despite these changes no differences were found regarding the LC3-II/LC3-
I ratio between TRAP1-silenced cells and the control, which suggests that autophagy is not 
defective in these cells although it might occur in a lesser extent that in control cells. 
Alternatively, due to the limitations associated with LC3 analysis to infer autophagy flux 
(reviewed in [519]), measurement of p62 degradation may is an important tool. Our data 
demonstrated that TRAP1 silencing resulted in decreased p62 levels, thus suggesting an 
increased autophagic flux. Surprisingly, although p62 expression levels can also reflect 
alterations in ubiquitinated proteins [521] ubiquitin content was not altered in these cells 
indicating that changes in p62 expression are not dependent on ubiquitin levels. During 
autophagy, p62 binds to LC3-II being engulfed by the autophagosome and degraded along 
with polyubiquitinated cargos. Under normal circumstances, low LC3-II levels 
accompanied by low p62 levels could indicate elevated autophagic flux. However, our 
results suggest LC3-II decreased levels may result from the decreased ATG12-ATG5 
expression, which is required for efficient LC3 lipidation. Consequently, changes in p62 
levels in TRAP1-depleted MRC-5 cells can only be the result from the decreased LC3-II 
protein content. 
TRAP1 depletion results in decreased cell growth and reduction of the autophagy levels, 
consequently, cell treatment with the mTOR inhibitor, rapamycin, was shown to restore 
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cell proliferation rates in these cells. Conversely, autophagy inhibition in these cells 
resulted in an accentuated decrease in cell proliferation, whereas control cells 
proliferation was not affected by either rapamycin or 3-MA treatment. Altogether, these 
findings suggest that TRAP1 plays a role in the maintenance of the autophagy levels. 
Autophagy occurs at low basal levels in virtually all cells and plays an important role in 
cellular homeostasis and genomic integrity [538]. Therefore, autophagy disruption often 
results in the accumulation of abnormal proteins and organelles. Our results suggest that 
TRAP1 plays a role in the regulation of autophagy levels, which is necessary to maintain 
cell proliferation levels. In addition TRAP1 loss did not altered lysosomal content and 
LAMP2A protein levels, thus it seems TRAP1 has only a mild effect on autophagy, which is 
not enough to activate compensatory pathways. 
Our results showed that TRAP1 depletion did not affect the apparent activity of the 
initiator caspases 9 and 8; however, surprisingly caspase 12-like activity was decreased in 
Figure 8.13 - Effect of TRAP1
silencing in both ubiquitin
and LAMP2A content. (A and
C) The extent of protein
ubiquitination was evaluated
in total protein extracts of
MRC-5 cells. TRAP1 silencing
showed similar ubiquitin
content when compared to
siCTL cell group. (B-C)
Protein content of LAMP2A, a
receptor for chaperone-
mediated autophagy, was
similar between both groups.
Protein levels were
normalized to actin (N=4),
bars show mean±SEM. Panel
C show representative
western blot for the above
mentioned proteins together
with their respective loading
controls (actin). a – siTRAP1
and b – siCTL.  
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Figure 8.14 - TRAP1 silencing effect on caspase-like activities and BCL-2 family protein 
levels. The activities of initiator caspases (8, 9 and 12) and effector caspases (3/7)-like were 
evaluated 72 hours post-transfection. (A-C) There were no differences in activity of initiator 
caspases 8 and 9 but caspase 12 activity was lower in siTRAP1 group. (D) Effector caspase 
3/7 activity was increased upon TRAP1 silencing. Moreover, no alterations in protein 
content were observed regarding BH3 family of pro-apoptotic protein BAX (E) or anti-
apoptotic BCL-xL (F) and BCL-2 (G). Protein levels were normalized to actin (N=4). Bars 
show mean±SEM (* p<0.05; *** p<0.001, two-tailed Student’s t-test). 
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TRAP1 silenced MRC-5 cells. Alterations in cellular homeostasis that result in the 
accumulation of unfolded proteins and aggregates in the ER trigger a signaling pathway 
called the UPR. TRAP1 has been previously implicated in the regulation of the UPR in the 
ER, and its depletion was shown to promote caspase 4 activity and induce cell death [451]. 
Therefore, it is unclear how TRAP1 depletion in our setup resulted in a decreased caspase 
12 activity. Nevertheless, since previous works were mainly performed in tumor cell lines 
the divergence between results further suggests that TRAP1-depletion effects may be 
dependent on its expression levels, subcellular localization and type of cell. Moreover, 
TRAP1 depletion resulted in apparent increased caspase 3/7 activation, although there 
were no changes in the pro- and anti-apoptotic proteins balance therefore suggesting 
these cells do not undergo apoptosis resulting from TRAP1 silencing.  
8.4 Conclusions 
Several works reported the efficacy of HSP90 inhibitors in promoting tumor cell death 
without affecting the normal counterparts. Our findings suggest that in addition to the 
distinct levels of TRAP1 found in tumor versus normal cells, differences in its intracellular 
distribution may also contribute for HSP90 inhibitors efficacy. TRAP1 was shown to 
localize predominantly in extramitochondrial sites and its depletion did not affected 
mitochondrial physiology or morphology. Despite not affecting mitochondrial function, 
TRAP1 appears to play an important role in autophagy levels maintenance, which in turn 
seems to be important for cell growth. However, the TRAP1 role in autophagy is not yet 
fully understood and requires further investigation. Moreover, TRAP1 seems to mildly 
regulate autophagy in MRC-5 cells, as its loss did not resulted in activation of 
compensatory autophagy mechanisms or cell death. 
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Chapter 9  
 
Final Conclusions 
 
Heat shock proteins are highly conserved molecular chaperones that are required for cell 
survival under stress. HSPs have important cytoprotective properties, which are closely 
related with their primary functions as molecular chaperones. HSPs play key roles in 
processes of protein quality control by assisting protein folding, prevent aggregation of 
un- or mis-folded proteins and assist in the translocation of proteins to their correct 
intracellular localization. In addition to these functions HSPs also have essential anti-
apoptotic properties allowing cell survival and proliferation in unfavorable 
environments. Therefore, considering that apoptosis evasion and unlimited proliferative 
capability constitute two core characteristics of tumor development, it is not surprising to 
think that HSPs are important components of the oncogenic process. In fact, HSPs are 
overexpressed in a wide range of human carcinomas contributing to the several of the 
malignant traits that define cancerous growth proposed by Hanahan and Weinberg [45]. 
Furthermore, members of the HSP90 family are thought to promote tumor cell survival 
due to their role in maintaining stability and activity of a diverse range of client proteins 
[435]. 
TRAP1 was identified as a mitochondrial member of the HSP90 family which is generally 
overexpressed in tumor cells. An increasing amount of knowledge on TRAP1 role in 
tumorigenesis has been generated. The present dissertation first aimed at the 
identification of the several classic traits of mitochondrial dysfunction resultant from 
TRAP1 loss [536], in the two cell lines. In accordance with previous works, our results 
indicate that TRAP1 plays an important role in maintaining mitochondria homeostasis and 
thus conferring tumor cells a growth advantage. Similarly to what has been described in 
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other cell models TRAP1 depletion led to mitochondrial depolarization and increased ROS 
production in A549 cells (Fig.9.1). However, this study brought new clues on how TRAP1 
modulates oxidative stress in tumor cells as its loss resulted in increased p66SHC Ser36 
phosphorylation with no alterations in SOD2 expression. Although more work needs to be 
done to better understand whether increased p66SHC Ser36 phosphorylation is cause or 
consequence of ROS increase, our data suggests that TRAP1 is somehow involved in the 
regulation of p66SHC levels as TRAP1-silencing in MRC-5 cells also resulted in alteration 
in the levels of this protein without affecting ROS production. 
Another important characteristic of TRAP1 that has been broadly explored for cancer 
therapy is its differential expression in normal versus tumor cells. In this regard, several 
studies have identified mitochondrial-targeted HSP90 inhibitors, gamitrinibs, as 
powerful anti-cancer tools. Suppression of TRAP1 and HSP90 activities by such agents 
causes inhibition of cell proliferation and cell death in tumor cells while not affecting non-
neoplastic cells (revised in [454]). However, in addition to variations in its expression 
levels, our data suggests that TRAP1 may also differentially localize in normal (e.g. MRC-5 
cells) versus tumor cells (e.g. A549 cells), which further explains the level of success of 
gamitrinibs in cancer therapy. In accordance, TRAP1-depletion in MRC-5 cells had no 
implications in mitochondrial physiology, which may be due to the fact that in these cells, 
and in contrast to what was observed in A549 cells, TRAP1 seems to preferentially localize 
in extramitochondrial sites and thus not have such an important role in the maintenance 
of mitochondrial homeostasis. 
Since its discovery, several works linked TRAP1 cytoprotective functions to its role in 
mPTP modulation [304, 474]. Mitochondrial TRAP1, along with HSP90 and HSP60, was 
shown to bind CypD, which has been proposed to impair mPTP opening [302, 304]. 
Although our findings support the hypothesis that TRAP1 modulates mPTP these suggest a 
far more complex involvement of this chaperone in this process. Unlike what was 
expected TRAP1 loss in A549 cells resulted in pore closure under normal growth 
conditions. Nevertheless, these apparently contradictory results are interesting as, to our 
knowledge, this is the first study directly exploring TRAP1 role in mPTP modulation. 
However, the significance of this mPTP closure as well as a deeper knowledge on how 
TRAP1 is actually involved in its modulation needs to be further explored. A more closed 
status of the mPTP under basal conditions may result from an adaptive response to 
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Figure 9.1 - Effects of TRAP1 disruption in A549 cells. TRAP1 silencing (represented in a 
lighter color) results in mitochondria depolarization (1), and increased ROS production 
accompanied by increased p66SHC phosphorylation in its Ser36 residue (2). In addition, 
TRAP1 modulates the mPTP, with its depletion resulting in a more closed mPTP 
conformation (3). The observed decreased oxygen consumption together with the remaining 
alterations in mitochondrial function may indicate inhibition of the ETC and/or the 
phosphorylative system (4). Besides the functional alterations, TRAP1 depletion results in 
mitochondrial fragmentation (5) resulting from increased DRP1 expression. Although A549 
TRAP1-silenced cells experience an accumulation of damaged, fragmented mitochondria, 
the macroautophagy pathway (represented in a lighter color) levels are decreased (6), 
which might be explained by the decreased ubiquitin content (7) in these cells. These 
findings suggest that although TRAP1-depleted cells accumulate intracellular trash, this is 
not eliminated through autophagy due to the decreased ubiquitination (7). In fact, TRAP1 
silencing results in increased lysosomal and LAMP2A content indicating an increase in the 
CMA pathway (8), probably in an attempt to compensate for the low macroautophagy 
levels. Eventually, the accumulation of intracellular damage may culminate in cell death. 
Accordingly, TRAP1 silencing results in increased caspase 3/7-like activity (9) while shifting 
the BAX/BCL-xL balance towards apoptosis (10). Considering that the increase in caspase 
3/7 activity was not accompanied by alterations in any of the analyzed initiator caspases 
activities, we hypothesize that other mechanisms might be involved in this activation, 
  
9. CHAPTER 
178 Inês A. Barbosa │ University of Coimbra 
namely by the release of lysosomal cathepsins through LMP (illustrated by dashed circle). 
Abbreviations: BAX - BCL-2 associated X protein; BCL-xL - B-cell lymphoma extra large 
protein; CMA – chaperone mediated autophagy; CypD – cyclophilin D; DRP1- dynein-related 
protein 1; ETC – electron transport chain; HSP – heat shock protein; LAMP2A - lysosome-
associated membrane protein type 2A; mPTP – mitochondrial permeability transition pore; 
ROS – reactive oxygen species; TBP7 - Tat-binding protein 7; TRAP1 – tumor necrosis factor 
receptor associated protein 1. 
increased stress resulting from TRAP-1 silencing, although the next exact mechanism of 
how that occurs is still unknown. 
In addition to the observed decrease in ΔΨm and increased ROS production, our data 
showed that TRAP1 loss in A549 cells also resulted in decreased oxygen consumption. 
Together, these results suggest an inhibition of the ETC or upstream metabolite 
transporters, or even inhibition of the phosphorylative system, although the 
mitochondrial depolarization associated with TRAP1 silencing suggests that the former 
two are more likely. In support to this hypothesis, previous works demonstrated that 
TRAP1 interacts with complex IV of the ETC [503] increasing its activity and thus 
improving mitochondrial function [444]. 
Besides maintaining mitochondrial function, TRAP1 was also described to play a role in 
mitochondrial dynamics [514, 515]. TRAP1 loss in A549 resulted in mitochondrial 
fragmentation accompanied by an increase in DRP1 expression. Although our results are 
in accordance with the work of Takamura and collaborators showing that TRAP1 controls 
mitochondrial fusion/fission balance mainly through the expression of fission proteins, 
such as DRP1, the authors observed mitochondria elongation [515] rather than 
fragmentation as we, and Butler and colleagues [514], reported. As discussed in Chapter 8, 
MRC-5 cells did not show any alterations in mitochondrial function or dynamics upon 
TRAP1 silencing indicating that in these cells TRAP1 does not play such an important role 
in mitochondrial maintenance as in A549 cells. Notwithstanding, TRAP1 depletion in 
MRC-5 cells resulted in decreased levels of autophagy-related proteins, although in a 
lesser extent than in A549 cells. LC3 is the mammalian homolog of Atg8 in yeast [342]. 
The 30KDa LC3 protein first undergoes post-translational modifications that culminate 
with its conversion in the 18KDa cytosolic form LC3-I, which is conjugated to PE through a 
conjugation process similar to the one occurring to ubiquitin to form the 16KDa LC3-II 
[518]. LC3 lipidation constitutes an essential step in the autophagy process as LC3-II is 
recruited to the autophagosomal membranes. Thus, LC3-II is considered a marker for 
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autophagy and the amount of LC3-II is closely correlated with the number of 
autophagosomes [332]. Therefore, comparison of the amount of LC3-II has been 
considered the most accurate method to detect alterations in the autophagic flux [519]. 
Our results showed a lower LC3-II content in both A549 and MRC-5 cells upon TRAP1 
silencing suggesting that cells lacking TRAP1 accumulate less autophagic vesicles 
containing LC3-II. However, the amount of LC3-II at this specific time point does not 
implicate a decreased autophagic flux to which the measurement of the amount of p62 
may bring more information [519]. The measurement of the p62 levels constitutes another 
method to evaluate the autophagic flux. Here, we showed that this protein was decreased 
in both A549 and MRC-5 cells after TRAP1 silencing. 
If one analyzes these results independently, the observed overall decrease in the 
expression of proteins from the autophagic machinery and decreased p62 levels seem to 
indicate that the cellular quality control systems are working properly and that there is no 
accumulation of intracellular garbage. However, our results, in particular for A549 cells, 
showed that TRAP1-depleted cells had less overall ubiquitin content. Therefore, we 
hypothesize that although there might be an increased damage in these cells, probably 
due to increased oxidative stress and mitochondrial dysfunction, protein aggregates and 
defective organelles are not being targeted to autophagy which consequently leads to a 
reduction in autophagy levels. In support to this hypothesis, we observed increased 
lysosome content and elevated LAMP2A levels suggesting an increased CMA pathway, 
which is often activated as a compensatory mechanism upon macroautophagy 
impairment. Unlike macroautophagy, CMA constitutes a mechanism through which 
damaged proteins expressing a KFERQ motif are targeted to degradation and thus it is not 
dependent on protein ubiquitination [367]. Consequently, increased CMA may indicate 
increased protein damage one which is not solved by the macroautophagy machinery due 
to decreased protein ubiquitination. 
Intriguingly, MRC-5 cells, which also showed decreased p62 expression, did not reveal 
alterations regarding ubiquitin levels. In MRC-5 cells, TRAP1 depletion seems to have a 
milder effect on cellular homeostasis suggesting these cells are not as “dependent” on 
TRAP1 for the maintenance of mitochondrial function and autophagy as A549 cells. 
Although further studies have to be preformed in order to ascertain the significance of 
these results, results regarding MRC-5 cells seem to indicate a higher autophagic flux 
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suggesting that, unlike in A549 cells, TRAP1 does not play a predominant role in 
homeostasis maintenance in MRC-5 cells. 
In addition to decreased autophagy levels, TRAP1-depleted cells showed lower growth 
rates than the controls. Interestingly, when both cell lines were treated with rapamycin, a 
mTOR inhibitor used to induce autophagy [539], TRAP1-silenced cells presented higher 
proliferation rates, whereas inhibition of autophagy with 3-MA had the opposite result. 
Moreover, A549 control cells showed growth inhibition for both treatments, while MRC-5 
cells controls were not widely affected by either rapamycin or 3-MA. Together these 
findings suggest that TRAP1 role in the maintenance of autophagy levels allows tumor cell 
homeostasis and thus contributes to tumor growth. 
Finally, TRAP1 depletion results in apparent activation of caspase-3 and shifts the 
BAX/BCL-xL ratio in favor of the apoptotic signal in A549 but not in MRC-5 cells. In 
conclusion, based on the obtained results, we propose that TRAP1 promotes tumorigenesis 
by not only maintaining mitochondrial function and integrity, but also allowing the 
maintenance of constant autophagy levels which are thought to be beneficial for cell 
growth. Therefore, TRAP1 depletion results in mitochondrial damage, decreased 
autophagy levels and consequent accumulation of misfolded proteins and damaged 
organelles, to which cells respond by increasing CMA levels. However, CMA capability is 
limited and thus when the increased damage is higher than cell buffering ability, there is 
activation of the apoptotic pathway. 
Our work indicates a highly complex and variable role for TRAP1 in neoplastic 
development, depending on tissue/cell type and reliance on TRAP1. Also important 
appears to be the localization of TRAP1. Finally, we can hypothesize that the predominant 
metabolism of the cancer cell itself may also impact how TRAP1 regulates mitochondrial 
metabolism. 
TRAP1-directed therapies may need to have in account several heterogeneity factors 
which can pre-dispose cells to multiple phenotypes after TRAP1 silencing/inhibition. This 
can not only compromise the efficacy of anti-cancer therapy directed to that target but 
also increase damage to healthy cells. 
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Chapter 10  
 
Future Perspectives 
 
This dissertation has contributed with new insights on the role of TRAP1 in mitochondrial 
homeostasis providing information regarding its mechanisms of action in two cell lines, 
one of them with tumoral origin. This study brought new clues for future investigations 
on this chaperone function as well as its role as an anti-cancer target. Despite this, further 
work is still required in order to better clarify and complement some of our results. 
 
With the purpose of better understanding the role of p66SHC in the increase in 
oxidative stress of TRAP1-depleted cells, we plan on investigating whether 
TRAP1 directly interacts with p66SHC. Moreover, SHC1 silencing in these cells 
followed by evaluation of ROS content, specially in TRAP1-silenced cells, will 
bring valuable information on the relevance of p66SHC function in oxidative 
stress generation. Therefore, we would expect to observe lower ROS content in 
double-silenced cells if the massive ROS production was indeed a result of 
p66SHC activation by TRAP1. In addition, this will allow us to discriminate if 
ROS increase is responsible for the modulation of mitochondrial morphology and 
autophagy. 
 
To further explore TRAP1 role in mPTP modulation, we will first verify whether 
if in A549 cells, similarly to what has been described to other models, TRAP1 
interacts with CypD. If so, and considering that TRAP1 function in mPTP has 
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been attributed to this interaction, it would be interesting to follow CypD 
expression and content in longer time points, than the ones used in this study 
after TRAP1 depletion. As described in Chapter 7, higher PPIF expression, 
although not translated in an increment of CypD protein levels was observed. 
The evaluation of CypD content in a wider time frame can give us valuable 
information to contrast with previous works [304, 474] and to confirm the 
hypothesis that TRAP1 modulation of mPTP is due to alterations of CypD content. 
Alternatively, to evaluate mPTP sensitivity, we will subject the cells to a calcium-
challenging event, i.e. increasing cytoplasmic calcium concentration by a low 
ionomycin concentration, in order to promote mitochondrial-calcium 
accumulation and consequently trigger mPTP. In this assay we will follow mPTP 
opening in a real-time manner by microplate reader or by confocal microscopy. 
If TRAP1-depleted cells show a higher sensibility to mPTP opening after this 
stimulus, we will conclude that, although mPTP is in a more closed conformation 
under basal conditions, the threshold for its opening is decreased.  
 
Regarding oxygen consumption, further assays need to be performed in order to 
address the hypothesis of ETC inhibition. First, oxygen consumption levels will 
be evaluated in intact cells and in the presence of oligomycin (Complex V, i.e. 
ATP synthase, inhibitor) and FCCP (uncoupler). The different consumption rates 
will allow discriminating between effects at the ETC level or at the 
phosphorylative system. Additionally, the assay will be performed with 
permeabilized cells which although not being a physiologic situation are close to 
the isolated mitochondrial fractions technique, allowing the incubation with 
different mitochondrial substrates/inhibitor to pin-point the specific point of 
TRAP1-deppletion effect. Alternatively, if TRAP1-depleted cells have impaired 
mitochondria and rely more in glycolysis, growing such cells in galactose-only 
medium containing pyruvate/glutamine would result in massive cell death or at 
least arrest of cell cycle. Evaluation of adenine nucleotide levels by HPLC will 
also indicate the energetic status of these cells and would give a better idea if the 
impaired mitochondria and possible metabolic shift are still able to provide 
enough energy for normal cellular physiology. 
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Since literature is not coherent regarding TRAP1 effects on respiratory 
complexes it would be interesting to evaluate isolated enzymatic activities for the 
different ETC enzymes. Moreover, evaluation of the multimeric ETC complexes 
by blue-native electrophoresis in addition to the same evaluation after 
immunoprecipitation of TRAP1 will allow proof of concept of TRAP1 interaction 
and inhibition of ETC enzymes. However, a previous report also stated that 
differential TRAP1 effects on oxygen consumption are dependent on the 
expression of c-src [504]. Therefore, it would be interesting to evaluate the 
content of this protein as well as it activation by Tyr-416 phosphorylation in 
A549 cells since this information is lacking in the literature. 
 
Lysosomal membrane permeabilization (LMP) results in cathepsin release from 
the lysosomal lumen to the cytosol [533]. In order to test the hypothesis of 
cathepsin-dependent caspase 3 activation in TRAP1-depleted cells, we will first 
evaluate whether in these cells LMP is verified. Accordingly, LMP will be 
measured through immunofluorescence using acridine orange, which emits red 
fluorescence when present in lysosomes and loses fluorescence after LMP [540]. 
The advantage of using this probe instead of lysotracker green is that the latter 
continues to stain de-acidified lysosomes, while the former allows a better 
analysis of LMP extent. In addition and to complement this study, we will also 
use antibodies against cathepsin B and D, and lysosomal membrane proteins, 
such as LAMP-1, and evaluate the distribution of the proteases in the cell by 
immunofluorescence. In this case we expect to observe a diffuse cathepsin B or D 
staining throughout the entire cell suggestive of LMP. Alternatively, proteases 
activity will be monitored in cytosolic extracts using cathepsin specific 
substrates.  
 
 Although we observed increased caspase 3-like activity for both cell lines and a 
shift in the BAX/BCL-xL balance in favor of apoptosis in A549 cells, further 
analysis would allow us to evaluate whether these cells are undergoing apoptotic 
cell death. An approach to this goal will be achieved by using the dual staining 
propidium iodide and bromodeoxyuridine to monitor cell death and cell division 
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[541]. This will allow us to understand if caspase 3 activation culminates with cell 
death or if TRAP1 depletion just arrests cell cycle. 
 
In Chapter 8, we showed that TRAP1 seems to preferentially locate in 
extramitochondrial sites in MRC-5 cells. In order to confirm this statement we 
will proceed to subcellular fractioning namely nuclei, cytoplasm, and 
mitochondria and evaluate TRAP1 content in each of these extracts. We expect to 
observe low levels of TRAP1 in the mitochondrial fraction corroborating our 
initial hypothesis of differential TRAP1 effects due to subcellular localization. If 
we verify this, it would be interesting to express bioengineered TRAP1 with and 
without the mitochondrial-targeting sequence in A549 TRAP1-depleted cells. We 
hypothesize that only TRAP1 present in mitochondria will be able to prevent the 
traits associated with the chaperone silencing thus demonstrating the 
importance of TRAP1 compartmentalization in tumor development. 
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